<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(MARK ONE)
<TABLE>
<S> <C>
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.
</TABLE>
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1999
OR
<TABLE>
<S> <C>
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
</TABLE>
FOR THE TRANSITION PERIOD FROM ______________ TO ______________
Commission File Number: 0-12798
__CHIRON CORPORATION__
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
DELAWARE 94-2754624
-------- ---------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
</TABLE>
4560 HORTON STREET, EMERYVILLE, CALIFORNIA 94608
(Address of principal executive offices) (Zip code)
(510) 655-8730
(Registrant's telephone number, including area code)
NOT APPLICABLE
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes __X__ No ______
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
<TABLE>
<S> <C>
TITLE OF CLASS OUTSTANDING AT OCTOBER 31, 1999
Common Stock, $0.01 par value 181,650,478
</TABLE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
CHIRON CORPORATION
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE NO.
PART I. FINANCIAL INFORMATION --------
<S> <C>
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets as of
September 30, 1999 and December 31, 1998............... 3
Condensed Consolidated Statements of Operations for the
three and nine months ended September 30, 1999 and
1998................................................... 4
Condensed Consolidated Statements of Comprehensive
Income for the three and nine months ended
September 30, 1999 and 1998............................ 5
Condensed Consolidated Statements of Cash Flows for the
nine months ended September 30, 1999 and 1998.......... 6
Notes to Condensed Consolidated Financial Statements.... 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS..................... 16
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK............................................. 28
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS................................. 28
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.................. 29
SIGNATURES.................................................. 31
</TABLE>
2
<PAGE>
ITEM 1. FINANCIAL STATEMENTS
CHIRON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1999 1998
-------------- -------------
(UNAUDITED)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................. $ 205,768 $ 513,315
Short-term investments in marketable debt securities...... 699,612 716,619
---------- ----------
Total cash and short-term investments................... 905,380 1,229,934
Accounts receivable, net.................................. 197,419 167,588
Inventories............................................... 95,149 79,862
Other current assets...................................... 78,086 153,558
---------- ----------
Total current assets.................................... 1,276,034 1,630,942
Noncurrent investments in marketable debt securities........ 647,631 360,069
Property, plant, equipment, and leasehold improvements, at
cost:
Land and buildings........................................ 143,022 141,452
Laboratory, production, and office equipment.............. 310,612 236,803
Leasehold improvements.................................... 69,226 84,607
Construction-in-progress.................................. 27,998 38,321
---------- ----------
550,858 501,183
Less accumulated depreciation and amortization............ (232,396) (198,102)
---------- ----------
Net property, plant, equipment, and leasehold
improvements.......................................... 318,462 303,081
Purchased technology, net................................... 12,518 14,753
Other intangible assets, net................................ 146,973 167,534
Investments in equity securities and affiliated companies... 35,794 27,456
Other assets................................................ 37,156 20,429
---------- ----------
$2,474,568 $2,524,264
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 44,562 $ 44,833
Accrued compensation and related expenses................. 46,739 40,727
Short-term borrowings and current portion of long-term
debt.................................................... 24,123 17,554
Note payable to Novartis.................................. 66,830 63,945
Current portion of unearned revenue....................... 36,413 41,893
Taxes payable............................................. 31,919 180,536
Other current liabilities................................. 120,606 167,947
---------- ----------
Total current liabilities............................... 371,192 557,435
Long-term debt.............................................. 350,736 338,158
Other noncurrent liabilities................................ 65,497 82,869
---------- ----------
Total liabilities....................................... 787,425 978,462
---------- ----------
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock.............................................. 1,819 1,799
Additional paid-in capital................................ 2,039,149 1,979,615
Accumulated deficit....................................... (331,599) (437,873)
Accumulated other comprehensive (loss) income............. (7,351) 2,261
Treasury stock, at cost (432,712 shares).................. (14,875) --
---------- ----------
Total stockholders' equity.............................. 1,687,143 1,545,802
---------- ----------
$2,474,568 $2,524,264
========== ==========
</TABLE>
THE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ARE AN
INTEGRAL PART OF THIS STATEMENT.
3
<PAGE>
CHIRON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------- -------------------------
1999 1998 1999 1998
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Revenues:
Product sales, net.......................... $ 114,006 $ 112,813 $ 308,295 $ 278,091
Equity in earnings of unconsolidated joint
businesses................................ 23,297 21,255 58,431 51,493
Collaborative agreement revenues............ 18,442 24,278 59,603 73,110
Royalty and license fee revenues............ 36,524 49,756 96,292 81,325
Other revenues.............................. 12,107 7,868 46,425 28,128
----------- ----------- ----------- -----------
Total revenues............................ 204,376 215,970 569,046 512,147
----------- ----------- ----------- -----------
Operating expenses:
Cost of sales............................... 53,580 51,063 138,215 124,462
Research and development.................... 75,473 67,348 216,732 196,238
Selling, general, and administrative........ 41,802 40,745 128,617 103,533
Write-off of purchased in-process
technologies.............................. -- -- -- 1,645
Restructuring and reorganization charges
(Note 3).................................. (1,290) 6,401 2,062 11,339
Other operating expenses.................... 2,471 3,179 7,164 8,142
----------- ----------- ----------- -----------
Total operating expenses.................. 172,036 168,736 492,790 445,359
----------- ----------- ----------- -----------
Income from operations........................ 32,340 47,234 76,256 66,788
Gain on sale of assets........................ -- 1,510 -- 7,751
Interest expense.............................. (6,158) (6,009) (17,866) (18,638)
Other income, net............................. 19,685 5,035 63,061 21,196
----------- ----------- ----------- -----------
Income from continuing operations before
income taxes................................ 45,867 47,770 121,451 77,097
Provision for income taxes.................... 826 13,856 18,938 15,539
----------- ----------- ----------- -----------
Income from continuing operations............. 45,041 33,914 102,513 61,558
----------- ----------- ----------- -----------
Discontinued operations (Note 2):
Income (loss) from discontinued
operations................................ -- 5,001 -- (8,107)
Gain on disposal of discontinued
operations................................ 23,288 45,520 26,297 110,852
----------- ----------- ----------- -----------
Net income.................................... $ 68,329 $ 84,435 $ 128,810 $ 164,303
=========== =========== =========== ===========
Basic earnings per share (Note 1):
Income from continuing operations........... $ 0.25 $ 0.19 $ 0.57 $ 0.35
=========== =========== =========== ===========
Net income.................................. $ 0.38 $ 0.47 $ 0.71 $ 0.93
=========== =========== =========== ===========
Diluted earnings per share (Note 1):
Income from continuing operations........... $ 0.24 $ 0.19 $ 0.55 $ 0.34
=========== =========== =========== ===========
Net income.................................. $ 0.36 $ 0.47 $ 0.69 $ 0.91
=========== =========== =========== ===========
</TABLE>
THE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ARE AN
INTEGRAL PART OF THIS STATEMENT.
4
<PAGE>
CHIRON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
(IN THOUSANDS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------- -------------------------
1999 1998 1999 1998
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net income.................................... $ 68,329 $ 84,435 $ 128,810 $ 164,303
----------- ----------- ----------- -----------
Other comprehensive income (loss):
Foreign currency translation adjustment:
Change in foreign currency translation
adjustment during the period............ 6,236 7,893 (13,500) 6,910
Plus: reclassification adjustment for loss
included in discontinued operations..... -- -- -- 2,087
----------- ----------- ----------- -----------
Net foreign currency translation
adjustment.............................. 6,236 7,893 (13,500) 8,997
----------- ----------- ----------- -----------
Unrealized gains (losses) from investments:
Unrealized holding gains (losses) arising
during the period......................... 880 (2,375) 4,793 (8,744)
Reclassification adjustment for net losses
(gains) included in net income net of tax
benefit (provision) of $26 and $311 for
the three months ended September 30, 1999
and 1998, respectively, and ($531) and
($253) for the nine months ended
September 30, 1999 and 1998,
respectively.............................. 86 553 (905) (448)
----------- ----------- ----------- -----------
Net unrealized gains (losses) from
investments............................... 966 (1,822) 3,888 (9,192)
----------- ----------- ----------- -----------
Other comprehensive income (loss)............. 7,202 6,071 (9,612) (195)
----------- ----------- ----------- -----------
Comprehensive income.......................... $ 75,531 $ 90,506 $ 119,198 $ 164,108
=========== =========== =========== ===========
</TABLE>
THE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ARE AN
INTEGRAL PART OF THIS STATEMENT.
5
<PAGE>
CHIRON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS)
<TABLE>
<CAPTION>
NINE MONTHS ENDED
SEPTEMBER 30,
-------------------------
1999 1998
----------- -----------
<S> <C> <C>
Net cash (used in) provided by operating activities......... $ (37,092) $ 85,766
----------- -----------
Cash flows from investing activities:
Purchases of investments in marketable debt securities.... (1,130,974) (371,343)
Proceeds from sale and maturity of investments in
marketable debt securities.............................. 867,365 192,406
Capital expenditures...................................... (55,742) (82,480)
Proceeds from disposal of discontinued operations......... 46,912 298,939
Proceeds from sale of assets.............................. -- 38,312
Business acquired, net of cash acquired................... -- (54,770)
Purchases of investments in equity securities and
affiliated companies.................................... -- (6,000)
Other, net................................................ (11,108) (23,314)
----------- -----------
Net cash used in investing activities................... (283,547) (8,250)
----------- -----------
Cash flows from financing activities:
Net proceeds from (repayment of) short-term borrowings.... 7,934 (129,800)
Proceeds from issuance of debt............................ 8,114 --
Repayment of debt and capital leases...................... (1,987) (1,693)
Proceeds from issuance of common stock.................... 31,683 35,962
Proceeds from reissuance of treasury stock................ 36,408 --
Payments to acquire treasury stock........................ (69,060) --
----------- -----------
Net cash provided by (used in) financing activities..... 13,092 (95,531)
----------- -----------
Net decrease in cash and cash equivalents............... (307,547) (18,015)
Cash and cash equivalents at beginning of the period........ 513,315 98,483
----------- -----------
Cash and cash equivalents at end of the period.............. $ 205,768 $ 80,468
=========== ===========
</TABLE>
THE ACCOMPANYING NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ARE AN
INTEGRAL PART OF THIS STATEMENT.
6
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 1--THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The information presented in the accompanying Condensed Consolidated
Financial Statements at September 30, 1999, and for the three and nine months
ended September 30, 1999 and 1998, is unaudited, but includes all normal
recurring adjustments which the management of Chiron Corporation ("Chiron" or
the "Company") believes to be necessary for fair presentation of the periods
presented.
For the three and nine months ended September 30, 1999, the Company's
results include a $2.0 million and $8.4 million reduction, respectively, in
other operating expenses resulting from a change in estimated tax accruals
related to certain employee payments recorded in 1995 in connection with the
Novartis transaction. For the three and nine months ended September 30, 1999,
the Company's results also include a $23.3 million and $26.3 million adjustment,
respectively, to the gain on disposal of discontinued operations resulting from
net tax benefits of adjustments to the sales price of Chiron Diagnostics, the
disposal of most of the Claremont facility and adjustments to certain deductions
and credits based on the filing of the Company's 1998 income tax returns, as
well as changes in estimated accruals created at the time of disposal.
For the three and nine months ended September 30, 1998, the Company's
results include a $3.3 million and $9.3 million reduction, respectively, in cost
of sales due to a change in estimated property tax accruals created in prior
periods. For the nine months ended September 30, 1998, the Company's results
include a $3.6 million reduction in restructuring and reorganization charges due
to a revised estimate of property and other tax-related accruals recorded in
1995 in connection with the idling of the Puerto Rico facility and a $2.0
million reduction in selling, general, and administrative expenses due to
changes in estimated accruals created in prior periods.
During the second quarter of 1999, the Company completed the implementation
of an integrated information system. As a result, certain previously reported
amounts have been reclassified to conform with the current period presentation.
The condensed consolidated balance sheet amounts at December 31, 1998 have been
derived from audited financial statements. Interim results are not necessarily
indicative of results for a full year. This information should be read in
conjunction with Chiron's audited consolidated financial statements for the year
ended January 3, 1999, which are included in the Annual Report on Form 10-K
filed by the Company with the Securities and Exchange Commission.
In the first quarter of 1998, Chiron completed the sale of its ophthalmics
business ("Chiron Vision") to Bausch & Lomb Incorporated ("B&L"), and in the
fourth quarter of 1998, Chiron completed the sale of its IN VITRO diagnostics
business ("Chiron Diagnostics") to Bayer Corporation ("Bayer") (see Note 2). The
accompanying Condensed Consolidated Statements of Operations for the three and
nine months ended September 30, 1998 reflect the after-tax results of Chiron
Diagnostics as discontinued operations.
On March 31, 1998, in an acquisition accounted for under the purchase method
of accounting, Chiron acquired the remaining 51% interest in Chiron Behring
GmbH & Co ("Chiron Behring"), not previously owned, from Hoechst AG. Beginning
in the second quarter of 1998, the results of Chiron Behring were consolidated
with those of the Company.
Prior to January 1999, the results of Chiron's Italian subsidiary ("Chiron
S.p.A.") were reported on a one-month lag. In the first quarter of 1999, the
results of Chiron S.p.A. were brought current. As a result, during the first
quarter of 1999, the Company recorded a loss of approximately $5.2 million for
the month of December 1998 as a component of "Accumulated deficit" in the
accompanying Condensed Consolidated Balance Sheets.
7
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 1--THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
FISCAL YEAR
Effective with the beginning of fiscal year 1999, the Company changed its
fiscal year from a 52 or 53-week year ending on the Sunday nearest the last day
in December to coincide with a calendar year ending on December 31. In 1998, the
Company's fiscal year was a 53-week year ending on January 3, 1999 and the third
fiscal quarter was a 13-week period ending on September 27, 1998. For
presentation purposes, the 1998 dates used in the condensed consolidated
financial statements and notes refer to the fiscal month-end.
INVENTORIES
Inventories are stated at the lower of cost or market using the moving
weighted-average cost method as of September 30, 1999. For the period ending
December 31, 1998, vaccine inventories were valued using the last-in, first-out
("LIFO") method. In the second quarter of 1999, the Company changed its
inventory valuation methodology for vaccine inventories from LIFO to the moving
weighted-average cost method. The effect of this change in methodology was not
material to the financial statements. Inventories consist of the following (in
thousands):
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1999 1998
-------------- -------------
<S> <C> <C>
Finished goods.......................................... $19,036 $12,301
Work-in-process......................................... 58,765 54,333
Raw materials........................................... 17,348 13,228
------- -------
$95,149 $79,862
======= =======
</TABLE>
INCOME TAXES
The 1999 estimated annual tax provision is expected to be approximately 27%
of pretax income from continuing operations, prior to the recognition of
deferred tax assets through a reduction in the valuation allowance associated
with such assets. The actual tax provision for the three and nine months ended
September 30, 1999 includes the reduction in the state deferred tax asset
valuation allowance of $9.1 million and $14.4 million, respectively. The
valuation allowance was reduced because management believes that it is more
likely than not that the deferred tax assets to which the valuation allowance
related will be realized. In addition, in the third quarter of 1999, the Company
recorded as additional paid-in capital approximately $27.9 million resulting
from the tax benefits related to the Company's stock option plans.
Income tax expense for the nine months ended September 30, 1998 was based on
actual year-to-date effective tax rate on pretax income from continuing
operations of approximately 20%, after taking into account federal deferred tax
assets recognized through a reduction in the valuation allowance associated with
such assets. The actual 1998 annual effective tax rate of 20% reflects the
deferred tax assets that were recognized during the second half of 1998 through
a reduction in the valuation allowance associated with such assets.
PER SHARE DATA
Basic earnings per share is based upon the weighted-average number of common
shares outstanding. Diluted earnings per share is based upon the
weighted-average number of common shares and dilutive potential common shares
outstanding. Dilutive potential common shares could result from (i) the assumed
exercise of outstanding stock options, warrants, and equivalents, which are
included under the treasury-stock method;
8
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 1--THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
(ii) performance units to the extent that dilutive shares are assumed issuable;
and (iii) convertible debentures, which are included under the if-converted
method.
The following table sets forth the computation for basic and diluted
earnings per share on income from continuing operations (in thousands, except
per share data):
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------- -------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C>
Income (Numerator):
Income from continuing operations available to common
stockholders........................................ $ 45,041 $ 33,914 $102,513 $ 61,558
Plus: Interest on 1.9% convertible debentures, net of
taxes............................................... 1,936 -- 1,936 --
-------- -------- -------- --------
Income available to common stockholders, plus assumed
conversions......................................... $ 46,977 $ 33,914 $104,449 $ 61,558
-------- -------- -------- --------
Shares (Denominator):
Weighted-average common shares outstanding............ 181,419 177,820 181,160 177,086
Effect of dilutive securities:
Options and equivalents............................. 4,686 1,937 3,948 2,447
Warrants............................................ 319 135 265 170
1.9% convertible debentures......................... 8,785 -- 2,928 --
-------- -------- -------- --------
Weighted-average common shares outstanding, plus
assumed conversions................................. 195,209 179,892 188,301 179,703
-------- -------- -------- --------
Basic earnings per share................................ $ 0.25 $ 0.19 $ 0.57 $ 0.35
======== ======== ======== ========
Diluted earnings per share.............................. $ 0.24 $ 0.19 $ 0.55 $ 0.34
======== ======== ======== ========
</TABLE>
9
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 1--THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
The following table sets forth the computation of basic and diluted earnings
per share on net income (in thousands, except per share data):
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------- -------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C>
Income (Numerator):
Net income available to common stockholders........... $ 68,329 $ 84,435 $128,810 $164,303
Plus: Interest on 1.9% convertible debentures, net of
taxes............................................... 1,936 -- 1,936 --
-------- -------- -------- --------
Income available to common stockholders, plus assumed
conversions......................................... $ 70,265 $ 84,435 $130,746 $164,303
-------- -------- -------- --------
Shares (Denominator):
Weighted-average common shares outstanding............ 181,419 177,820 181,160 177,086
Effect of dilutive securities:
Options and equivalents............................. 4,686 1,937 3,948 2,447
Warrants............................................ 319 135 265 170
1.9% convertible debentures......................... 8,785 -- 2,928 --
-------- -------- -------- --------
Weighted-average common shares outstanding, plus
assumed conversions................................. 195,209 179,892 188,301 179,703
-------- -------- -------- --------
Basic earnings per share................................ $ 0.38 $ 0.47 $ 0.71 $ 0.93
======== ======== ======== ========
Diluted earnings per share.............................. $ 0.36 $ 0.47 $ 0.69 $ 0.91
======== ======== ======== ========
</TABLE>
For the three months ended September 30, 1999 and 1998, options to purchase
1,950,000 and 14,717,000 shares, respectively, and for the nine months ended
September 30, 1999 and 1998, options to purchase 6,121,000 and 13,821,000
shares, respectively, with exercise prices greater than the average market price
of common stock, were excluded from the respective computations of diluted
earnings per share as their inclusion would be antidilutive.
Also excluded from the computations of dilutive earnings per share were
3,240,000 and 12,026,000 shares for the three and nine months ended
September 30, 1999 and the three and nine months ended September 30, 1998,
respectively, of common stock issuable upon conversion of the Company's
convertible subordinated debentures as the interest, net of tax, per common
share obtainable on conversion exceeds basic earnings per share.
TREASURY STOCK
Treasury stock is stated at cost. Gains on reissuance of treasury stock are
credited to additional paid-in capital. Losses on reissuance of treasury stock
are charged to additional paid-in capital to the extent of available net gains
on reissuance of treasury stock. Otherwise, losses are charged to accumulated
deficit. For the three and nine months ended September 30, 1999, the Company
charged losses of $17.3 million to accumulated deficit.
10
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 2--DISCONTINUED OPERATIONS
On December 29, 1997, Chiron completed the sale of all of the outstanding
capital stock of Chiron Vision to B&L for approximately $300.0 million in cash,
subject to certain post-closing adjustments. The sale was completed under the
terms of a Stock Purchase Agreement (the "B&L Agreement"), dated as of
October 21, 1997, between Chiron and B&L. Chiron Vision's cash and cash
equivalents totaling $2.7 million, certain Chiron Vision real estate assets (the
"real estate assets") with a carrying value of $25.1 million and Chiron Vision's
future noncancelable operating lease costs totaling $1.1 million were retained
by the Company upon the completion of the sale. The Company has provided
customary indemnities under the terms of the B&L Agreement.
For a period of three years following the completion of the sale, Chiron
Vision has the right to use a portion of the real estate assets, which were
occupied at closing, on a rent-free basis. As of September 30, 1999 and
December 31, 1998, the real estate assets, which represent all of the remaining
net assets of Chiron's discontinued operations, are recorded in the accompanying
Condensed Consolidated Balance Sheets as "Other current assets". In July 1999,
the Company sold a portion of these real estate assets and recognized a gain of
$4.8 million, which includes a net income tax benefit of $2.9 million related to
cumulative differences in the basis of the assets sold.
On November 30, 1998, Chiron completed the sale of its IN VITRO diagnostics
business to Bayer for $1,013.8 million in cash, subject to certain post-closing
adjustments. The sale was completed under the terms of a Stock Purchase
Agreement (the "Bayer Agreement"), dated as of September 17, 1998, between
Chiron and Bayer. The results of operations for Chiron Diagnostics are reported
as a discontinued operation for the three and nine months ended September 30,
1998 in the accompanying Condensed Consolidated Statements of Operations. Chiron
has provided customary indemnities under the terms of the Bayer Agreement.
For the three and nine months ended September 30, 1998, Chiron Diagnostics
recognized total revenues of $134.6 million and $412.8 million, respectively.
For the three and nine months ended September 30, 1998, "Income (loss) from
discontinued operations" are reported net of income tax provisions of less than
$0.1 million and $3.0 million, respectively. For the three months ended
September 30, 1999 and 1998, and for the nine months ended September 30, 1999
and 1998, "Gain on disposal of discontinued operations" includes the sale of the
real estate assets and income tax benefits of $15.3 million, $45.5 million,
$16.0 million and $14.3 million, respectively.
For the three months ended September 30, 1999, basic and diluted earnings
per share from discontinued operations was $0.13 and $0.12, respectively. For
the three months ended September 30, 1998, basic and diluted earnings per share
from discontinued operations was $0.28. For the nine months ended September 30,
1999, basic and diluted earnings per share from discontinued operations was
$0.14. For the nine months ended September 30, 1998, basic and diluted earnings
per share from discontinued operations was $0.58 and $0.57, respectively.
NOTE 3--RESTRUCTURING AND REORGANIZATION CHARGES
In 1999 and 1998, the Company recorded restructuring and reorganization
charges related to the integration of its worldwide vaccines operations, the
closure of its Puerto Rico and St. Louis facilities and the ongoing
rationalization of its business operations. The integration of its worldwide
vaccines operations consisted of termination and other employee-related costs
recognized in connection with the elimination of 28 positions in the Company's
Italian manufacturing facility and facility-related costs. The closure of its
Puerto Rico and St. Louis, Missouri facilities and the ongoing rationalization
of its business operations consisted of termination and
11
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 3--RESTRUCTURING AND REORGANIZATION CHARGES (CONTINUED)
other employee-related costs recognized in connection with the elimination of
400 positions in manufacturing, research and development, sales, marketing, and
other administrative functions, and facility-related costs.
In the nine months ended September 30, 1999, the Company recorded
restructuring and reorganization charges of $2.1 million, which included a
benefit of $1.3 million recorded in the third quarter of 1999 and a charge of
$3.4 million recorded in the first quarter of 1999. The benefit of $1.3 million
related to revised estimates of property and other tax-related accruals recorded
in connection with the idling of the St. Louis facility, as well as revised
estimates of termination and other employee-related costs recorded in connection
with the elimination of 400 positions. As of September 30, 1999, 301 of these
400 positions had been eliminated. The charge of $3.4 million related to
termination and other employee-related costs recognized in connection with the
elimination of 28 positions at the Company's Italian manufacturing facility. As
of September 30, 1999, 20 of these 28 positions had been eliminated.
In the nine months ended September 30, 1998, the Company recorded
restructuring and reorganization charges of $11.3 million, of which $6.4 million
was recognized in the third quarter of 1998, related to the integration of its
worldwide vaccines operations, closure of its Puerto Rico and St. Louis
facilities and the ongoing rationalization of its business operations.
The current status of the accrued restructuring and reorganization charges
is summarized as follows (in thousands):
<TABLE>
<CAPTION>
AMOUNT
AMOUNT OF AMOUNT OF UTILIZED AMOUNT TO
ACCRUAL AT TOTAL TOTAL THROUGH BE UTILIZED
DECEMBER 31, RESTRUCTURING RESTRUCTURING SEPTEMBER 30, IN FUTURE
1998 CHARGE BENEFIT 1999 PERIODS
------------- ------------- ------------- -------------- -----------
<S> <C> <C> <C> <C> <C>
Employee-related costs............... $15,390 $2,826 $ (832) $10,803 $6,581
Other facility-related costs......... 3,931 1,099 (1,031) 1,789 2,210
------- ------ ------- ------- ------
19,321 3,925 (1,863) 12,592 8,791
Discontinued operations.............. 4,475 -- -- 3,789 686
------- ------ ------- ------- ------
$23,796 $3,925 $(1,863) $16,381 $9,477
======= ====== ======= ======= ======
</TABLE>
The liabilities related to restructuring and reorganization charges are
expected to be substantially settled within 12 months of accruing the related
charges.
NOTE 4--AGREEMENT WITH HOECHST AG
Effective July 1, 1996, Chiron purchased a 49% interest in the human vaccine
business of Behringwerke AG, a subsidiary of Hoechst AG. The total acquisition
price, which was paid in cash, was approximately $120.0 million, including costs
directly related to the acquisition. Of the acquisition price, approximately
$97.0 million was allocated to various intangible assets such as goodwill,
trademarks, and patents, and is being amortized on a straight-line basis over
lives ranging from five to 20 years.
From July 1, 1996 through March 31, 1998 (period of joint ownership), Chiron
and Hoechst AG operated the vaccine business as a joint venture under the name
Chiron Behring GmbH & Co. Chiron accounted for its 49% interest under the equity
method and recognized revenues of $2.4 million as a component of "Equity in
earnings of unconsolidated joint businesses" in the accompanying Condensed
Consolidated Statements of Operations for the nine months ended September 30,
1998.
12
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 4--AGREEMENT WITH HOECHST AG (CONTINUED)
In the second quarter of 1998, in an acquisition accounted for under the
purchase method of accounting, Chiron acquired the remaining 51% interest in
Chiron Behring from Hoechst AG. The purchase price of approximately $113.1
million, including acquisition costs, was allocated to the acquired assets and
liabilities assumed based upon their estimated fair value on the date of
acquisition. In connection with the acquisition, liabilities assumed were as
follows (in thousands):
<TABLE>
<S> <C>
Cash acquired............................................... $ 57,119
Fair value of all other assets acquired..................... 206,922
Carrying value of original investment in Chiron Behring..... (117,157)
Cash paid................................................... (111,889)
Acquisition costs........................................... (1,180)
---------
Liabilities assumed......................................... $ 33,815
=========
</TABLE>
At the time of acquisition, Chiron expensed $1.6 million of purchased
in-process technologies. Other purchased intangible assets of approximately
$135.0 million, including goodwill, trademarks, patents, and customer list, are
being amortized over their estimated useful lives of four to 17 years on a
straight-line basis. Chiron Behring's operating results were included in
Chiron's consolidated operating results beginning in the second quarter of 1998.
The following unaudited pro forma information presents the results of
continuing operations of Chiron and Chiron Behring for the nine months ended
September 30, 1998 with pro forma adjustments as if Chiron's acquisition of the
remaining 51% interest in Chiron Behring had been consummated as of January 1,
1998. The pro forma information does not purport to be indicative of what would
have occurred had the acquisition been made as of that date or of results that
may occur in the future. The unaudited pro forma information is as follows (in
thousands, except per share data):
<TABLE>
<CAPTION>
NINE MONTHS ENDED
SEPTEMBER 30, 1998
-------------------
<S> <C>
Total revenues.............................................. $546,108
Income from continuing operations........................... $ 79,227
Pro forma earnings per share from continuing operations:
Basic..................................................... $ 0.45
Diluted................................................... $ 0.44
</TABLE>
NOTE 5--SEGMENT INFORMATION
Chiron is organized based on the products and services that it offers. Under
this organizational structure, the Company has the following three reportable
segments: (i) biopharmaceuticals, (ii) vaccines, and (iii) blood testing. The
biopharmaceuticals segment consists of products and services related to
therapeutics, with an emphasis on oncology, serious infectious diseases, and
cardiovascular diseases as well as the development and acquisition of
technologies related to recombinant proteins, gene therapy, small molecules and
genomics. The vaccines segment consists principally of products and services
related to adult and pediatric vaccines sold primarily in Germany and Italy, and
also sold in other international markets. The blood testing segment consists of
an alliance with Gen-Probe Incorporated ("Gen-Probe") and Chiron's one-half
interest in the pretax operating earnings of its joint business with
Ortho-Clinical Diagnostics, Inc. ("Ortho"), a Johnson & Johnson company.
Chiron's alliance with Gen-Probe is focused on developing and selling products
using nucleic acid
13
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 5--SEGMENT INFORMATION (CONTINUED)
testing ("NAT") to screen blood and plasma for infection by viruses. Chiron's
joint business with Ortho sells a line of immunodiagnostic tests, other than
nucleic acid tests, required to screen blood for hepatitis viruses and
retroviruses, and provides supplemental tests and microplate-based instrument
systems to automate test performance and data collection.
Certain revenues and expenses, particularly Novartis research and
development funding, certain royalty revenues, and unallocated corporate
expenses, are not viewed by management as belonging to any one reportable
segment. As a result, these items have been aggregated into an "Other" segment,
as permitted by Statement of Financial Accounting Standards No. 131,
"Disclosures about Segments of an Enterprise and Related Information" ("SFAS
131").
The accounting policies of the Company's reportable segments are the same as
those described in Note 1--The Company and Summary of Significant Accounting
Policies. Chiron evaluates the performance of its segments based on each
segment's income (loss) from continuing operations, excluding certain special
items, such as the write-off of purchased in-process technologies and
restructuring and reorganization charges, which are shown as reconciling items
in the table below.
The following segment information excludes all significant intersegment
transactions as these transactions are eliminated for management reporting
purposes (in thousands):
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------- -------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C>
REVENUES
Biopharmaceuticals, includes equity in earnings of
unconsolidated joint businesses of $33 and $0 for the
three and nine months ended September 30, 1998,
respectively............................................. $ 59,921 $ 69,773 $215,576 $222,868
Vaccines, includes equity in earnings of unconsolidated
joint businesses of $319 and ($485) for the three months
ended September 30, 1999 and 1998, respectively, and $963
and $304 for the nine months ended September 30, 1999 and
1998, respectively....................................... 84,692 72,217 188,873 142,295
Blood testing, includes equity in earnings of
unconsolidated joint businesses of $22,978 and $21,707
for the three months ended September 30, 1999 and 1998,
respectively, and $57,468 and $51,189 for the nine months
ended September 30, 1999 and 1998, respectively.......... 32,943 28,302 83,594 69,706
Other...................................................... 26,820 45,678 81,003 77,278
-------- -------- -------- --------
Total revenues............................................. $204,376 $215,970 $569,046 $512,147
======== ======== ======== ========
</TABLE>
14
<PAGE>
CHIRON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
SEPTEMBER 30, 1999
(UNAUDITED)
NOTE 5--SEGMENT INFORMATION (CONTINUED)
The following segment information excludes all significant intersegment
transactions as these transactions are eliminated for management reporting
purposes (in thousands):
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------- -------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C>
INCOME FROM CONTINUING OPERATIONS
Biopharmaceuticals........................................ $(22,941) $10,306 $(27,708) $ 23,953
Vaccines.................................................. 13,187 (719) (3,093) (35,758)
Blood testing............................................. 21,167 19,555 47,765 47,889
Other..................................................... 19,637 24,493 61,354 43,688
-------- ------- -------- --------
Segment income from operations.......................... 31,050 53,635 78,318 79,772
Operating income (expense) reconciling items:
Write-off of purchased in-process technologies.......... -- -- -- (1,645)
Restructuring and reorganization charges................ 1,290 (6,401) (2,062) (11,339)
-------- ------- -------- --------
Income from operations.................................... 32,340 47,234 76,256 66,788
Gain on sale of assets.................................. -- 1,510 -- 7,751
Interest expense........................................ (6,158) (6,009) (17,866) (18,638)
Other income, net....................................... 19,685 5,035 63,061 21,196
-------- ------- -------- --------
Income from continuing operations before income taxes..... $ 45,867 $47,770 $121,451 $ 77,097
======== ======= ======== ========
</TABLE>
NOTE 6--CONTINGENCIES
The Company is party to various claims, investigations, and legal
proceedings arising in the ordinary course of business. These claims,
investigations, and legal proceedings relate to intellectual property rights,
contractual rights and obligations, employment matters, claims of product
liability, and other issues. While there is no assurance that an adverse
determination of any of such matters could not have a material adverse impact in
any future period, management does not believe, based upon information known to
it, that the final resolution of any of these matters will have a material
adverse effect upon the Company's consolidated financial position and annual
results of operations and cash flows.
NOTE 7--SUBSEQUENT EVENTS
In February 1999, the Company's Board of Directors authorized the repurchase
of up to 2.5 million shares of Chiron common stock from time to time on the open
market to offset the dilution associated with the operation of the Company's
stock option and employee stock purchase plans and the granting of share rights.
Effective October 7, 1999, the Company's Board of Directors approved a 4.0
million share increase, thereby bringing the total number of shares authorized
for repurchase to 6.5 million shares.
On November 1, 1999, the Company entered into a patent and license
agreement. Under this agreement, the Company will pay $12.5 million, consisting
of $5.0 million in cash and $7.5 million as a forgiveable note payable to the
licensor, in licensing fees. In addition, the Company may make total payments of
$12.0 million if certain development objectives are met.
15
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
THIS QUARTERLY REPORT ON FORM 10-Q CONTAINS FORWARD-LOOKING STATEMENTS.
THESE INCLUDE STATEMENTS CONCERNING PLANS, OBJECTIVES, GOALS, STRATEGIES, FUTURE
EVENTS OR PERFORMANCE, AND ALL OTHER STATEMENTS WHICH ARE OTHER THAN STATEMENTS
OF HISTORICAL FACT, INCLUDING, WITHOUT LIMITATION, STATEMENTS CONTAINING WORDS
SUCH AS "BELIEVES", "ANTICIPATES", "EXPECTS", "ESTIMATES", "PROJECTS", "WILL",
"MAY", "MIGHT", AND WORDS OF A SIMILAR NATURE. THE FORWARD-LOOKING STATEMENTS
CONTAINED IN THIS REPORT REFLECT MANAGEMENT'S CURRENT BELIEFS AND EXPECTATIONS
ON THE DATE OF THIS REPORT. ACTUAL RESULTS, PERFORMANCE OR OUTCOMES MAY DIFFER
MATERIALLY FROM THOSE EXPRESSED IN THE FORWARD-LOOKING STATEMENTS. SOME OF THE
IMPORTANT FACTORS WHICH, IN THE VIEW OF CHIRON CORPORATION ("CHIRON" OR THE
"COMPANY"), COULD CAUSE ACTUAL RESULTS TO DIFFER ARE DISCUSSED UNDER THE CAPTION
"FACTORS THAT MAY AFFECT FUTURE RESULTS." THE COMPANY UNDERTAKES NO OBLIGATION
TO PUBLICLY ANNOUNCE ANY REVISIONS TO THESE FORWARD-LOOKING STATEMENTS TO
REFLECT FACTS OR CIRCUMSTANCES OF WHICH MANAGEMENT BECOMES AWARE AFTER THE DATE
THEREOF.
THE DISCUSSION BELOW SHOULD BE READ IN CONJUNCTION WITH PART I, ITEM
1,"FINANCIAL STATEMENTS", OF THIS QUARTERLY REPORT ON FORM 10-Q AND PART II,
ITEMS 7, 7A, AND 8, "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS", "QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK", AND "FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA", RESPECTIVELY,
OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED JANUARY 3, 1999.
Chiron is a biotechnology company that participates in three global
healthcare businesses: biopharmaceuticals, vaccines, and blood testing. The
biopharmaceuticals segment consists of products and services related to
therapeutics, with an emphasis on oncology, serious infectious diseases, and
cardiovascular diseases as well as the development and acquisition of
technologies related to recombinant proteins, gene therapy, small molecules and
genomics. The vaccines segment consists principally of adult and pediatric
vaccines sold primarily in Germany and Italy, and also sold in other
international markets. The blood testing segment consists of an alliance with
Gen-Probe Incorporated ("Gen-Probe") and Chiron's one-half interest in the
pretax operating earnings of its joint business with Ortho-Clinical
Diagnostics, Inc. ("Ortho"), a Johnson & Johnson company. Chiron's alliance with
Gen-Probe is focused on developing and selling products using nucleic acid
testing ("NAT") to screen blood and plasma for infection by viruses. Chiron's
joint business with Ortho sells a line of immunodiagnostic tests, other than
nucleic acid tests, required to screen blood for hepatitis viruses and
retroviruses, and provides supplemental tests and microplate-based instrument
systems to automate test performance and data collection.
On December 29, 1997, Chiron completed the sale of its ophthalmics business
("Chiron Vision") to Bausch & Lomb Incorporated ("B&L") and on November 30,
1998, Chiron completed the sale of its IN VITRO diagnostics business ("Chiron
Diagnostics") to Bayer Corporation ("Bayer"). The Company's Condensed
Consolidated Statements of Operations reflect the after-tax results of Chiron
Diagnostics as discontinued operations for the three and nine months ended
September 30, 1998.
On March 31, 1998, in an acquisition accounted for under the purchase method
of accounting, Chiron acquired the remaining 51% interest in Chiron Behring GmbH
& Co ("Chiron Behring") from Hoechst AG. Beginning in the second quarter of
1998, the results of Chiron Behring were consolidated with those of the Company.
RESULTS OF OPERATIONS
REVENUES
BIOPHARMACEUTICAL PRODUCT SALES For the three months ended September 30,
1999 and 1998, product sales from the biopharmaceuticals segment were $36.6
million and $46.8 million, respectively. For the nine months ended
September 30, 1999 and 1998, biopharmaceutical product sales were $134.6 million
and $144.1 million, respectively. In 1999 and 1998, biopharmaceutical product
sales consisted principally of Proleukin-Registered Trademark-(aldesleukin,
interleukin-2), Betaseron-Registered Trademark- (interferon beta-1b) and PDGF
(recombinant human platelet-derived growth factor -rhPDGF-BB).
16
<PAGE>
PROLEUKIN-REGISTERED TRADEMARK- Chiron sells Proleukin-Registered
Trademark- directly in the U.S. and certain international markets. For the three
months ended September 30, 1999 and 1998, sales of Proleukin-Registered
Trademark- were $18.7 million and $22.3 million, respectively. For the nine
months ended September 30, 1999 and 1998, sales of Proleukin-Registered
Trademark- were $81.8 million and $66.2 million, respectively. Management
believes that the third quarter 1999 decrease in Proleukin-Registered Trademark-
product sales as compared with 1998 is primarily due to a shift in purchases by
distributors from the third quarter 1999 to the second quarter 1999 in
anticipation of the July 1999 price increase. Impacting the year-to-date
increase in Proleukin-Registered Trademark- product sales are continued volume
growth in existing indications, price increases which occurred during the
period, and expansion into additional countries. The Company continues to pursue
the use of Proleukin-Registered Trademark- for additional indications, including
human immunodeficiency virus ("HIV"). The Company also anticipates further
geographic expansion of Proleukin-Registered Trademark- into additional
countries.
BETASERON-REGISTERED TRADEMARK- Chiron manufactures Betaseron-Registered
Trademark- for Berlex Laboratories, Inc. ("Berlex") and its parent company,
Schering AG of Germany. Chiron earns a partial payment for Betaseron-Registered
Trademark- upon shipment to Berlex and Schering AG and a subsequent additional
payment upon sales by Berlex and Schering AG. Accordingly, Chiron's revenues
from Betaseron-Registered Trademark- tend to fluctuate based upon the inventory
management practices of Berlex and Schering AG. For the three months ended
September 30, 1999 and 1998, revenues from Betaseron-Registered Trademark- were
$17.9 million and $15.3 million, respectively. For the nine months ended
September 30, 1999 and 1998, revenues from Betaseron-Registered Trademark- were
$46.5 million and $46.6 million, respectively. Management believes that the
increase in Betaseron-Registered Trademark- revenues in the third quarter 1999
as compared with the third quarter 1998 is primarily related to the approval of
Betaseron-Registered Trademark- for secondary progressive multiple sclerosis in
Europe, Canada and Australia in 1999.
PDGF Chiron manufactures PDGF for Ortho-McNeil Pharmaceutical, Inc., a
Johnson & Johnson ("J&J") company. PDGF is the active ingredient in
Regranex-Registered Trademark-(becaplermin) Gel, a treatment for diabetic foot
ulcers. Regranex-Registered Trademark- Gel was approved by the FDA in
December 1997 and was launched commercially in early 1998. Sales of PDGF to J&J
decreased $9.8 million from the three months ended September 30, 1998 to the
three months ended September 30, 1999 and $27.2 million from the nine months
ended September 30, 1998 to the nine months ended September 30, 1999. The third
quarter 1999 and year-to-date activity in PDGF sales are primarily related to a
lack of orders from J&J in 1999 and an increase in the product returns allowance
in the third quarter 1999. The increase to the product returns allowance is
primarily due to additional historical return information, now that PDGF has
been in the commercial market for over 12 months. As Regranex-Registered
Trademark- is the first product of its kind, the Company believes it will take
time for the market to fully develop. In addition, Chiron's sales of PDGF will
tend to fluctuate based upon the inventory management practices of J&J.
Regranex-Registered Trademark- Gel was recently approved for use in the
treatment of diabetic foot ulcers in Canada and Europe. However, even with these
approvals, Chiron's sales to date have largely filled J&J's initial inventory
requirements for product launch, and as a result, no significant sales of PDGF
to J&J are expected until the second quarter of 2000.
VACCINE PRODUCT SALES Chiron sells pediatric and adult vaccines in Germany,
Italy, other international markets, and in the U.S. Certain of the Company's
vaccine products, particularly its flu vaccine, are seasonal and typically have
higher sales in the third quarter of the year. For the three months ended
September 30, 1999 and 1998, vaccine product sales were $70.6 million and $60.7
million, respectively. The increase in product sales for the three months ended
September 30, 1999 as compared with the same period in 1998 is primarily due to
the change in timing of reporting the results of the Company's Italian
subsidiary. Historically, the results of the Company's Italian subsidiary were
reported on a one-month lag; however, during the first quarter 1999, the Company
eliminated the lag such that these results are now reported on a current basis.
As a result of this change, the Company recorded a significant amount of flu
vaccine sales during the third quarter 1999, which were historically recorded
during the fourth quarter.
For the nine months ended September 30, 1999 and 1998, vaccine product sales
were $153.8 million and $119.1 million, respectively. The increase in sales for
the nine months ended September 30, 1999 as compared with the same period in
1998 is primarily due to the change in timing of reporting the results of the
Company's Italian subsidiary (see above) and Chiron's acquisition of the
remaining 51% interest in, and consolidation of, Chiron Behring during the
second quarter of 1998. Also affecting vaccine product sales for the nine months
ended September 30, 1999 was a one-time $4.2 million sale of adult influenza
vaccine to Argentina in the first quarter 1999.
17
<PAGE>
In August 1999, Chiron filed an application for approval to market
Menjugate-TM-, its vaccine against meningococcal meningitis caused by the
bacterium N. MENINGITIDIS serogroup C, in the United Kingdom. The Company has
received orders for Menjugate-TM- shipments, which are scheduled to begin in
March 2000. These orders are subject to final approval by the United Kingdom's
Medicines Control Agency ("MCA"). There can be no assurance as to the receipt of
regulatory approval or the timing of any such regulatory approval.
BLOOD TESTING PRODUCT SALES During the second quarter 1999, the Company
began recognizing revenues for sales of its nucleic acid tests that are used to
screen blood and plasma under an investigational new drug ("IND") application in
the U.S. Product sales related to these tests were $2.0 million and $3.9 million
for the three and nine months ended September 30, 1999, respectively.
As with any new product, there can be no assurance that healthcare providers
will adopt the Company's nucleic acid testing technology. In addition, sales of
the Company's nucleic acid tests may be affected by the presence of a
competitive product, the availability of reimbursement from the government and
government regulations relating to the pricing of healthcare products.
EQUITY IN EARNINGS OF UNCONSOLIDATED JOINT BUSINESSES For the three months
ended September 30, 1999 and 1998, Chiron recognized equity in earnings of
unconsolidated joint businesses of $23.3 million and $21.3 million,
respectively. For the nine months ended September 30, 1999 and 1998, Chiron
recognized equity in earnings of unconsolidated joint businesses of $58.4
million and $51.5 million, respectively. In 1999, equity in earnings of
unconsolidated joint businesses consisted substantially of revenues generated by
Chiron's joint business with Ortho. In 1998, equity in earnings of
unconsolidated joint businesses also included one quarter of earnings from
Chiron's 49% share of the after-tax operating results of Chiron Behring.
CHIRON-ORTHO JOINT BUSINESS For the three months ended September 30, 1999
and 1998, Chiron's earnings from its joint business with Ortho were $23.0
million and $21.7 million, respectively. For the nine months ended
September 30, 1999 and 1998, these earnings were $57.5 million and $51.2
million, respectively. The overall fluctuations in earnings from the joint
business are primarily due to certain adjustments made during the first quarters
of 1999 and 1998. In the first quarter 1999, an annual inventory adjustment
resulted in a charge of $0.7 million as compared with a charge of $4.1 million
recognized in the first quarter 1998. Also contributing to the increase in
earnings in 1999 as compared with 1998, were higher foreign affiliate profits
and a first-quarter 1998 one-time contract termination fee.
CHIRON BEHRING On July 1, 1996, Chiron acquired a 49% interest in Chiron
Behring. On March 31, 1998, Chiron acquired the remaining 51% interest in Chiron
Behring (refer to Note 4 of "Notes to Condensed Consolidated Financial
Statements"). From July 1, 1996 through the first quarter 1998, equity in
earnings of unconsolidated joint businesses included Chiron's 49% share of the
after-tax operating results of Chiron Behring. Chiron's share of earnings from
the joint business, including amortization of intangibles, was $2.4 million for
the three months ended March 31, 1998. Beginning in the second quarter 1998,
Chiron Behring's results were consolidated with those of the Company.
COLLABORATIVE AGREEMENT REVENUES Chiron recognizes collaborative agreement
revenues for fees received for research services as they are performed and fees
received upon the achievement of specified milestones. For the three months
ended September 30, 1999 and 1998, Chiron recognized collaborative agreement
revenues of $18.4 million and $24.3 million, respectively. For the nine months
ended September 30, 1999 and 1998, collaborative agreement revenues were $59.6
million and $73.1 million, respectively. The decrease in collaborative agreement
revenues in 1999 as compared with 1998 is partially due to a contractual
decrease in payments received by the Company under a November 1996 consent
agreement between Chiron, Novartis AG ("Novartis"), and the Federal Trade
Commission related to the Herpes Simplex Virus-thymidine kinase (HSV-tk) gene in
the field of gene therapy (for more information, refer to the Company's Annual
Report on Form 10-K for the year ended January 3, 1999).
The remaining decrease is primarily due to an agreement with Novartis, under
which Novartis agreed to provide research funding for certain projects through
1999 (for more information, refer to the Company's Annual Report on Form 10-K
for the year ended January 3, 1999). In September 1999, Chiron and Novartis
determined to amend this agreement. This amendment will increase the aggregate
maximum amount of funding provided by Novartis from $250.0 million to $265.0
million. Under this agreement, for the three months ended
18
<PAGE>
September 30, 1999 and 1998, Chiron recognized collaborative agreement revenues
of $10.0 million and $15.6 million, respectively. For the nine months ended
September 30, 1999 and 1998, revenues recognized under this agreement were $39.0
million and $47.2 million, respectively.
Collaborative agreement revenues tend to fluctuate based on the amount of
research services performed, the status of projects under collaboration, and the
achievement of milestones. Due to the nature of the Company's collaborative
agreement revenues, results in any one period are not necessarily indicative of
results to be achieved in the future. The Company's ability to generate
additional collaborative agreement revenues may depend, in part, on its ability
to initiate and maintain relationships with potential and current collaborative
partners. There can be no assurance that such relationships will be established
or that current collaborative agreement revenues will not decline. In
particular, the research funding agreement with Novartis (see above) expires by
its terms on December 31, 1999, and there can be no assurance that new
relationships will be established.
ROYALTY AND LICENSE FEE REVENUES The Company receives royalties and license
fees for products or technologies that are marketed, distributed, or used by
third parties. For the three months ended September 30, 1999 and 1998, Chiron
recognized royalty and license fee revenues of $36.5 million and $49.8 million,
respectively. For the nine months ended September 30, 1999 and 1998, royalty and
license fee revenues were $96.3 million and $81.3 million, respectively. The
increase in royalty and license fee revenues in 1999 as compared with 1998 is
primarily due to a cross-license agreement with Bayer whereby Chiron agreed to
grant to Bayer rights under certain Chiron patents, including rights under
patents relating to HIV and hepatitis C virus. In exchange for these rights,
Bayer paid to Chiron a license fee of $100.0 million, which is refundable in
decreasing amounts over a period of three years. During the three and nine
months ended September 30, 1999, Chiron recognized license fee revenues of $10.0
million and $30.0 million, respectively, which represent the portions of the
$100.0 million payment that became nonrefundable during the periods. For the
three months ended September 30, 1999, other items contributing to royalty and
license fee revenues were $7.3 million of royalties generated from Schering AG's
European sales of Betaferon-Registered Trademark- and $5.8 million of royalties
related to Chiron's vaccine products. For the nine months ended September 30,
1999, other items contributing to royalty and license fee revenues were $21.4
million of royalties generated from Schering AG's European sales of
Betaferon-Registered Trademark-, $9.9 million of royalties related to insulin
products, and $15.4 million related to vaccine products. In the third quarter
1998, Chiron recognized $24.0 million related to a license fee received from
SmithKline Beecham to use certain human vaccine product technologies. In the
first quarter 1998, Chiron recognized $5.0 million related to a license fee
received from Pharmacia & Upjohn Company to research, develop, manufacture, and
commercialize therapeutic products for the treatment of hepatitis C virus in
humans.
Royalty and license fee revenues may fluctuate based on the nature of the
related agreements and the timing of receipt of license fees. Results in any one
period are not necessarily indicative of results to be achieved in the future.
In addition, the Company's ability to generate additional royalty and license
fee revenues may depend, in part, on its ability to market and capitalize on its
technologies. There can be no assurance that the Company will be able to do so
or that future royalty and license fee revenue will not decline.
OTHER REVENUES For the three months ended September 30, 1999 and 1998,
Chiron recognized other revenues of $12.1 million and $7.9 million,
respectively. For the nine months ended September 30, 1999 and 1998, these
revenues were $46.4 million and $28.1 million, respectively. Contributing to the
increase in other revenues were contract manufacturing revenues which increased
to $2.2 million in the third quarter 1999 from $0.1 million in the comparable
period in 1998 as a result of a new contract manufacturing agreement. Also
included in other revenues during the third quarters 1999 and 1998 were
approximately $6.8 million and $5.9 million, respectively, of commission
revenues received on sales of hepatitis B products and immunoglobulin products.
For the nine months ended September 30, 1999, other revenues primarily
consisted of a $9.7 million milestone payment related to the FDA's approval of
DepoCyt-Registered Trademark- in April 1999, $10.7 million related to contract
manufacturing and $18.0 million related to commission revenues. For the nine
months ended September 30, 1998, other revenues primarily consisted of $9.8
million of revenues related to Aredia-Registered Trademark- (pamidronate
disodium for injection) recognized under an arrangement which terminated in
April 1998, pursuant to which Chiron promoted Aredia-Registered Trademark- on
behalf of Novartis, and $12.2 million of commission revenues.
19
<PAGE>
In October 1999, SkyePharma, Inc. ("SkyePharma"), the manufacturer of
DepoCyt-Registered Trademark-, discovered two DepoCyt-Registered Trademark- lots
that did not meet manufacturing specifications and, as a result, recalled all
DepoCyt-Registered Trademark- vials from these lots. The commercial supply of
this product is on hold while the Company and SkyePharma investigate the cause.
Management of the Company does not believe that this event will have a material
impact on the results of operations for fiscal year 1999. The impact of this
event on future shipments of DepoCyt-Registered Trademark- is not yet known.
The Company's other revenues may fluctuate due to the nature of the revenues
recognized and the timing of events giving rise to these revenues. There can be
no guarantee that the Company will be successful in obtaining additional
revenues or that these revenues will not decline.
COSTS AND EXPENSES
GROSS PROFIT For the three months ended September 30, 1999 and 1998, gross
profit as a percentage of net product sales was 53% and 55%, respectively. For
each of the nine months ended September 30, 1999 and 1998, gross profit as a
percentage of net product sales was 55%. In the third quarter 1999, Chiron
recognized a $2.7 million reduction in sales related to the PDGF product returns
allowance. Excluding this reduction, gross profit as a percentage of sales would
have been 54% for the three months ended September 30, 1999. In the third
quarter 1998, Chiron recognized a $3.3 million reduction in cost of goods sold
related to a change in estimated property tax accruals created in prior periods.
Excluding this reduction, gross profit as a percentage of net product sales
would have been 53% for the three months ended September 30, 1998. Also
impacting Chiron's gross profit for the nine months ended September 30, 1998 was
a $6.0 million reduction in cost of goods sold related to a change in estimated
property tax accruals created in prior periods. Excluding this reduction, gross
profit as a percentage of net product sales would have been 53% for the nine
months ended September 30, 1998.
The increase in gross profit margins in the third quarter 1999 as compared
to the third quarter 1998 is primarily related to a significant improvement in
vaccine product gross profit due to manufacturing efficiencies resulting from
increased production and a favorable mix of vaccine product sales. The increase
in gross profit margins during the nine months ended September 30, 1999 as
compared to the nine months ended September 30, 1998 is primarily related to
(i) a slight increase in sales of biopharmaceutical products as a percentage of
sales and biopharmaceutical product gross profit; and (ii) a significant
improvement in vaccine product gross profit due to manufacturing efficiencies
resulting from increased production and a favorable mix of vaccine product
sales.
The Company's gross profit percentages may fluctuate significantly in future
periods as the Company's product mix continues to evolve.
RESEARCH AND DEVELOPMENT For the three months ended September 30, 1999 and
1998, Chiron recognized research and development expenses of $75.5 million and
$67.3 million, respectively. For the nine months ended September 30, 1999 and
1998, Chiron's research and development expenses were $216.7 million and $196.2
million, respectively. The Company's research and development expenses may
fluctuate from period to period depending upon the stage of certain projects and
the level of clinical trial-related activities. The increase in research and
development spending in 1999 as compared with 1998 was due, in part, to $2.6
million and $3.0 million milestone payments made during the third and second
quarters of 1999, respectively, related to the Company's collaboration agreement
with Medivir AB. Also contributing to the increase in research and development
expense was the furtherance of the Company's clinical trials related to
Proleukin-Registered Trademark- for HIV, Insulin-Like Growth Factor-1 ("IGF-1")
for osteoarthritis, Fibroblast Growth Factor ("FGF") for coronary artery disease
and Tissue Factor Pathway Inhibitor ("TFPI") for sepsis.
In November 1999, Chiron entered into a patent and license agreement
relating to FGF. Under this agreement, the Company will pay $12.5 million,
consisting of $5.0 million in cash and $7.5 million as a forgiveable note
payable, in licensing fees to Scios, Inc. In addition, Chiron may make total
payments of $12.0 million if certain development objectives are met.
SELLING, GENERAL, AND ADMINISTRATIVE For the three months ended
September 30, 1999 and 1998, Chiron recognized selling, general, and
administrative ("SG&A") expenses of $41.8 million and $40.7 million,
respectively. For the nine months ended September 30, 1999 and 1998, Chiron
recognized SG&A expenses of
20
<PAGE>
$128.6 million and $103.5 million, respectively. The increase in SG&A expenses
in 1999 as compared with 1998 is primarily due to the acquisition and
consolidation of Chiron Behring, which contributed $10.2 million to SG&A
expenses. SG&A expenses also increased as a result of the Company's worldwide
implementation of its integrated information system in April 1999, the launch of
DepoCyt-Registered Trademark- and the nucleic acid testing segment of its blood
testing business, and certain patent defense legal costs.
OTHER OPERATING EXPENSES In the nine months ended September 30, 1999, the
Company recorded restructuring and reorganization charges of $2.1 million, which
included a benefit of $1.3 million recorded in the third quarter 1999 and a
charge of $3.4 million recorded in the first quarter 1999. The benefit of $1.3
million related to revised estimates of property and other tax-related accruals
recorded in connection with the idling of the St. Louis facility, as well as
revised estimates of termination and other employee-related costs recorded in
connection with the elimination of 400 positions. As of September 30, 1999, 301
of these 400 positions had been eliminated. The charge of $3.4 million related
to termination and other employee-related costs recognized in connection with
the elimination of 28 positions at the Company's Italian manufacturing facility.
As of September 30, 1999, 20 of these 28 positions had been eliminated. In the
nine months ended September 30, 1998, the Company recorded restructuring and
reorganization charges of $11.3 million, of which $6.4 million was recognized in
the third quarter 1998, related to the integration of its worldwide vaccines
operations, closure of its Puerto Rico and St. Louis facilities and the ongoing
rationalization of its business operations.
During the three and nine months ended September 30, 1999, Chiron recognized
a reduction in other operating expenses of $2.0 million and $8.4 million,
respectively, resulting from a change in estimated tax accruals related to
certain employee payments recorded in 1995 under a series of agreements between
Chiron and Novartis (for more information, refer to the Company's Annual Report
on Form 10-K for the year ended January 3, 1999).
NON-OPERATING INCOME AND EXPENSE
Other income, net, primarily consists of interest and investment income on
the Company's cash and investment balances and other non-operating gains and
losses. For the three months ended September 30, 1999 and 1998, Chiron
recognized interest and investment income of $20.2 million and $5.7 million,
respectively. For the nine months ended September 30, 1999 and 1998, interest
and investment income totaled $60.9 million and $20.0 million, respectively. The
increase in interest and investment income in 1999 as compared with 1998 is
primarily due to higher average cash and investment balances attributable to the
net cash proceeds received from the sale of Chiron Diagnostics in
November 1998. Interest expense remained fairly constant at $6.2 million and
$6.0 million for the three months ended September 30, 1999 and 1998,
respectively, and $17.9 million and $18.6 million for the nine months ended
September 30, 1999 and 1998, respectively.
INCOME TAXES
The 1999 estimated annual tax provision is expected to be approximately 27%
of pretax income from continuing operations, prior to the recognition of
deferred tax assets through a reduction in the valuation allowance associated
with such assets. The actual tax provision for the three and nine months ended
September 30, 1999 includes the reduction in the state deferred tax asset
valuation allowance of $9.1 million and $14.4 million, respectively. The
valuation allowance was reduced because management believes that it is more
likely than not that the deferred tax assets to which the valuation allowance
related will be realized.
NEW ACCOUNTING STANDARD
In June 1998, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 133, "Accounting for Derivative Instruments
and Hedging Activities" ("SFAS 133"), which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments
embedded in other contracts, and for hedging activities. In June 1999, SFAS 133
was amended by SFAS No. 137, "Accounting for Derivative Instruments and Hedging
Activities--Deferral of the Effective Date of SFAS 133". As a result of this
amendment, SFAS 133 shall be effective for all fiscal quarters of all fiscal
years beginning after June 15, 2000.
21
<PAGE>
In accordance with SFAS 133, an entity is required to recognize all
derivatives as either assets or liabilities in the statement of financial
position and measure those instruments at fair value. SFAS 133 requires that
changes in the derivative's fair value be recognized currently in earnings
unless specific hedge accounting criteria are met. Special accounting for
qualifying hedges allows a derivative's gains and losses to offset related
results on the hedged item in the income statement, and requires that a company
formally document, designate, and assess the effectiveness of transactions that
receive hedge accounting. The Company is currently evaluating the effect that
implementation of SFAS 133 will have on its results of operations and financial
position and anticipates that it will implement SFAS 133 during the first fiscal
quarter of 2001.
LIQUIDITY AND CAPITAL RESOURCES
Chiron's capital requirements have generally been funded from operations,
cash and investments on hand, debt borrowings, issuance of common stock, and
off-balance sheet financing. Chiron's cash and investments in marketable debt
securities, which totaled $1.6 billion at September 30, 1999, are invested in a
diversified portfolio of investment grade financial instruments, including money
market instruments, corporate notes and bonds, government or government agency
securities, and other debt securities. By policy, the amount of credit exposure
to any one institution is limited; however, these investments are generally not
collateralized and primarily mature within three years.
SOURCES AND USES OF CASH
Chiron had cash and cash equivalents of $205.8 million and $80.5 million at
September 30, 1999 and 1998, respectively. Through the nine months ended
September 30, 1999, net cash used in operating activities was $37.1 million as
compared with net cash provided by operating activities of $85.8 million in
1998. Through the nine months ended September 30, 1999, the Company paid $179.7
million in estimated taxes primarily related to the sale of the Company's IN
VITRO diagnostics business. This use of cash was partially offset by $54.0
million in federal and state tax refunds received and net income of $128.8
million for the nine months ended September 30, 1999.
Through the nine months ended September 30, 1999, net cash used in investing
activities consisted of purchases of investments in marketable debt securities
of $1.1 billion, capital expenditures of $55.7 million, and other uses of cash
of $11.1 million. Partially offsetting these uses of cash were proceeds from the
sale and maturity of investments in marketable debt securities of $867.4 million
and proceeds from disposal of discontinued operations of $46.9 million.
Through the nine months ended September 30, 1999, net cash provided by
financing activities primarily consisted of $68.1 million from the issuance of
common stock and the reissuance of treasury stock related to stock option
exercises, $7.9 million related to short-term borrowings and $8.1 million in
proceeds from the issuance of long-term debt. This was partially offset by $2.0
million related to the repayment of debt and capital leases and $69.1 million
related to the acquisition of treasury stock.
In February 1999, the Company's Board of Directors authorized the repurchase
of up to 2.5 million shares of Chiron common stock from time to time on the open
market to offset the dilution associated with the operation of the Company's
stock option and employee stock purchase plans and the granting of share rights.
In October 1999, the Board of Directors approved a 4.0 million share increase,
thereby bringing the total number of shares authorized for repurchase to 6.5
million shares. As of September 30, 1999, 2.5 million shares had been
repurchased.
The Company is currently evaluating a number of business development
opportunities. To the extent that the Company is successful in reaching
agreements with third parties, these transactions may involve the expenditure of
a significant amount of the Company's current investment portfolio.
BORROWING ARRANGEMENTS
Under a revolving, committed, unsecured credit agreement with a major
financial institution, Chiron can borrow up to $100.0 million in the U.S. This
credit facility is guaranteed by Novartis under a November 1994 Investment
Agreement, provides various interest rate options, and matures in
February 2003. There were no
22
<PAGE>
borrowings outstanding under this credit facility at September 30, 1999. Chiron
also has credit facilities outside the U.S. which allow for total borrowings of
$63.1 million. Under these credit facilities, $22.7 million of borrowings were
outstanding at September 30, 1999.
In September 1999, Chiron and Novartis determined to amend the
November 1994 Investment Agreement. This amendment will reduce the maximum
amount of Chiron obligations that Novartis will guarantee from $725.0 million to
$702.5 million.
YEAR 2000
Chiron is dependent on a number of computer systems and applications to
conduct its business. In the past, many computer programs were written using two
digits rather than four to identify the relevant year. These programs may not be
able to distinguish between 21st and 20th century dates (for example, "00" may
be read as the year 1900 when the year 2000 is intended). This could result in
significant system failures or miscalculations. Accordingly, the Company has
developed a comprehensive risk-based plan designed to make its computer hardware
and communication systems, software applications, and facilities and other
non-information technology-related functions Year 2000 compliant. The plan
covers three phases including (i) planning, (ii) assessment, and
(iii) implementation. The Company has completed the planning and assessment
phases and has substantially completed the implementation phase. With regard to
the Company's computer hardware and communication systems, Chiron has completed
its initial technology refresh program which was developed in conjunction with
International Business Machines, Inc. ("IBM") to update and standardize the
Company's computer hardware and communication systems. In the third quarter
1999, the Company continued its technology refresh program, which it will
complete in November 1999. With regard to the Company's software applications,
the Company has identified critical and non-critical software applications and
has remediated all mission critical and substantially all non-critical
applications in all material respects. Certain non-critical user specific
applications based on compliant software platforms are in testing and will be
completed in November 1999.
With regard to the Company's key facilities and other non-information
technology-related functions, including research, manufacturing, and inventory
management practices, the Company has completed its remediation plans for its
critical systems and substantially completed its remediation plans for its
non-critical systems. Some non-critical embedded systems remediation has been
rescheduled to November 1999 due to manufacturing schedules and vendor changes.
The Company has a facility in Amsterdam, The Netherlands, which is currently
being marketed for sale. Due to the Company's manufacturing requirements, the
Company plans to operate this facility until the end of 1999, at which time, the
Company intends to complete certain upgrades within its embedded systems. The
Company believes that it will be able to sell the facility in its current state
and does not consider this facility to be a significant Year 2000 risk.
The Company is using both internal and external resources to prepare for the
Year 2000. Although the Company believes that it should be able to substantially
complete the implementation of critical internal aspects of its Year 2000 plan
prior to the commencement of the Year 2000, even with substantial completion of
internal remediation plans, the Company's customers, suppliers, and distributors
also present risk of their own Year 2000 compliance over which the Company has
no control. The Company has surveyed and assessed its critical suppliers and
other external relationships to determine the extent to which the Company may be
vulnerable to such parties' failure to resolve their own Year 2000 issues. Where
practicable, the Company is attempting to mitigate its risks with respect to the
failure of these entities to be Year 2000 compliant and has prepared contingency
plans accordingly. The Company cannot reasonably estimate the effect, if any,
from the failure of such parties to be Year 2000 compliant. However, the Company
believes that its contingency plans will substantially mitigate all significant
risks resulting from such parties' failure to resolve their Year 2000 issues.
The SEC has requested that companies disclose the most likely worst case
scenario that could occur as a result of the Year 2000. The Company believes
that its most likely worst case scenario would be delays in product shipments
due to a complete or partial manufacturing shutdown. To address the
manufacturing shutdown scenario, the Company plans, among other things, to
increase its inventory and re-prioritize staff assignments, as needed, but does
not believe that such a scenario is likely to occur.
23
<PAGE>
In addition to the Company's remediation efforts, the Company is also
implementing contingency plans and preparing for the year-end rollover and leap
year. The Company's contingency plans include, among other things, the
implementation of specific plans to ensure that the necessary precautions are
taken to prevent and/ or address an unexpected system failure. The Company has
scheduled contingency plan drills for November and December 1999. The Company
also intends to increase certain raw material and finished goods inventories to
mitigate external and internal risks. The Company's plans also include placing
teams in all critical locations to monitor and protect critical systems during
the year-end rollover period. The Company intends to monitor its computer
hardware and communication systems, software applications, and facilities and
other non-information technology-related functions for Year 2000 issues through
March 2000.
The Company may incur significant costs in preparing for the Year 2000.
Costs associated with preparing for the Year 2000 are not expected to exceed
$4.0 million, and include costs related to contingency plans, which may not
require execution. The costs related to the technology refresh program and the
integrated information system are not included in the above estimates as Year
2000 compliance is incidental to the operational benefits expected to be derived
from these programs. As of September 30, 1999, total costs incurred to date have
been funded through operations and approximate $2.7 million. The Company
anticipates funding its remaining Year 2000 expenditures with cash on hand and
cash generated through operations.
EURO CONVERSION
On January 1, 1999, eleven European Union member countries established fixed
conversion rates between their existing currencies ("legacy currencies") and one
common currency, the Euro. The Euro is currently traded on currency exchanges
and can be used in business transactions. The Company believes that its
financial systems are Euro-ready in all material respects. However, the Company
is still in the process of evaluating the effect, if any, that the Euro may have
on its product pricing and gross profit percentages.
FACTORS THAT MAY AFFECT FUTURE RESULTS
As a biotechnology company, Chiron is engaged in a rapidly evolving and
often unpredictable business. The forward-looking statements contained in this
Report and in other periodic reports, press releases and other statements issued
by the Company from time to time reflect management's current beliefs and
expectations concerning objectives, plans, strategies, future performance, and
other future events. The following discussion highlights some of the factors,
many of which are beyond the Company's control, which could cause actual results
to differ.
PROMISING TECHNOLOGIES ULTIMATELY MAY NOT PROVE SUCCESSFUL
The Company focuses its research and development activities on areas in
which it has particular strengths, and on technologies that appear promising.
These technologies often are on the "cutting edge" of modern science. As a
result, the outcome of any research or development program is highly uncertain.
Only a very small fraction of such programs ultimately result in commercial
products or even product candidates. Product candidates that initially appear
promising often fail to yield successful products. In many cases, preclinical or
clinical studies will show that a product candidate is not efficacious (that is,
it does not have the intended therapeutic or prophylactic effect), or that it
raises safety concerns or has other side effects which outweigh the intended
benefit. Success in preclinical or early clinical trials (which generally focus
on safety issues) may not translate into success in large-scale clinical trials
(which are designed to show efficacy), often for reasons that are not fully
understood. And even after a product is approved and launched, general usage or
post-marketing studies may identify safety or other previously unknown problems
with the product which may result in regulatory approvals being suspended,
limited to narrow indications, or revoked, or which may otherwise prevent
successful commercialization.
24
<PAGE>
REGULATORY APPROVALS
The Company is required to obtain and maintain regulatory approval in order
to market most of its products. Generally, these approvals are on a
product-by-product and country-by-country basis, and, in the case of therapeutic
products, a separate approval is required for each therapeutic indication. See
Item 1, "Business--Government Regulation" in the Company's Annual Report on
Form 10-K for the year ended January 3, 1999. Product candidates that appear
promising based on early, and even large-scale, clinical trials may not receive
regulatory approval. The results of clinical trials often are susceptible to
varying interpretations that may delay, limit or prevent approval or result in
the need for post-marketing studies.
MANUFACTURING
Most of the Company's products are biologics. Manufacturing biologic
products is complex. Unlike chemical pharmaceuticals, a biologic product
generally cannot be sufficiently characterized (in terms of its physical and
chemical properties) to rely on assaying of the finished product alone to ensure
that the product will perform in the intended manner. Accordingly, it is
essential to be able to both validate and control the manufacturing process:
that is, to show that the process works, and that the product is made strictly
and consistently in compliance with that process. Slight deviations in the
manufacturing process may result in unacceptable changes in the products that
may result in lot failures. Manufacturing processes which are used to produce
the (smaller) quantities of material needed for research and development
purposes may not be successfully scaled up to allow production of commercial
quantities at reasonable cost or at all. All of these difficulties are
compounded when dealing with novel biologic products that require novel
manufacturing processes. Accordingly, manufacturing is subject to extensive
government regulation. Even minor changes in the manufacturing process require
regulatory approval, which, in turn, may require further clinical studies.
PATENTS HELD BY THIRD PARTIES MAY DELAY OR PREVENT COMMERCIALIZATION
Third parties, including competitors, have patents and patent applications
in the U.S. and other significant markets that may be useful or necessary for
the manufacture, use, or sale of certain of the Company's products and products
in development. It is likely that third parties will obtain other such patents
in the future. Certain of these patents may be sufficiently broad to prevent or
delay Chiron from manufacturing or marketing products important to the Company's
current and future business. The scope, validity, and enforceability of such
patents, if granted, the extent to which Chiron may wish or need to obtain
licenses to such patents, and the cost and availability of such licenses cannot
be accurately predicted. If Chiron does not obtain such licenses, products may
be withdrawn from the market or delays could be encountered in market
introduction while an attempt is made to design around such patents.
Alternatively, Chiron could find that the development, manufacture, or sale of
such products is foreclosed. Chiron could also incur substantial costs in
challenging the validity and scope of such patents.
PRODUCT ACCEPTANCE
The Company may experience difficulties in launching new products, many of
which are novel products based on technologies that are unfamiliar to the
healthcare community. There can be no assurance that healthcare providers and
patients will accept such products. In addition, government agencies as well as
private organizations involved in healthcare from time to time publish
guidelines or recommendations to healthcare providers and patients. Such
guidelines or recommendations can be very influential, and may adversely affect
the usage of the Company's products directly (for example, by recommending a
decreased dosage of the Company's product in conjunction with a concomitant
therapy) or indirectly (for example, by recommending a competitive product over
the Company's product).
COMPETITION
Chiron operates in a highly competitive environment, and the competition is
expected to increase. Competitors include large pharmaceutical, chemical and
blood testing companies, as well as biotechnology companies. Some of these
competitors, particularly large pharmaceutical and blood testing companies, have
greater resources than the Company. Accordingly, even if the Company is
successful in launching a product, it
25
<PAGE>
may find that a competitive product dominates the market for any number of
reasons, including the possibility that the competitor may have launched its
product first; the competitor may have greater marketing capabilities; or the
competitive product may have therapeutic or other advantages. The technologies
applied by the Company and its competitors are rapidly evolving, and new
developments frequently result in price competition and product obsolescence.
CHIRON'S PATENTS MAY NOT PREVENT COMPETITION OR GENERATE REVENUES
Chiron seeks to obtain patents on its inventions. Without the protection of
patents, competitors may be able to use the Company's inventions to manufacture
and market competing products without being required to undertake the lengthy
and expensive development efforts made by Chiron and without having to pay
royalties or otherwise compensate Chiron for the use of the invention.
There can be no assurance that patents and patent applications owned or
licensed to Chiron will provide substantial protection. Important legal
questions remain to be resolved as to the extent and scope of available patent
protection for biotechnology products and processes in the U.S. and other
important markets. It is not known how many of the Company's pending patent
applications will be granted, or the effective coverage of those that are
granted. In the U.S. and other important markets, the issuance of a patent is
neither conclusive as to its validity nor the enforceable scope of its claims.
The Company has engaged in significant litigation to determine the scope and
validity of certain of its patents and expects to continue to do so in the
future.
Even if the Company is successful in obtaining and defending patents, there
can be no assurance that these patents will provide substantial protection. The
length of time necessary to successfully resolve patent litigation may allow
infringers to gain significant market advantage. Third parties may be able to
design around the patents and develop competitive products that do not use the
inventions covered by the patents. Many countries, including certain countries
in Europe, have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties (for example, the third party's
product is needed to meet a threat to public health or safety in that country,
or the patent owner has failed to "work" the invention in that country, or the
third party has patented improvements) and most countries limit the
enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may be limited to monetary relief and may
be unable to enjoin infringement, which could materially diminish the value of
the patent.
AVAILABILITY OF REIMBURSEMENT; GOVERNMENT AND OTHER PRESSURES ON PRICING
In the U.S. and other significant markets, sales of the Company's products
may be affected by the availability of reimbursement from the government or
other third parties, such as insurance companies. It is difficult to predict the
reimbursement status of newly approved, novel biotechnology products, and
current reimbursement policies for existing products may change. In certain
foreign markets, governments have issued regulations relating to the pricing and
profitability of pharmaceutical companies. There have been proposals in the U.S.
(at both the federal and state level) to implement such controls. The growth of
managed care in the U.S. also has placed pressure on the pricing of healthcare
products. These pressures can be expected to continue.
COSTS ASSOCIATED WITH REFOCUSING AND EXPANDING THE BUSINESS
The Company is refocusing its efforts on its core businesses and on
improving operational efficiencies. In addition, management expects to grow the
business in areas in which the Company can be most competitive, either through
in-licensing, collaborations, or acquisitions of products or companies. In
connection with these efforts, the Company may incur significant charges, costs,
and expenses which could impact the Company's profitability, including
impairment losses, restructuring charges, the write-off of purchased in-process
technology, transaction-related expenses, costs associated with integrating new
businesses, and the cost of amortizing goodwill and other intangibles.
26
<PAGE>
OTHER NEW PRODUCTS AND SOURCES OF REVENUE
Many products in the Company's current pipeline are in relatively early
stages of research or development. The Company's ability to grow earnings in the
near-to medium-term may depend, in part, on its ability to initiate and maintain
other revenue generating relationships with third parties, such as licenses to
certain of the Company's technologies, and on its ability to identify and
successfully acquire rights to later-stage products from third parties. There
can be no assurance that such other sources of revenue will be established.
INTEREST RATE AND FOREIGN CURRENCY EXCHANGE RATE FLUCTUATIONS
In 1998, the Company sold certain businesses for cash, including its IN
VITRO diagnostics and ophthalmics businesses, and as a result has significant
cash balances and short-term investments. The Company's financial results
therefore are sensitive to interest rate fluctuations in the U.S. In addition,
the Company sells products in many countries throughout the world, and its
financial results could be significantly affected by fluctuations in foreign
currency exchange rates or by weak economic conditions in foreign markets.
COLLABORATION PARTNERS
An important part of the Company's business strategy depends upon
collaborations with third parties, including research collaborations and joint
efforts to develop and commercialize new products. As circumstances change, the
Company and its corporate partners may develop conflicting priorities or other
conflicts of interest. The Company may experience significant delays and incur
significant expenses in resolving these conflicts and may not be able to resolve
these matters on acceptable terms. Even without conflicts of interest, the
parties may differ in their views as to how best to realize the value associated
with a current product or a product in development. In some cases, the corporate
partner may have responsibility for formulating and implementing key strategic
or operational plans. Decisions by corporate partners on key clinical,
regulatory, marketing (including pricing), inventory management, and other
issues may prevent successful commercialization of the product or otherwise
impact the Company's profitability.
STOCK PRICE VOLATILITY
The price of the Company's stock, like that of other biotechnology
companies, is subject to significant volatility. Any number of events, both
internal and external to the Company, may affect the stock price. These include,
without limitation, results of clinical trials conducted by the Company or by
its competitors; announcements by the Company or its competitors regarding
product development efforts, including the status of regulatory approval
applications; the outcome of legal proceedings, including claims filed by the
Company against third parties to enforce its patents and claims filed by third
parties against the Company relating to patents held by the third parties; the
launch of competing products; the resolution of (or failure to resolve) disputes
with collaboration partners; corporate restructuring by the Company; licensing
activities by the Company; and the acquisition or sale by the Company of
products, products in development, or businesses.
In connection with its research and development collaborations, from time to
time the Company invests in equity securities of its corporate partners. The
price of these securities also is subject to significant volatility and may be
affected by, among other things, the types of events that affect the Company's
stock. Changes in the market price of these securities may impact the Company's
profitability.
TAX
The Company is taxable principally in the U.S., Germany, Italy, and The
Netherlands. All of these jurisdictions have in the past and may in the future
make changes to their corporate tax rates and other tax laws, which could
increase the Company's tax provision in the future. The Company has negotiated a
number of rulings regarding income and other taxes that are subject to periodic
review and renewal. If such rulings are not renewed or are substantially
modified, taxes payable in particular jurisdictions could increase. While the
Company believes that all material tax liabilities are properly reflected in its
balance sheet, the Company is presently under audit in several jurisdictions,
and there can be no assurance that Chiron will prevail in all cases in the event
the taxing authorities disagree with its interpretations of the tax law. In
addition, the Company has assumed liabilities for all income taxes incurred
prior to the sales of its former subsidiaries, Chiron Vision
27
<PAGE>
Corporation (subject to certain limitations) and Chiron Diagnostics Corporation.
Future levels of research and development spending, capital investment, and
export sales will impact the Company's entitlement to related tax credits and
benefits which have the effect of lowering its effective tax rate.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
MARKET RISK MANAGEMENT The Company's cash flow and earnings are subject to
fluctuations due to changes in foreign currency exchange rates, interest rates,
and fair value of equity securities held. The Company attempts to limit its
exposure to some or all of these market risks through the use of various
financial instruments. There were no significant changes in the Company's market
risk exposures through the nine months ended September 30, 1999. For further
discussion of the Company's market risk exposures, refer to Part II, Item 7A,
"Quantitative and Qualitative Disclosures About Market Risk" in Chiron's Annual
Report on Form 10-K for the fiscal year ended January 3, 1999.
PART II
ITEM 1. LEGAL PROCEEDINGS
The Company is party to certain lawsuits and legal proceedings, which are
described in Part I, Item 3, "Legal Proceedings," of the Company's Annual Report
on Form 10-K for the year ended January 3, 1999, in Part II, Item 1, "Legal
Proceedings", of the Company's Quarterly Reports on Form 10-Q for the periods
ended March 31, 1999 and June 30, 1999. The following is a description of
material developments during the period covered by this Quarterly Report and
should be read in conjunction with the Annual Report on Form 10-K and the first
and second Quarterly Reports on Form 10-Q.
CONNAUGHT LABORATORIES, LIMITED
Chiron is involved in lawsuits in Italy and certain other countries with
Connaught Laboratories Limited ("Connaught") relating to TriAcelluvax-TM-, the
Company's diptheria/tetanus/acellullar pertussis vaccine. Litigation in Milan,
Italy relating to the Italian counterpart of Connaught's European Patent 0 527
753 is currently pending. On October 6, 1999, Connaught filed suit against
Chiron in the Milan court alleging infringement of its European Patent Number
322,115 (the "'115 patent"). The '115 patent contains claims relating to
pertussis toxin mutants. Connaught seeks a declaration of infringement of the
Italian counterpart to the '115 patent and seeks damages and injunctive relief
to prevent the manufacture and sale in Italy of Chiron's vaccines,
Acelluvax-TM-, Acelluvax DTP-TM-, and Triacelluvax-TM-.
FEDERAL EXPRESS
On September 3, 1999, Federal Express Corporation ("Federal Express") filed
suit in the Supreme Court of the State of New York, County of Orange against
Perseptive Biosystems, Inc, Perkin-Elmer Corporation, PE Biosystems Group, and
PE Corporation (together, the "PE Defendants") and Chiron. The matter has been
removed to the United States District Court for the Southern District of New
York. The Federal Express complaint relates to a fire that allegedly destroyed a
Federal Express aircraft and the majority of its cargo in September 1996.
Federal Express claims breach of contract, negligence and product liability with
regard to equipment owned and shipped by Chiron and designed, manufactured,
packaged and prepared for shipping by the PE Defendants and seeks damages,
interest, costs and fees. Federal Express alleges that improper packing and
shipping procedures were a proximate cause of the destruction of the plane. The
National Transportation Safety Board, an agency of the federal government, had
previously investigated the circumstances surrounding the incident and issued a
letter of no determination as to the cause of the fire. It is not known when nor
on what basis this litigation will be concluded.
F. HOFFMANN-LAROCHE AG
Chiron is involved in certain lawsuits in the United States, The
Netherlands, Japan, Germany, and other countries with F. Hoffmann-LaRoche AG and
several of its affiliated companies concerning infringement and/or validity of
certain patents related to HCV and HIV technology.
28
<PAGE>
In January 1998, Chiron initiated an action against F. Hoffmann-LaRoche AG
and several of its affiliated companies (collectively, "Roche") in the United
States District Court for the Northern District of California. The Company
asserted that Roche's manufacture and sale of Amplicor HCV Test and Amplicor HCV
Monitor Test constituted infringement of Chiron's U.S. Patent Nos. 5,712,088
(the "'088 patent"), 5,714,596 (the "'596 patent"), and 5,863,719 (the "'719
patent"). The action sought damages, injunctive relief, and a declaratory
judgment that Chiron is the sole and exclusive owner of the patents in suit. The
parties' cross-motions for summary judgment on Roche defenses based upon prior
licenses were resolved in Chiron's favor in June 1999. In October 1999, Roche
filed counterclaims against Chiron which challenge the validity and
enforceability of the patents in suit. Roche also seeks to recover treble
damages and an injunction against Chiron for alleged breaches of state and
federal antitrust statutes relating to Chiron's HCV licensing practices.
Roche has appealed the injunction granted by the Regional Court in
Dusseldorf, Germany against manufacture or sale by Roche of HCV immunoassay
kits.
A suit filed in October 1998 by Roche AG against Chiron and Ortho is pending
in the Federal Court of Australia, New South Wales District Registry, and is
seeking revocation of Australian patent number 624105, relating to HCV
technology.
In May 1999, Chiron and Gen-Probe, Incorporated ("Gen-Probe") initiated
action in the Tribunal of Milan, Italy, against Roche AG and several of its
European affiliates (together, "Roche"). The lawsuit seeks a cross-border
declaration that Gen-Probe's Transcription Mediated Amplification System ("TMA")
which is used in Chiron/Gen-Probe blood screening kits, does not infringe
Roche's European Patent 0 505 012 (the "'012 patent") which relates to PCR
technology. The plaintiffs also seek an assessment of the '012 patent and a
declaration of nullity of the Italian counterpart of the '012 patent.
It is not known when nor on what basis these matters will be concluded.
ORTHO DIAGNOSTIC SYSTEMS, INC.
On March 31, 1999, Chiron filed a lawsuit against Ortho Diagnostic
Systems, Inc. in the United States District Court for the Northern District of
California. The suit concerns certain issues relating to the conduct of the
parties' joint business and seeks to compel arbitration of those issues. On
November 1, 1999, the Court entered judgment in Chiron's favor, ordering Ortho
to submit the underlying issues to arbitration. It is not known when nor on what
basis this matter will be concluded.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
<TABLE>
<CAPTION>
EXHIBIT
NUMBER EXHIBIT
- --------------------- -------
<C> <S>
3.01 Restated Certificate of Incorporation of the Registrant, as
filed with the Office of the Secretary of State of Delaware
on August 17, 1987, incorporated by reference to
Exhibit 3.01 of the Registrant's report on Form 10-K for
fiscal year 1996.
3.02 Certificate of Amendment of Restated Certificate of
Incorporation of the Registrant, as filed with the Office of
the Secretary of State of Delaware on December 12, 1991,
incorporated by reference to Exhibit 3.02 of the
Registrant's report on Form 10-K for fiscal year 1996.
3.03 Certificate of Amendment of Restated Certificate of
Incorporation of the Registrant, as filed with the Office of
the Secretary of State of Delaware on May 22, 1996,
incorporated by reference to Exhibit 3.04 of the
Registrant's report on Form 10-Q for the period ended
June 30, 1996.
3.04 Bylaws of the Registrant, as amended, incorporated by
reference to Exhibit 3.04 to the Registrant's report on
Form 10-Q for the period ended June 30, 1999.
</TABLE>
29
<PAGE>
<TABLE>
<CAPTION>
EXHIBIT
NUMBER EXHIBIT
- --------------------- -------
<C> <S>
4.01 Indenture, dated as of May 21, 1987, between Cetus
Corporation and Bankers Trust Company, Trustee (initially
filed as Exhibit 4.01 to the Registrant's report on
Form 10-Q for the period ended September 30, 1994),
incorporated by reference to Exhibit 4.01 of the
Registrant's report on Form 10-Q for the period ended
June 30, 1999.
4.02 First Supplemental Indenture, dated as of December 12, 1991,
by and among the Registrant, Cetus Corporation, and Bankers
Trust Company, incorporated by reference to Exhibit 4.02 of
the Registrant's report on Form 10-K for fiscal year 1997.
4.03 Second Supplemental Indenture, dated as of March 25, 1996,
by and among the Registrant, Cetus Oncology Corporation
(formerly Cetus Corporation), and Bankers Trust Company,
incorporated by reference to Exhibit 4.03 of the
Registrant's report on Form 10-Q for the period ended
June 30, 1996.
4.04 Indenture, dated as of November 15, 1993, between the
Registrant and The First National Bank of Boston, as Trustee
(initially filed as Exhibit 4.03 of the Registrant's report
on Form 10-K for fiscal year 1993), incorporated by
reference to Exhibit 4.04 of the Registrant's report on
Form 10-K for fiscal year 1998.
10.306 HCV Probe License and Option Agreement dated September 26,
1999, between Abbott Laboratories, an Illinois corporation,
and the Registrant. (Certain information has been omitted
from the Agreement and filed separately with the Securities
and Exchange Commission pursuant to a request by Registrant
for confidential treatment pursuant to Rule 24b-2. The
omitted confidential information has been identified by the
following statement "Confidential Treatment Requested".)
10.614 Letter Agreement dated May 28, 1999 between the Registrant
and Paul J. Hastings, as supplemented by Promissory Note
dated July 20, 1999, executed by Mr. Hastings.*
10.707 Amendment dated as of January 3, 1995 among Ciba-Geigy
Limited, Ciba-Geigy Corporation, Ciba Biotech
Partnership, Inc. and the Registrant (initially filed as
Exhibit 10.61 of the Registrant's current report on
Form 8-K dated January 4, 1995).
10.708 Supplemental Agreement dated as of January 3, 1995 among
Ciba-Geigy Limited, Ciba-Geigy Corporation, Ciba Biotech
Partnership, Inc. and the Registrant (initially filed as
Exhibit 10.61 of the Registrant's current report on
Form 8-K dated January 4, 1995).
10.709 Amendment with Respect to Employee Stock Option Arrangements
dated as of January 3, 1995 among Ciba-Geigy Limited,
Ciba-Geigy Corporation, Ciba Biotech Partnership, Inc. and
the Registrant (initially filed as Exhibit 10.62 of the
Registrant's current report on Form 8-K dated January 4,
1995).*
10.716 Letter Agreement dated September 30, 1999, between Novartis
Corporation and the Registrant. (Certain information has
been omitted from the Agreement and filed separately with
the Securities and Exchange Commission pursuant to a request
by Registrant for confidential treatment pursuant to
Rule 24b-2. The omitted confidential information has been
identified by the following statement: "Confidential
Treatment Requested".)
27 Financial Data Schedule for the Nine Months ended
September 30, 1999.
27.1 Financial Data Schedule for the Nine Months ended
September 27, 1998.
</TABLE>
(b) Reports on Form 8-K
None.
- ------------------------
* Management contract, compensatory plan or arrangement.
30
<PAGE>
CHIRON CORPORATION
SEPTEMBER 30, 1999
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
<TABLE>
<S> <C> <C>
CHIRON CORPORATION
DATE: November 12, 1999 BY: /s/ SEAN P. LANCE
--------------------------------------
Sean P. Lance
Chairman; Chief Executive Officer
DATE: November 12, 1999 BY: /s/ JAMES R. SULAT
--------------------------------------
James R. Sulat
Vice President; Chief Financial Officer
DATE: November 12, 1999 BY: /s/ DAVID V. SMITH
--------------------------------------
David V. Smith
Vice President; Controller and
Principal Accounting Officer
</TABLE>
31
<PAGE>
REDACTED
Exhibit 10.306
**CONFIDENTIAL TREATMENT
REQUESTED**
HCV PROBE LICENSE AND OPTION AGREEMENT
BETWEEN
CHIRON CORPORATION
AND
ABBOTT LABORATORIES
<PAGE>
HCV PROBE LICENSE AND OPTION AGREEMENT
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
RECITALS 3
ARTICLE 1: DEFINITIONS 3
ARTICLE 2: LICENSE GRANT 13
ARTICLE 3: OPTION GRANTS 15
ARTICLE 4: PAYMENTS, ROYALTIES 18
ARTICLE 5: RECORDS AND REPORTS 19
ARTICLE 6: OTHER ACTIONS 21
ARTICLE 7: REPRESENTATIONS AND WARRANTIES 21
ARTICLE 8: TERM AND TERMINATION 23
ARTICLE 9: CONFIDENTIALITY 25
ARTICLE 10: INDEMNITY 26
ARTICLE 11: ALTERNATIVE DISPUTE RESOLUTION 28
ARTICLE 12: MISCELLANEOUS 28
ARTICLE 13: FIELD RESTRICTIONS AND OTHER COVENANTS 31
ARTICLE 14: INFRINGEMENT BY THIRD PARTIES 33
ARTICLE 15: EUROPEAN COMMUNITY PROVISIONS 35
ATTACHMENT 1: ALTERNATIVE DISPUTE RESOLUTION
EXHIBIT A: COMPENSATION TO CHIRON
EXHIBIT B: PATENT LIST
EXHIBIT C: EXISTING LICENSES
SCHEDULE 1.1: [CONFIDENTIAL TREATMENT REQUESTED] PATENT LIST
SCHEDULE C-1: REDACTED BAYER CROSS LICENSE
</TABLE>
2
<PAGE>
HCV PROBE LICENSE AND OPTION AGREEMENT
This agreement (hereinafter "Agreement") is made by and between CHIRON
CORPORATION, a Delaware corporation, of 4560 Horton Street, Emeryville,
California 94608 (hereinafter referred to as "CHIRON") and ABBOTT
LABORATORIES, an Illinois corporation, of 100 Abbott Park Road, Abbott Park,
Illinois 60064-3500 (hereinafter referred to as "ABBOTT").
BACKGROUND
WHEREAS, CHIRON currently owns or controls certain patent rights relating to
the hepatitis C virus ("HCV"), as defined below.
WHEREAS, ABBOTT wishes to engage in the development and commercialization of
assays for the detection of nucleic acid sequences for use in in vitro
diagnostics Directed to HCV, as defined below.
WHEREAS, CHIRON is willing to grant licenses to ABBOTT under certain patent
rights relating to HCV for use in assays for the detection of nucleic acid
sequences for use in in vitro diagnostics (excluding use in Blood Screening,
as defined below), all on the terms and conditions set forth herein.
WHEREAS, the parties desire to grant to each other options to acquire patent
rights to certain existing and future technology, with CHIRON granting
options to ABBOTT in the field of in vitro diagnostics for assays for the
detection of nucleic acid sequences and ABBOTT granting options to CHIRON in
Blood Screening, on the terms and conditions set forth below.
NOW, THEREFORE, in consideration of the above provisions and the mutual
covenants contained herein, CHIRON and ABBOTT hereby agree as follows:
ARTICLE 1
DEFINITIONS
In this Agreement the following words and phrases shall have the following
meanings:
1.1 "ABBOTT HCV Sequence Patent Rights" means any and all Valid Claims
(as defined below) of United States and foreign patents and patent
applications: (a) which claim an HCV nucleic acid sequence(s) or a method to
use (other than in the manufacture of peptides) or detect such sequence(s)
specifically; (b) which are owned by, licensed to or otherwise controlled by
ABBOTT or its Affiliates (as defined below), with right to license or
sublicense; and (c) with respect to which ABBOTT has the right to grant the
option provided
3
<PAGE>
for in Section 3.4 of this Agreement. Expressly excluded from
ABBOTT HCV Sequence Patent Rights are any right to patents or applications
directed to [CONFIDENTIAL TREATMENT REQUESTED], including, without
limitation, the patents and applications identified on Schedule 1.1.
1.2 "ABBOTT Non-HCV/HIV Analyte Patent Rights" means any and all Valid
Claims of United States and foreign patents and patent applications: (a)
which claim any nucleic acid sequence(s), other than HCV or HIV (as defined
below); (b) which is a blood borne, infectious disease virus to the extent
such Valid Claims cover the detection of any nucleic acid sequences of such
infectious disease virus; (c) which are owned by, licensed to or otherwise
controlled by ABBOTT or its Affiliates, with right to license or sublicense;
and (d) with respect to which ABBOTT has the right to grant the option
provided for in Section 3.2 of this Agreement.
1.3 "ABBOTT Optioned Rights" means ABBOTT HCV Sequence Patent Rights
and the ABBOTT Non-HCV/HIV Analyte Patent Rights.
1.4 "ADR" means Alternative Dispute Resolution in accordance with
Article 11.
1.5 "Affected Region" has the meaning set forth in paragraph 9 of
Exhibit A.
1.6 "Affiliate" means an entity that directly, or indirectly through
one or more intermediaries, controls or is controlled by or is under common
control with, a specified entity. For the purposes of this definition,
"control" (including with correlative meanings, the terms "controlling",
"controlled by" and "under common control with"), as applied to any entity,
means: (a) the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of that entity, whether
through the ownership of voting securities or by contract or otherwise; or
(b) the ownership of at least fifty percent (50%) of the voting securities of
that entity. Notwithstanding anything to the contrary contained herein,
"Affiliate" shall not include, in the case of CHIRON, Novartis AG or any
Affiliate of Novartis AG (other than CHIRON and any of its direct or indirect
subsidiaries), unless Novartis shall have acquired direct control of a
majority of the Board of Directors of CHIRON.
1.7 "Aggregated Products" means the number of: (a) Licensed Products
(as defined below) and (b) Competitive Products (as defined below) sold in a
Region (as defined below) or a country.
1.8 "Authorized Distributor" means a BONA FIDE, unaffiliated
distributor, but excluding any entity which is a Major IVD Manufacturer (as
defined below) that is not licensed in the Field (as defined below) under one
or more of the Licensed Patents (as defined below) or is affiliated with, or
directly or indirectly
4
<PAGE>
controlled by, such a Major IVD Manufacturer, except to the extent that such
unlicensed Major IVD Manufacturer or its Affiliates distributes Licensed
Product for ABBOTT or its Affiliates on a local country basis and in the same
manner in which it distributes other diagnostic products for ABBOTT or its
Affiliates and ABBOTT and its Affiliates are not otherwise selling Licensed
Products in such country.
1.9 "Average Unit Price" or "AUP" means, with respect to a Calendar
Quarter (as defined below), Net Sales (as defined below) of ABBOTT or its
Affiliates calculated on a per unit basis and, as applicable, the average
unit price of Competitive Products, in a country or Region, on a
product-by-product basis, using customary and reasonable methodologies for
determining average unit pricing generally consistent with the definition
herein of Net Sales, during the preceding two (2) Calendar Quarters.
1.10 "Bayer" means Bayer A.G, a German corporation, Bayer Corporation,
an Indiana corporation, and Affiliates of Bayer A.G or Bayer Corporation. For
the avoidance of doubt, Chiron Diagnostics Corporation is an Affiliate of
Bayer.
1.11 "Bayer Cross-License" means the Cross-License Agreement by
and between Chiron Diagnostics Corporation and CHIRON dated November 30,
1998, as amended from time to time.
1.12 "Blood Screening" means the commercial use of products that detect
nucleic acid sequences(s) for: (a) the screening of blood, plasma or blood
components intended for transfusion or for use in blood products (e.g.,
without limitation, immunoglobulins); or (b) confirmatory or supplemental
testing of the same samples otherwise screened for purposes described in
Section 1.12(a).
1.13 "Calendar Quarter" means the three (3) month period beginning
January 1, April 1, July 1 or October 1. For Net Sales outside the United
States, the Calendar Quarter and Calendar Year (as defined below) shall be
consistent with ABBOTT financial reporting practices, which currently
utilizes a one month lag.
1.14 "Calendar Year" means January 1 through December 31.
1.15 "CHIRON Competitive Product" means a Competitive Product
manufactured or sold by CHIRON or its Affiliates and that is not effectively
burdened by a royalty obligation under any Licensed Patent.
1.16 "CHIRON Future HCV Sequence Patent Rights" means any and all Valid
Claims of United States and foreign patents and patent applications: (a)
which are based upon inventions conceived [CONFIDENTIAL TREATMENT REQUESTED]
(as defined below); (b) which claim HCV nucleic acid sequence(s)
5
<PAGE>
or a method to use (other than in the manufacture of peptides) or detect such
sequences specifically; (c) which are owned by, licensed to or otherwise
controlled by CHIRON or its Affiliates, with rights to license or sublicense;
and (d) with respect to which CHIRON has the right to grant the option
provided for in Section 3.3 of this Agreement. For purposes of this
Agreement, an invention will be deemed to have been conceived if there is a
patent, patent application, written invention disclosure statement or other
tangible document (whether or not witnessed) describing such invention.
1.17 "CHIRON Non-HCV/HIV Analyte Patent Rights" means any and all Valid
Claims of U.S. and foreign patents and patent applications: (a) which claim
any nucleic acid sequence(s), other than HCV or HIV; (b) which is a blood
borne, infectious disease virus to the extent such Valid Claims cover the
detection of any nucleic acid sequence(s) of such infectious disease virus;
(c) which are owned by, licensed to or otherwise controlled by CHIRON or its
Affiliates, with right to license or sublicense; and (d) with respect to
which CHIRON has the right to grant the option provided for in Section 3.1 of
this Agreement. The CHIRON Non-HCV/HIV Analyte Patent Rights do not include
the CHIRON Non-HCV/HIV Patents (as defined below).
1.18 "CHIRON Non-HCV/HIV Patents" shall have the meaning provided in
Section 1.11 of the Bayer Cross License, as of the date hereof. For the
avoidance of doubt, CHIRON Non-HCV/HIV Patents shall be subject to any CHIRON
obligations to Bayer pursuant to the Bayer Cross License, including, without
limitation, CHIRON's obligations pursuant to Section 2.2 of the Bayer Cross
License.
1.19 "CHIRON Optioned Rights" means the CHIRON Future HCV Sequence
Patent Rights and the CHIRON Non-HCV/HIV Analyte Patent Rights.
1.20 "Competitive Product" means a Product (as defined below) which is
sold in the Field and which competes with a Licensed Product sold by ABBOTT
or its Affiliates in a Region or country.
1.21 "Current Activities of Roche" means commercial activities engaged
in by Roche with respect to the detection of nucleic acid sequences of HCV as
of the Effective Date.
1.22 "Directed to HCV" means that the claim or technology in question is
directed to methods, compositions, reagents or kits specifically for use in
nucleic acid-based diagnostic assays for the detection of HCV nucleic acid
sequence(s), or specifically for use in the manufacture of any compositions
or reagents for use in, or manufacture of nucleic acid-based diagnostic
assays for detection of HCV nucleic acid sequence(s) (excluding, for example,
PCR claims and technology and other methods for detection of nucleic acid
sequence(s) generally which involve nucleic acid amplification). The
terminology "specifically for use" as used in this Section 1.22, is intended
to exclude inventions suitable for use with
6
<PAGE>
viruses or analytes other than HCV (including by way of example and not by
way of limitation, inventions relating to PCR, or assay formats, improved
expression systems, detectable labels, instrumentation, packaging and the
like), which shall not be considered "specifically for use" in HCV detection
as contemplated by this Section 1.22 and shall therefore not be considered as
"Directed to HCV" hereunder.
1.23 "Earned Royalty" shall have the meaning specified in paragraph 2 of
Exhibit A.
1.24 "Effective Date" means the date of full execution of this Agreement.
1.25 "End User" means a person or entity who is a final purchaser of a
Product, and whose use of a Product results in the Product's consumption,
destruction or loss of activity.
1.26 "Eligible Third Party License" means a license agreement in the
Field entered into by CHIRON or Bayer or their respective Affiliates with a
Licensed Third Party (as defined below) after the Effective Date and includes
any material amendment made after the Effective Date to a license existing on
the Effective Date, other than the Bayer Cross License, which: (a) grants
such Licensed Third Party the license under one or more of the Licensed
Patents to make, have made, use, import, offer for sale or sell Product which
ABBOTT is licensed to make, have made, use, import, offer for sale or sell
under this Agreement; and (b) imposes payment obligations which would have
the effect of providing more favorable license payment terms to such Licensed
Third Party than the terms to ABBOTT under this Agreement, or would otherwise
give rise to an adjustment pursuant to Section 6(b) of Exhibit A.
1.27 "Field" means the commercial use of human IN VITRO diagnostic
products that detect nucleic acid sequences of HCV. Expressly excluded from
the Field are: (a) products in Blood Screening; (b) products for screening or
testing of samples containing pooled specimens from more than one individual;
and (c) products specifically labeled or promoted for use in the
Transplantation Field (as defined below).
1.28 "First Commercial Sale Date" means the date of the first commercial
sale of a Licensed Product by ABBOTT or its Affiliates to an unaffiliated
third party anywhere in the world.
1.29 "Foundational Patents" means the Licensed Patents identified in
Exhibit B which are stated therein to be Foundational Patents.
1.30 "HCV" means any viral isolate of the hepatitis C virus described in
the Licensed Patents or classified as HCV by the International Committee on
the Taxonomy of Viruses (or any body that replaces such Committee) or any
subtype
7
<PAGE>
of such isolate and further includes any isolate that is at least forty
percent (40%) homologous to any such isolate and of the same genomic type and
substantially the same genomic organization, any isolate that has a genome
that either hybridizes to or is substantially identical to any such isolate
or its compliment, and any defective or modified form of any of the above
isolates.
1.31 "HCV Qualitative Assay," means a Product which: (a) is an assay;
(b) detects or measures the presence of HCV in an analyzed sample; (c) does
not determine the quantity of HCV in the analyzed sample; and (d) is not by
itself, through a single use, capable of being used as an HCV Genotyping
Assay or an HCV Resistance Assay (as each is defined below).
1.32 "HCV Quantitative Assay," means a Product which: (a) is an assay;
(b) measures the presence of HCV in an analyzed sample; (c) does determine
the quantity of HCV in the analyzed sample; and (d) is not by itself, through
a single use, capable of being used as an HCV Genotyping Assay or an HCV
Resistance Assay.
1.33 "HCV Genotyping Assay" means a Product which is an assay or method
(e.g., sequencing) that is labeled or promoted as being useful through a
single use to determine and differentiate between two (2) or more families
(e.g., genotype 1, genotype 2, etc.) of an HCV virus that are present in an
analyzed sample.
1.34 "HCV Resistance Assay" means a Product which is an assay or method
(e.g., sequencing) that is labeled or promoted as being useful to detect
through a single use the specific drug resistance mutation(s) present in the
HCV virus in an analyzed sample.
1.35 "HIV" means any viral isolate of the human immunodeficiency virus
classified as HIV by the International Committee on the Taxonomy of Viruses
(or any body that replaces such committee) and any subtype of such isolate.
1.36 "Infringing Third Party Sales" means sales of Products: (a) which
infringe one or more of the Licensed Patents; or (b) as to which a license
under one or more of the Licensed Patents has been granted, but as to which
the licensee is not paying royalties thereunder.
1.37 "Independent Auditor" means an auditor who is: (a) from an
internationally recognized auditing firm having no other substantial and
continuing engagement with either party or its Affiliates; (b) reasonably
acceptable to each party; and (c) experienced and qualified to perform
analyses required hereunder, including analyses of market share and average
unit pricing of products.
8
<PAGE>
1.38 "Licensed Patents" means: (a) the patents and applications
identified in Exhibit B and any continuation, continuation-in-part and
divisional applications therefrom; (b) any reissued or reexamined patents
obtained from such patents and applications; (c) all foreign counterparts of
such patents and applications; and (d) all future patents and applications
which are based on inventions conceived by CHIRON or its affiliates on or
before the Effective Date, to the extent the items described in clauses (a)
through (d) of this Section 1.38 contain a Valid Claim Directed to HCV which
covers the manufacture, use, sale, offer for sale or importation of a product.
1.39 "Licensed Product" means a Product which is manufactured, used,
offered for sale, imported or sold under circumstances which would, in the
absence of the licenses granted under Section 2.1, constitute an infringement
of a Valid Claim of the Licensed Patents.
1.40 "Licensed Third Party" means an unaffiliated third party to whom
CHIRON or Bayer or their respective Affiliates grants a license or a covenant
not to sue after the Effective Date, under which license or covenant not to
sue such third party is allowed to make, have made, use, import, offer for
sale or sell any Product, directly or indirectly, under one or more of the
Licensed Patents. Expressly excluded from Licensed Third Party are: (a) any
affiliate of CHIRON; (b) Bayer or any of its Affiliates (to the extent
operating under the Bayer Cross License); or (c) any entity which receives a
judicially, or other governmental agency, imposed license or freedom from
suit under any one or more of the licensed patents and does not otherwise
have a Voluntary License (as defined below).
1.41 "Major IVD Manufacturer" means a commercial entity (and its
Affiliates) that manufactures, sells and engages in other commercial
activities with respect to in-vitro diagnostic products, and has a
significant marketing presence in one or more regions. Major IVD
Manufacturers include ABBOTT, Bayer, Johnson & Johnson, Roche, Pasteur,
Sanofi, Dade Behring, Organon Teknika, Becton Dickinson, bioMerieux, BioRad,
Fujirebio and Beckman Coulter and each of their successors and assigns and
any other entity which commands in the future at least an equivalent presence
as measured by total product sales as do any of the foregoing entities as of
the Effective Date in such Region.
1.42 "Minimum Royalty" shall have the meaning specified in paragraph 3
of Exhibit A.
1.43 "Net Sales" means the amount billed or invoiced for Licensed
Products sold by ABBOTT or its Affiliates, less:
(a) Discounts actually allowed and taken;
(b) Amounts repaid or credited by reason of rejection or return;
9
<PAGE>
(c) To the extent separately stated on purchase orders, invoices or other
documents of sale, taxes levied on and/or other governmental charges made
as to production, transportation or insurance charges;
(d) The reasonable value of the instrument, instrument financing,
consumables other than the products in question and service components of
an operating or capital lease for instrumentation on which the Licensed
Products are used, for which the charges are included in the price of the
Licensed Products purchased by the lessee, provided that the methods for
determining such values shall be proposed by ABBOTT and subject to CHIRON's
written consent, not to be unreasonably withheld;
(e) Charges for freight, handling and transportation paid by the selling
entity; and
(f) Sales, use and value-added taxes and other similar taxes incurred and
separately stated on invoices.
(1) Net Sales shall include all sales to non-Affiliate third
parties, including sales to Authorized Distributors in countries where, due
to regulatory constraints and/or market practice, substantially all sales of
the relevant Licensed Product and Competitive Products are made through
distributors, provided that ABBOTT shall use reasonable efforts in connection
with sales to such Authorized Distributors to comply with clause (A)
immediately below. With respect to sales to all other Authorized
Distributors, if Net Sales are based on the transfer price to the Authorized
Distributor rather than End User sales, either: (A) Net Sales on which
royalties shall be calculated shall be deemed to be not less than the higher
of the average selling price for the applicable Product in the United States
or the European Union; or (B) the parties shall adopt another mechanism for
preserving for CHIRON the same economics as if such sales had been made by
ABBOTT or its Affiliate rather than the Authorized Distributor. Any such
mechanism shall be proposed by ABBOTT and shall be subject to CHIRON's
written consent, which shall not be unreasonably withheld. CHIRON shall not
withhold its consent to a proposal by ABBOTT to calculate Net Sales at
[CONFIDENTIAL TREATMENT REQUESTED] of the transfer price to an Authorized
Distributor or such lesser percentage as reflects reasonably the distributor
mark-ups prevailing generally in the relevant country.
(2) For clarity of understanding, Net Sales shall not include any
Licensed Product furnished to third parties for which no payment is received,
such as, experimental, test market, promotional or other free goods. On the
other hand, Net Sales shall include any Licensed Product furnished in return
for payment, whether or not such Licensed Product is for commercial, research
or other use. For clarity of understanding, Minimum Royalties shall apply to
each Unit of Licensed Product Shipped to a customer for any purpose, except
for Units
10
<PAGE>
Shipped to third parties at no charge for: (A) use in ABBOTT's preclinical or
clinical trials; (B) testing, quality control or evaluation purposes; or (C)
replacement of rejected or defective goods. Without limiting the foregoing,
Licensed Products furnished to third parties at price discounts, including,
without limitation, free goods furnished as part of sales promotions, shall
be subject to Minimum Royalties.
(3) A sale shall be deemed to have been made and Earned Royalties
or Minimum Royalties incurred, (except as specifically set forth in this
Section 1.43(3) when the Licensed Product is consumed, invoiced or shipped by
ABBOTT or its Affiliates to a non-Affiliate third party ("Shipped"); provided
that where an invoice is issued, the obligations to pay Earned Royalties and
Minimum Royalties hereunder shall arise on the invoice date. Sales to or
between Affiliates shall not be included in Net Sales or Minimum Royalties
until ABBOTT or its Affiliate consumes the Licensed Product in providing a
commercial service for a non-Affiliate third party or Ships the Licensed
Product to a non-Affiliate third party.
(4) In the event that Licensed Product subject to royalties
hereunder is sold in combination with another product or active component,
other than instrumentation covered under clause (d) above, for a single price
(a "Combination Product"), Net Sales from sales of a Combination Product, for
purposes of calculating royalties due under this Agreement, shall be
calculated by multiplying the Net Sales of that Combination Product by the
fraction A/(A+B), where A is the AUP in the country of sale, during the
applicable reporting period, of the Licensed Product subject to royalties
hereunder if sold separately in the country of sale, and B is the AUP in the
country of sale, during the applicable reporting period, of the other
product(s) or component(s) sold separately in the country of sale. In the
event that no such separate sales are made, Net Sales, for purposes of
determining royalty payments on such Combination Products, shall be a
reasonable apportionment of the gross amount invoiced therefor based upon the
relative contribution of the Licensed Product subject to royalties hereunder
to the price of the Combination Product. Such apportionment shall be
determined by ABBOTT based upon its past practice and experience, and shall
be subject to CHIRON's written consent, which shall not be unreasonably
withheld.
(5) In the event that ABBOTT or its Affiliates perform assays for
commercial purposes utilizing Licensed Products, Net Sales means the invoiced
amount for the patient result provided as a result of performance of such
assays, less a reasonable deduction for the value of the services and or
other products provided therewith, less the applicable deductions pursuant to
this Section 1.43. The allocation of value to services or other products
provided shall be determined by ABBOTT based upon its past practice and
experience, and shall be subject to CHIRON's written consent, which shall not
be unreasonably withheld.
11
<PAGE>
1.44 "Non-HCV Field" means the commercial use of human IN VITRO
diagnostic products that detect nucleic acid sequences of viruses other than
HCV. Expressly excluded from the Non-HCV Field are: (a) products in Blood
Screening; (b) products for screening or testing of samples containing pooled
specimens from more than one individual; and (c) products specifically
labeled or promoted for use in the Transplantation Field.
1.45 "Product(s)" means reagents, compositions or kits suitable for use
in the Field.
1.46 "Region" shall have the meaning provided in Section 2.1.3 (b)(i) of
the Bayer Cross License as amended from time to time, with ABBOTT's consent
not to be unreasonably withheld. At the Effective Date, "Region" means one
of the four (4) following regions:
Region I: North America (United States and possessions, Puerto Rico,
Canada and Mexico);
Region II: European Union;
Region III: Japan; or
Region IV: All other countries of the world.
1.47 [CONFIDENTIAL TREATMENT REQUESTED].
1.48 [CONFIDENTIAL TREATMENT REQUESTED].
1.49 "Shipped" has the meaning set forth in Section 1.43(3).
1.50 "Transplantation Field" means the commercial use of products that
detect nucleic acid sequences for the screening of any biological materials
intended for transfusion or transplantation, in each case from any donor,
including autologous donors, other than the transfusion or transplantation of
blood or its derivatives, components or replacements.
1.51 "Unit" means the number of individual patient results generated by
the use of a Licensed Product, such that the number of Units contained in
such Licensed Product equals the number of patient results which are obtained
through use of such Licensed Product, as determined in a manner to be
proposed by ABBOTT, and subject to CHIRON's written consent, which shall not
be unreasonably withheld. If future Licensed Products are developed by ABBOTT
or its Affiliates that do not contain reagents or other single-use consumable
materials, ABBOTT shall propose a method for calculating the number of Units
that may be generated by the use of such Licensed Product to CHIRON in
writing for CHIRON's approval, which shall not be unreasonably withheld.
12
<PAGE>
1.52 "Valid Claim" means a claim in any issued, active, unexpired patent
which has not been withdrawn, cancelled, lapsed or disclaimed, or held
unpatentable, invalid or generally unenforceable by a non-appealed or
nonappealable final decision by a court or other appropriate body of
competent jurisdiction. The scope of a Valid Claim shall be limited to its
terms as defined by any such court or decision-making body of competent
jurisdiction in a non-appealable or non-appealed final decision.
1.53 "Voluntary License" means a license or covenant not to sue granted
by contract under any one or more of the Licensed Patents to make, use, offer
for sale, import or sell Products in the Field, except to the extent granted
by compulsion of law, such as a compulsory license, whether by court order or
action of other governmental authority.
ARTICLE 2
LICENSE GRANT
2.1 Subject to the terms and conditions of this Agreement, CHIRON
hereby grants to ABBOTT and its Affiliates, so long as they remain Affiliates
of ABBOTT, a worldwide, semi-exclusive license, without the right to
sublicense, under Licensed Patents to research, develop, make, have made,
import, use, offer for sale and sell Licensed Products. CHIRON covenants not
to sue any End User of a Licensed Product (with respect to which ABBOTT has
performed all of its material obligations under this Agreement) to the extent
of activities in the Field or otherwise permitted under this Agreement.
Conversely, subject to Section 13.1, no immunity from suit shall apply to End
User activities in Blood Screening or otherwise outside of the Field. The
license granted hereunder shall be semi-exclusive to ABBOTT and its
Affiliates. Semi-exclusive means that, in addition to licenses to third
parties under existing agreements referenced in Exhibit C including, without
limitation, the [CONFIDENTIAL TREATMENT REQUESTED], and licenses that may be
granted by such licensees, including licenses that may be granted by
[CONFIDENTIAL TREATMENT REQUESTED], CHIRON retains the right to practice
under the Licensed Patents and/or to grant additional licenses under one or
more of the Licensed Patents in the Field as follows:
(a) CHIRON may grant up to [CONFIDENTIAL TREATMENT REQUESTED] in the
Field, if CHIRON is not engaged in the sale of Products;
(b) If CHIRON has not granted [CONFIDENTIAL TREATMENT REQUESTED] under
Section 2.1(a) and CHIRON is not then engaged in the sale of Products,
CHIRON shall have the right, in its sole discretion, in lieu of such
worldwide license, to grant [CONFIDENTIAL TREATMENT REQUESTED] under the
Licensed Patents in the Field in each Region;
13
<PAGE>
(c) If CHIRON chooses to engage in the sale of Products, such activities
shall replace the [CONFIDENTIAL TREATMENT REQUESTED] CHIRON is permitted to
grant under Section 2.1(a) if CHIRON's sales are worldwide; or, if CHIRON's
sales are regional, such activities shall replace the [CONFIDENTIAL
TREATMENT REQUESTED] CHIRON is permitted to grant under Section 2.1(b) in
each Region in which CHIRON sells such Products;
(d) Licenses granted under Section 2.1(a) or 2.1(b) shall not include the
right to grant sublicenses, except to Affiliates for so long as they remain
Affiliates of the licensee, and shall contain provisions no less
restrictive than those set forth in Sections 13.1 and 13.2;
(e) In the event that a license granted by CHIRON pursuant to Section
2.1(a) or (b) is terminated, CHIRON shall have the right to replace such
license with a new license, consistent with the limitations required hereby
and the scope, field and territory of the license that is replaced.
Notwithstanding anything herein to the contrary, the [CONFIDENTIAL
TREATMENT REQUESTED], if terminated, could be replaced by a new license to
a new licensee and containing terms determined by CHIRON in its discretion
without any restrictions imposed by this Agreement other than paragraph 5
of Exhibit A. Conversely, if the replacement license for a license granted
pursuant to Section 2.1(a) or (b) is other than to [CONFIDENTIAL TREATMENT
REQUESTED], other restrictions, including paragraph 6 of Exhibit A, shall
apply;
(f) Following the last to expire of the Foundational Patents, the license
hereunder shall be nonexclusive; and
(g) Notwithstanding this Section 2.1, CHIRON retains the nonexclusive
right under the Licensed Patents to conduct research in any field,
including to develop Products, and all rights outside of the Field and the
Transplantation Field, including the nonexclusive right to practice and to
grant licenses under the Licensed Patents to make, have made, use, import,
offer for sale and sell any products in the Transplantation Field.
2.2 EXCLUSION FROM LICENSE. ABBOTT acknowledges that neither ABBOTT
nor its Affiliates are licensed under this Agreement to perform research or
to develop any product other than a Licensed Product or any other product
licensed to ABBOTT by CHIRON.
2.3 TRANSPLANTATION FIELD. Subject to the terms and conditions of this
Agreement, CHIRON hereby grants to ABBOTT and its Affiliates, so long as they
remain Affiliates of ABBOTT, a worldwide, nonexclusive license, without the
right
14
<PAGE>
to sublicense, under Licensed Patents to research, develop, make, have made,
import, use, offer for sale and sell reagents, compositions or kits for use
in the Transplantation Field, which reagents, compositions or kits are
manufactured, used, offered for sale or sold under circumstances which would,
in the absence of the license granted under this Section 2.3, constitute an
infringement of a Valid Claim of the Licensed Patents. CHIRON covenants not
to sue any End User of such reagents, compositions or kits (with respect to
which ABBOTT has performed all of its material obligations under this
Agreement) to the extent of activities in the Transplantation Field or as
otherwise permitted under this Agreement. Conversely, no immunity from suit
under this Section 2.3 shall apply to End User activities in Blood Screening
or otherwise outside of the Transplantation Field. The license granted under
this Section 2.3, and the products which are the subject of this license,
shall be subject to all of the terms and conditions of this Agreement, in the
same manner as if such products were Licensed Products, except that Sections
2.1, 7.3, 13.3 and 14.2 shall not apply and paragraphs 5, 6(b), 8 and 9 of
Exhibit A shall apply to provide ABBOTT the same adjustments as are then
applicable to Licensed Products; provided that products in the
Transplantation Field will not be used as the basis for any adjustments under
such paragraphs.
ARTICLE 3
OPTION GRANTS
3.1 CHIRON NON-HCV/HIV ANALYTE PATENT RIGHTS. Subject to the terms and
conditions of this Agreement, CHIRON grants to ABBOTT a nonexclusive option,
exercisable only on an analyte-by-analyte basis, to obtain one or more
nonexclusive, worldwide licenses, or sublicenses, as the case may be, on
commercially reasonable terms, with right to sublicense ABBOTT Affiliates
only, under the CHIRON Non-HCV/HIV Analyte Patent Rights, to make, have made,
use, import, offer for sale and sell products in the Non-HCV Field and/or the
Transplantation Field.
3.2 ABBOTT NON-HCV/HIV ANALYTE PATENT RIGHTS. Subject to the terms and
conditions of this Agreement, ABBOTT grants to CHIRON a nonexclusive option,
exercisable only on an analyte-by-analyte basis, to obtain one or more
nonexclusive, worldwide licenses, or sublicenses, as the case may be, on
commercially reasonable terms, with right to sublicense CHIRON Affiliates
only, under the ABBOTT Non-HCV/HIV Analyte Patent Rights, to make, have made,
use, import, offer for sale and sell products in Blood Screening and/or the
Transplantation Field.
3.3 CHIRON FUTURE HCV SEQUENCE PATENT RIGHTS. Subject to the terms and
conditions of this Agreement, CHIRON grants to ABBOTT a nonexclusive option
to obtain one or more nonexclusive, worldwide licenses, or sublicenses, as
the case may be, with right to sublicense to ABBOTT Affiliates
15
<PAGE>
only, under the CHIRON Future HCV Sequence Patent Rights, to make, have made,
use, import, offer for sale and sell Products and/or products in the Field
and the Transplantation Field. Such license or sublicense shall be on
commercially reasonable terms. [CONFIDENTIAL TREATMENT REQUESTED].
3.4 ABBOTT HCV SEQUENCE PATENT RIGHTS. Subject to the terms and
conditions of this Agreement, ABBOTT grants to CHIRON a nonexclusive option
to obtain one or more nonexclusive, worldwide licenses, or sublicenses, as
the case may be, with right to sublicense, under the ABBOTT HCV Sequence
Patent Rights, to make, have made, use, import, offer for sale and sell
products in Blood Screening and/or the Transplantation Field.
[CONFIDENTIAL TREATMENT REQUESTED].
3.5 OPTION TERMS. As to any Valid Claim(s) included within CHIRON
Optioned Rights or ABBOTT Optioned Rights, the options set forth in Sections
3.1 to 3.4 may be exercised at any time after the Effective Date during the
life of such patent(s), by written notice from the option grantee to the
option grantor identifying the patent(s) under which the grantee wishes to
obtain a license; provided, however, that the option with respect to any
patent or application (and the patents resulting therefrom) shall terminate
if the option grantee challenges the validity or enforceability of any claim
of such patent or application to the extent that such claim recites activity
covered by the option. [CONFIDENTIAL TREATMENT REQUESTED] of the option
grantor's receipt of such notice, the grantor and the grantee shall exert
reasonable best efforts to negotiate a mutually acceptable license agreement
granting the optioned patent rights in question from the option grantor to
the option grantee. The terms of such license agreement will be subject to
the following:
(a) [CONFIDENTIAL TREATMENT REQUESTED]. If the parties cannot agree upon
royalty, or any other commercial term, they will proceed to ADR in
accordance with Article 11 of this Agreement to determine the terms that
are to be commercially reasonable. As to each patent licensed, royalties
will be due for the life of the patent on a country-by-country basis;
(b) Net sales will be defined in substantially the same manner as in
Section 1.43 of this Agreement;
(c) A "Most Favored Licensee" clause shall be provided as to future
granted licenses and, to the extent practical, parity as to the essential
economic terms with previously granted licenses;
(d) The licensor will be able to terminate the agreement only for any
material breach of the agreement, subject to notification, reasonable
opportunity to cure, and alternative dispute resolution, or for the
licensee's
16
<PAGE>
challenge to the validity or enforceability of any patent claims
licensed under this Article 3;
(e) The licensee will be able to terminate the license agreement at any
time by giving the licensor prior written notice;
(f) The licensee will not have any right of enforcement, and will not
receive from the licensor any warranty of validity or noninfringement;
provided, however, the licensor shall disclose to the licensee prior to
entering into such license, any knowledge it has of any pending or written
threatened claim that is material to any challenge of validity or
enforceability, except to the extent that such disclosure is subject to an
obligation of confidentiality, protective order or legal privilege; and
(g) To the extent applicable, and excluding royalty terms, the remaining
terms of the license agreement will be modeled substantially after the
terms and conditions of this Agreement.
3.6 NEED FOR OPTION. CHIRON may, at any time hereunder, provide
written notification to ABBOTT that certain products being sold by ABBOTT are
believed by CHIRON to be covered by one or more Valid Claims of a patent
included within CHIRON Optioned Rights not licensed to ABBOTT. In the event
ABBOTT does not, within [CONFIDENTIAL TREATMENT REQUESTED] of receipt of such
notification, exercise the relevant option provided for under this Article 3
to obtain a license under such CHIRON Optioned Right, then CHIRON and ABBOTT
shall promptly thereafter confer in good faith to discuss their respective
positions concerning whether such products being sold by ABBOTT are covered
by a Valid Claim of the patent in question. If within [CONFIDENTIAL TREATMENT
REQUESTED] following the above-mentioned notification, the parties are unable
to agree as to whether such Products being sold by ABBOTT are covered by a
Valid Claim of the patent in question, the parties shall then promptly submit
such disagreement to ADR in accordance with Article 11. The ADR will address
infringement, enforceability and validity, unless the parties otherwise
mutually agree. This Section 3.6 shall apply in a reciprocal fashion in the
event ABBOTT provides written notification to CHIRON that certain products
being sold by CHIRON or its Affiliates are believed by ABBOTT to be covered by
a Valid Claim of a patent included within ABBOTT Optioned Rights.
3.7 OPTION EXERCISE. Neither ABBOTT nor CHIRON shall enter into any
agreement after the Effective Date extending any rights to third parties
under ABBOTT Optioned Rights or CHIRON Optioned Rights, respectively, which
would preclude the parties from fulfilling the respective option grants set
forth in Sections 3.1 to 3.4, or which would otherwise conflict or be
inconsistent with the obligations set forth herein, including said option
grants, without first providing [CONFIDENTIAL TREATMENT REQUESTED] prior
written notice to the other party of such intention. The option grantee shall
have the [CONFIDENTIAL
17
<PAGE>
TREATMENT REQUESTED] period in which to review its option. If the option
grantee fails to exercise the option in a timely manner, the option grantor
shall be entitled to enter into a commercial arrangement regarding the
subject matter of the option without regard to this Section 3.7.
3.8 EFFECT ON OPTION BY TERMINATION. Termination of this Agreement
pursuant to Article 8 shall terminate the provisions of this Article 3;
provided, however, that if at the time of such termination or, if prior
notification is required under Section 8.3, then if immediately prior to
delivery of such notification: (a) a license agreement pursuant to this
Article 3 is in effect, such license shall survive such termination under
Article 8 and shall remain in effect in accordance with its terms; or (b) a
party has properly exercised an option pursuant to this Article 3 and is
proceeding in good faith to negotiate a license agreement thereunder, the
parties shall complete such negotiations in good faith.
3.9 THIRD PARTY PATENTS. Each party shall use reasonable commercial
efforts to acquire the right to grant the options provided in this Article 3
when it acquires rights under patents of third parties.
ARTICLE 4
PAYMENTS, ROYALTIES
With respect both to Licensed Products sold or Shipped, ABBOTT shall
make payments to CHIRON as set forth in Exhibit A. Exhibit A also sets forth
the manner in which such payment to CHIRON may be adjusted.
ARTICLE 5
RECORDS AND REPORTS
5.1 SALE PRIOR TO THE EFFECTIVE DATE. ABBOTT hereby represents and
warrants to CHIRON that there have been no Products Shipped by ABBOTT or its
Affiliates prior to the Effective Date that would have given rise to a
royalty obligation under this Agreement had it then been in effect.
5.2 NET SALES REPORT. ABBOTT shall, within sixty (60) days after the
first day of each Calendar Quarter after the Effective Date deliver to CHIRON
a true and accurate report which shall state the amount of monies due
hereunder, if any, as Earned Royalties and Minimum Royalties, and shall
include all information reasonably necessary to calculate such amount,
including, but not limited to, the following information, presented by
country and Region and by product and Product Category (as defined in
paragraph 3 of Exhibit A):
18
<PAGE>
(a) the amount of Net Sales, expressed in United States Dollars (with
applicable exchange rates to the extent specifically requested in writing
by CHIRON), and the applicable Earned Royalty rate or rates, and all
credits and adjustments thereto;
(b) the number of Units Shipped and the applicable Minimum Royalty amount
or amounts, and adjustments to Units Shipped (returns, replacements, etc.);
and
(c) a statement of the basis for any deviation from the Earned Royalty
rates and Minimum Royalty amounts as expressed in paragraphs 2 and 3 of
Exhibit A, including the calculation of adjustments pursuant to paragraphs
7, 8 or 9 of Exhibit A.
5.3 PAYMENT DATES. Not later than the date each report required under
Section 5.2 is due, ABBOTT shall pay to CHIRON the royalty due under this
Agreement for the period covered by such report. If no royalties are due,
ABBOTT shall so report, stating the reasons why no such royalty is due.
5.4 PAYMENT PROCEDURES. ABBOTT shall pay royalties and all other
payments due hereunder to CHIRON in immediately available funds on the due
date by wire transfer to:
Bank of America- San Francisco
San Francisco, California
Account Name: Chiron Corporation
Account Number: [CONFIDENTIAL TREATMENT REQUESTED]
ABA #: [CONFIDENTIAL TREATMENT REQUESTED]
Reference: Abbott HCV Probe License Agreement
or at such place and in such other manner as CHIRON may designate in a notice
signed by CHIRON's Treasurer or Controller to ABBOTT.
5.5 TAXES ON ROYALTIES. ABBOTT shall deduct from amounts payable
hereunder all taxes assessed or imposed against, or required to be withheld
from, royalty payments due and shall pay such amount to the appropriate
fiscal or tax authorities on behalf of CHIRON. ABBOTT shall forward promptly
to CHIRON all tax receipts received by ABBOTT evidencing payment of such
taxes.
5.6 AUDIT. ABBOTT shall keep reasonably detailed and accurate records
and books of account to enable a determination of the amounts payable by
ABBOTT and its Affiliates to CHIRON hereunder. Upon thirty (30) days written
notice by CHIRON, and not more frequently than once per Calendar Year, CHIRON
may have such records and books of account examined during reasonable
business hours by a mutually acceptable independent certified public
accountant selected by CHIRON and at CHIRON's expense, whose acceptance shall
not unreasonably be withheld by ABBOTT, for the purpose of verifying the
19
<PAGE>
reports provided for in Section 5.2; provided that such independent
accountant agrees to provide CHIRON only the information necessary to verify
the calculation of amounts due hereunder. A copy of any final written report
provided by the independent accountant to CHIRON shall be given concurrently
to ABBOTT. Such examination shall not be permitted unless it is requested
within three (3) years following the end of the Calendar Year to which the
books and records pertain. Where such examination results in a finding that
ABBOTT underpaid CHIRON by more than [CONFIDENTIAL TREATMENT REQUESTED] over
the period audited, ABBOTT shall reimburse CHIRON for its reasonable costs
and expenses in conducting such examination. ABBOTT and CHIRON shall promptly
rectify any overpayments or underpayments by repaying such amounts together
with interest thereon at an annual rate equal to the lesser of: (a)
[CONFIDENTIAL TREATMENT REQUESTED] as published in the Wall Street Journal;
or (b) the maximum rates permitted by applicable law, from the time such
payment was originally due to the time it is paid.
5.7 CONFIDENTIALITY OF AUDIT. CHIRON agrees that all audited
information shall be confidential to ABBOTT and its Affiliates, and that any
person or entity conducting an audit on behalf of CHIRON pursuant to Section
5.6 shall be required to protect the confidentiality of such information.
5.8 PAYMENT IN UNITED STATES CURRENCY. All payments shall be made in
United States Dollars and shall be made on the dates set forth herein. The
Net Sales amount calculated hereunder for sales in countries other than the
United States shall be converted into equivalent United States Dollars in
accordance with the methods used for internal financial reporting purposes
within ABBOTT.
5.9 LATE PAYMENT FEE. Any payment, including, without limitation,
royalty payments, made by ABBOTT hereunder after the date such payment is
due, as set forth in this Article 5 hereof, shall bear interest at the lesser
of: (a) [CONFIDENTIAL TREATMENT REQUESTED] as published in the Wall Street
Journal; or (b) the maximum rate permitted by applicable law.
ARTICLE 6
OTHER ACTIONS
Immediately upon the Effective Date, or as soon as possible thereafter,
ABBOTT shall discontinue any opposition or challenge to the Licensed Patents,
to the extent that such challenge or opposition is directed against claims
that recite activity that is licensed to ABBOTT hereunder. In the event
ABBOTT challenges the validity or enforceability of any such claims within
Licensed Patents, or supports the challenge by a third party to the validity
or enforceability of any such claims within Licensed Patents (except to the
extent required by law or compulsory judicial process), the provisions of
Section 8.3(b) shall apply.
20
<PAGE>
ARTICLE 7
REPRESENTATIONS AND WARRANTIES
7.1 CORPORATE AUTHORITY. Each party represents and warrants to the
other party that it has the necessary corporate authority to enter into this
Agreement.
7.2 RIGHT TO GRANT. CHIRON represents and warrants to ABBOTT that
CHIRON has the right to grant the license granted to ABBOTT in Article 2
hereof and that CHIRON is the sole owner of the Licensed Patents, subject to
licenses existing as of the Effective Date and listed in Exhibit C and issues
raised in the [CONFIDENTIAL TREATMENT REQUESTED]. CHIRON represents and
warrants to ABBOTT that, to the best of its knowledge, neither CHIRON nor any
of its Affiliates have transferred to [CONFIDENTIAL TREATMENT REQUESTED] or
any if its Affiliates (a) before December 1, 1998, title to any patent or
patent application Directed to HCV in the Field existing on that date; or (b)
on or after that date, title to any patent, patent application or invention
Directed to HCV in the Field.
7.3 CURRENT LICENSES. CHIRON represents and warrants to ABBOTT that:
(a) as of the Effective Date the entities set forth in Exhibit C are the only
parties to which it has granted any licensed rights or other grants or
immunities to one or more of the Licensed Patents in the Field; (b) Exhibit C
contains a complete and accurate description of the effective scope, field
and territory of such grant as of the Effective Date; and (c) the copy of the
Bayer Cross License, as disclosed to ABBOTT and attached hereto in Schedule
C-1, contains all of the terms of Bayer's rights under the Licensed Patents.
CHIRON also represents and warrants that [CONFIDENTIAL TREATMENT REQUESTED]
except as disclosed in Exhibit C. Any grant of material additional rights in
the Field to [CONFIDENTIAL TREATMENT REQUESTED] under the Licensed Patents
would cause [CONFIDENTIAL TREATMENT REQUESTED] to become a Licensed Third
Party with respect to such additional rights.
7.4 COMPLETE PATENT LIST. CHIRON represents and warrants to ABBOTT
that, to the best of its knowledge and belief, Exhibit B contains a complete
list, as of the Effective Date, of all patents and patent applications owned
by, licensed to, or otherwise controlled by CHIRON or its Affiliates
containing claims Directed to HCV in the Field. To the extent that any other
patent or patent application owned by, licensed to or otherwise controlled by
CHIRON or its Affiliates and filed on or before the Effective Date contains a
claim Directed to HCV in the Field, such patent or patent application shall
be automatically added to the Licensed Patents. Upon ABBOTT's written
request, not more frequently than annually, CHIRON shall provide ABBOTT with
an updated Exhibit B and a report of the prosecution status of applications
within Licensed Patents.
21
<PAGE>
7.5 EXCLUSIONS. Nothing contained in this Agreement shall be construed
as:
(a) A representation or warranty by any party hereto as to the validity of
any patent rights which are the subject of this Agreement;
(b) A representation or warranty that anything made, used, imported,
offered for sale, sold or otherwise disposed of under any of the patent
rights which are the subject of this Agreement is or will be free from
infringement of patents of third parties;
(c) An obligation to bring or prosecute actions or suits against third
parties for infringement of any patent rights which are the subject of this
Agreement;
(d) A grant of any right to bring or prosecute actions or suits against
third parties for infringement of any patent rights which are the subject
of this Agreement; or
(e) A grant, by implication, estoppel or otherwise, of any license,
option, covenant or right other than those which are expressly stated
herein, including without limitation (i) any license under any patent or
patent application (or claim thereof) not within the Licensed Patents, or
(ii) any covenant by CHIRON not to sue under any such patent or patent
application (or claim thereof).
7.6 FURTHER ABBOTT ASSURANCE. ABBOTT acknowledges that the inclusion
of ABBOTT Affiliates within the license grant pursuant to Section 2.1 is
intended to enable ABBOTT to utilize the manufacturing and sales capabilities
of its Affiliates in connection with the manufacture and sale of Licensed
Products in a manner substantially similar to the involvement of such
Affiliates in the manufacture and sale of ABBOTT's products generally.
ABBOTT shall not, directly or indirectly, take any action having or intended
to have the effect of sublicensing ABBOTT's rights under any of the Licensed
Patents, other than to a BONA FIDE Affiliate, including, without limitation,
by creating Affiliates specifically in connection with Licensed Products, or
through other third party arrangements such as joint ventures,
collaborations, or distribution arrangements with distributors. ABBOTT and
its Affiliates are licensed hereunder to sell and distribute Licensed
Products only under the label, name and trademark rights owned by, licensed
to or otherwise controlled by ABBOTT or its Affiliates, and only through the
sales force of ABBOTT or its Affiliates, or through Authorized Distributors.
ABBOTT and its Affiliates are not licensed to perform OEM manufacturing of
Licensed Products for a third party other than an Authorized Distributor; to
supply Licensed Products for resale to any third party other than an
Authorized Distributor; to permit any Authorized Distributor or other third
party to sell any Licensed Products under another third party label, name or
trademark or to permit any Authorized Distributor or other third party to
22
<PAGE>
sell any Licensed Products under the Authorized Distributor's or any third
party's own label, name or trademark for use on an instrument bearing the
label name or trademark of a party other than ABBOTT or its Affiliates;
provided, however, that nothing in this Section 7.6 shall be construed to
limit the rights of ABBOTT or its Affiliates to engage in activities with
such third parties, to the extent such third parties have obtained rights
under the Licensed Patents permitting such activities.
7.7 LIMITATION OF WARRANTY. EXCEPT AS SPECIFICALLY SET FORTH HEREIN,
NO PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED,
ARISING BY LAW OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
ARTICLE 8
TERM AND TERMINATION
8.1 TERM. This Agreement shall be in effect from the Effective Date
until the last to expire of the Licensed Patents (the "Term"), unless earlier
terminated pursuant to Sections 8.2 and 8.3 below.
8.2 VOLUNTARY TERMINATION BY ABBOTT. ABBOTT shall have the right to
voluntarily terminate all, but not less than all, licenses granted to ABBOTT
and its Affiliates under this Agreement on a country-by-country basis, during
the Term, on not less than six (6) months prior written notice to CHIRON. For
avoidance of doubt, the termination provision in paragraph 1(b) of Exhibit A
shall not be subject to the prior notice requirement set forth in this
Section 8.2. Subject to Section 3.8, no such termination shall affect any
rights or licenses granted to CHIRON or its Affiliates hereunder.
8.3 TERMINATION BY CHIRON. CHIRON may terminate this Agreement only
upon any of the following grounds:
(a) ABBOTT's or its Affiliates' material breach of this Agreement,
including, without limitation, a breach resulting from ABBOTT's or its
Affiliates' failure to pay any sums due hereunder, where such breach shall
not have been remedied within thirty (30) days of the receipt of a written
notification from CHIRON identifying the breach and requiring its remedy;
whereupon termination under this Section 8.3 (a) shall be effective upon
the expiration of such thirty (30) day cure period, subject to Section 8.6;
or
(b) ABBOTT's or its Affiliates' challenge to the validity or
enforceability of any claim of a patent within the Licensed Patents to the
extent that such claim recites activity that is licensed to ABBOTT
hereunder, except
23
<PAGE>
through not more than one ADR proceeding with respect to each patent within
the Licensed Patents, including within such proceeding all directly-
related foreign counterparts of such patent or its support of a third
party's challenge to the validity or enforceability of any such claims of
a patent within Licensed Patents as described in Article 6.
8.4 ENFORCEMENT AFTER TERMINATION. Upon valid termination of this
Agreement under Section 8.2 or 8.3, ABBOTT and its Affiliates shall have no
further rights under Licensed Patents and CHIRON shall not be limited to its
remedies under this Agreement, to the extent of such termination.
8.5 ACCRUED RIGHTS. Termination of this Agreement for whatever reason
shall not affect any rights which have accrued prior to termination.
8.6 ABBOTT CHALLENGE TO TERMINATION. In the event ABBOTT provides
written notification to CHIRON prior to expiration of the thirty (30) day
notice/cure period referenced in Section 8.3(a) that ABBOTT disputes whether
the grounds for termination under Section 8.3(a) are present, such dispute
shall be submitted to ADR pursuant to Article 11. The thirty (30) day
notice/cure period shall be suspended during the pendancy of such ADR,
provided that during the pendancy of the ADR, ABBOTT shall continue to make
any disputed payments to CHIRON, on the condition that CHIRON shall repay
ABBOTT the amounts of such disputed payments if ABBOTT prevails in the ADR,
plus interest at the rate described in Section 5.9.
8.7 [CONFIDENTIAL TREATMENT REQUESTED].
8.8 AUDIT RESULTS NOT GROUNDS FOR TERMINATION. CHIRON's request for an
audit under Section 5.6 shall not be treated as a notice of breach under
Section 8.3(a). In the event such audit determines there has been an
underpayment by ABBOTT, such underpayment shall not constitute grounds for
termination by CHIRON under Section 8.3(a) unless: (a) ABBOTT has failed to
rectify such underpayment in accordance with Section 5.6; (b) ABBOTT has
failed to rectify such underpayment after notification and opportunity to
cure under Section 8.3 (a); and (c) any ADR requested by ABBOTT, pursuant to
Section 8.6, and directed to any dispute concerning such underpayment,
results in a determination favorable to CHIRON. Notwithstanding the
foregoing, during the pendancy of the ADR proceeding, ABBOTT shall continue
to make the disputed payments to CHIRON, on the condition that CHIRON shall
repay ABBOTT the amounts of such disputed payments with respect to which
ABBOTT prevails in the ADR, plus interest at the rate described in Section
5.9.
8.9 SURVIVAL. The following provisions of this Agreement shall survive
termination or expiration of this Agreement, in accordance with their
respective terms: Article 1; Sections 3.8, 5.6, 5.7, 8.4, 8.5 and 8.9;
Articles 9, 10, and 11;
24
<PAGE>
Sections 12.3 through 12.6 and 12.9 through 12.13; Section 15.1; and
Attachment 1.
ARTICLE 9
CONFIDENTIALITY
9.1 OBLIGATION. From time to time during the Term, CHIRON and ABBOTT
may provide to each other information concerning patents, patent
applications, license agreements and other confidential or proprietary
information related to this Agreement (the "Information"). Each party
receiving the Information (the "Receiving Party") shall during the Term and
for a period of three (3) years after termination hereof: (a) maintain the
Information in confidence; (b) not disclose the Information to any third
party, other than employees, agents or consultants of the Receiving Party or
its Affiliates or sublicensees who have a need to know the Information and
who are bound by confidentiality obligations to the Receiving Party no less
restrictive than those contained herein; and (c) not use the Information for
any purpose not directly related to performance hereunder or otherwise
authorized under this Agreement.
9.2 EXCLUSIONS. The obligations of this Article 9 shall not apply to
any Information which: (a) is or which becomes generally known to the public
by publication or by means other than a breach of a duty by the Receiving
Party; (b) is otherwise known by the Receiving Party at the time of
disclosure by the other party; (c) otherwise becomes available to the
Receiving Party from a third party not in breach of confidentiality
obligations to the other party; or (d) is developed by or for the Receiving
Party independent of any disclosure from the other party. The Receiving
Party also shall be permitted to make disclosures of Information which are
reasonably necessary in connection with a possible grant of a permitted
sublicense by the Receiving Party or in due diligence related to a possible
acquisition, merger, consolidation, substantial asset transfer or similar
transaction of the Receiving Party, provided that the recipient is bound to
the Receiving Party by confidentiality obligations with respect to the
Information no less restrictive than those contained herein. Nothing herein
shall prevent the Receiving Party from making such disclosures of Information
as are reasonably required by law, regulation (including 37 C.F.R. Section
1.56), or order of any court or governmental agency; provided that the
Receiving Party has provided reasonable advance notice to allow the
disclosing party the opportunity to seek a protective order or otherwise
contest, prevent or limit such disclosure.
9.3 RETURN OF INFORMATION. Upon termination of this Agreement for any
reason, the Receiving Party shall return, or at the option of the disclosing
party, certify destruction of, all Information and copies thereof; provided
that the Receiving Party may retain one copy thereof in its law department
files solely for evidentiary and regulatory purposes.
25
<PAGE>
9.4 DISCLOSURE OF AGREEMENTS AND TERMS. The parties shall cooperate
reasonably in the preparation of a joint press release disclosing the
existence of this Agreement. CHIRON may disclose any of the terms in the
Agreement to any Affiliate of CHIRON or Bayer or to any third party licensee
or prospective licensee of CHIRON or Bayer under one or more of the Licensed
Patents; provided that the recipient of such disclosure is obligated to
confidentiality terms no less restrictive that those contained in this
Article 9. CHIRON also may disclose any information contained in or regarding
this Agreement as may be required in its reasonable judgment by applicable
law, regulation or order of any court or governmental agency. Further, CHIRON
may determine in its discretion to file this Agreement under the Securities
and Exchange Act of 1934 or otherwise with any United States or foreign
governmental agency, even if that filing may result in this Agreement
becoming available to the public generally. CHIRON shall seek confidential
treatment for at least the essential financial terms hereof in connection
with any such filing, subject to applicable law and regulation, and shall
notify ABBOTT in advance of any such filing and consider such suggestions as
ABBOTT may make as to the terms herein as to which CHIRON should seek
confidential treatment; provided, however, that the final decisions as to
such matters shall be made by CHIRON in its discretion.
ARTICLE 10
INDEMNITY
10.1 ABBOTT INDEMNITY. ABBOTT shall indemnify, defend and hold harmless
CHIRON and its Affiliates and their officers, directors, shareholders,
employees, representatives and agents, against any claim, demand, loss,
damage or injury, including reasonable attorneys' fees, arising from,
relating to, or otherwise in respect of, the manufacture, use or sale of
Licensed Products, or any breach of any representation, warranty or covenant
under this Agreement; provided, however, that such indemnity shall not extend
to damages arising directly from any breach or willful or negligent act of
CHIRON or its Affiliates.
10.2 CHIRON INDEMNITY. CHIRON shall indemnify, defend and hold harmless
ABBOTT and its Affiliates and their officers, directors, shareholders,
employees, representatives and agents, against any claim, demand, loss,
damage or injury, including reasonable attorneys' fees and costs, arising
from, relating to, or otherwise in respect of, any breach by CHIRON or its
Affiliates of any representation, warranty or covenant under this Agreement;
provided, however, that such indemnity shall not extend to damages arising
directly from any breach or willful or negligent act of ABBOTT or its
Affiliates.
10.3 INDEMNIFICATION PROCEDURES. In the event either party claims
indemnification pursuant to this Article 10, the indemnified party shall
promptly notify the indemnifying party in writing upon becoming aware of any
claim to
26
<PAGE>
which such indemnification may apply. Delay in providing such notice shall
constitute a waiver of the indemnifying party's indemnity obligations
hereunder only if the indemnifying party's ability to defend such claim is
materially impaired thereby. The indemnifying party shall have the right to
assume and solely control the defense of the claim at its own expense. If
the right to assume and solely control the defense is exercised, the
indemnified party shall have the right to participate in, but not to control,
such defense at its own expense, and the indemnifying party's indemnity
obligations shall be deemed not to include attorneys' fees and litigation
expenses incurred by the indemnified party after the assumption of the
defense by the indemnifying party. If the indemnifying party does not assume
the defense of the claim, the indemnified party may defend the claim at the
indemnifying party's expense. The indemnified party shall not settle or
compromise the claim without the prior written consent of the indemnifying
party, and the indemnifying party shall not settle or compromise the claim in
any manner which would have an adverse effect on the indemnified party
without the consent of the indemnified party, which consent, in each case,
shall not be unreasonably withheld. The indemnified party shall reasonably
cooperate with the indemnifying party and shall make available to the
indemnifying party all pertinent information under the control of the
indemnified party, all at the expense of the indemnifying party.
10.4 SUNSET. The provisions of Sections 10.1 and 10.2 shall continue in
effect on a claim-by-claim basis, after the termination of this Agreement,
only until the expiration of the last to expire statute of limitations
applicable to such claim.
10.5 LIMITATION OF LIABILITY. Neither party shall be liable to the
other for any consequential, special, indirect or exemplary damages or for
the loss of profits arising from the performance or nonperformance of this
Agreement or any acts or omissions associated herewith.
ARTICLE 11
ALTERNATIVE DISPUTE RESOLUTION
The parties recognize that BONA-FIDE disputes may from time to time
arise which relate to any aspect of this Agreement, including, without
limitation, any of the parties' rights and/or obligations hereunder, and
including, without limitation, disputes relating to the interpretation, form,
validity, performance and/or termination of this Agreement or relating to
infringement, scope, claims construction, or (without limiting the effect of
Section 8.3(b)) validity or enforceability of the Licensed Patents. In the
event of the occurrence of any dispute, a party may, by notice to the other
party, have such dispute referred to their respective employees designated
below or their successors, for attempted resolution by good faith
negotiations within thirty (30) days after such notice is received. Said
designated officers are as follows:
27
<PAGE>
For ABBOTT:
PRESIDENT
DIAGNOSTICS DIVISION
For CHIRON:
PRESIDENT
BLOOD TESTING
In the event the designated officers, after such good faith
negotiations, are not able to resolve such dispute within such thirty (30)
day period, or any agreed extension thereof, a party may invoke the
provisions for binding ADR as set forth in Attachment I hereto. Neither
party shall seek recourse against the other hereunder in any court or other
forum, except as may be necessary to enforce a determination made in ADR
pursuant to this Article 11 and Attachment I.
ARTICLE 12
MISCELLANEOUS
12.1 ASSIGNMENT.
(a) ABBOTT and its Affiliates may not assign or transfer any rights
under this Agreement without the prior written consent of CHIRON, except to
an ABBOTT Affiliate, and then only for so long as the assignee remains an
ABBOTT Affiliate, or as part of the sale or transfer of all or
substantially all of ABBOTT's and all of its Affiliates' assets and
businesses to which this Agreement relates. In the case of a permitted
assignment or transfer, the performance of the assignee shall be guaranteed
by ABBOTT.
(b) CHIRON and its Affiliates may not assign or transfer any rights
under this Agreement without the prior written consent of ABBOTT, except to
a CHIRON Affiliate, and then only for so long as the assignee remains a
CHIRON Affiliate, or as part of the sale or transfer of all or
substantially all of CHIRON's and all of its Affiliates' assets and
businesses to which this Agreement relates. In the case of a permitted
assignment or transfer, the performance of the assignee shall be guaranteed
by CHIRON.
12.2 FORCE MAJEURE. A party hereto shall not be liable for, nor shall
this Agreement be terminable or cancelable by reason of, any delay or default
in any such party's performance hereunder, to the extent that such default or
delay is caused by events beyond such party's reasonable control including,
but not limited to: acts of God; regulation, law or action of any government
or agency thereof; war or insurrection; civil commotion; labor disturbances;
epidemic; or
28
<PAGE>
failure of suppliers, public utilities or common carriers. Each party shall
give prompt notice to the other party of such cause, and shall take whatever
reasonable steps are necessary to relieve the effect of such cause as rapidly
as possible.
12.3 SEVERABILITY. In the event that any one or more of the provisions
of this Agreement should for any reason be held by any court or authority
having jurisdiction over this Agreement or over the parties hereto to be
invalid, illegal or unenforceable, such provision or provisions shall be
reformed to approximate as nearly as possible the intent of the parties, in
such jurisdiction; elsewhere, this Agreement shall not be affected.
12.4 ENTIRE AGREEMENT. This Agreement together with the Exhibits,
Attachments and Schedules constitutes the entire agreement among the parties
relating to the subject matter of this Agreement. There are no other
understandings, representations or warranties of any kind.
12.5 AMENDMENT. This Agreement shall not be waived, altered, extended
or modified except by written agreement of the parties.
12.6 WAIVER. Failure by a party hereunder to enforce any right under
this Agreement shall not be construed as a waiver of such right or any other
rights under this Agreement; nor shall a waiver by a party hereunder in one
or more instances be construed as constituting a continuing waiver or as a
waiver in other instances.
12.7 COSTS. Each of the parties hereto shall be responsible for its
respective legal and other costs incurred in relation to the preparation of
this Agreement.
12.8 COUNTERPARTS. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed to be an original, but all of
which, taken together, shall constitute one and the same instrument.
Facsimile copies of signatures for a party shall be deemed to be originals
for purposes of execution of the Agreement and for determining the Effective
Date.
12.9 NOTICES.
(a) Any notice or other document to be given under this Agreement shall
be in writing and shall be deemed to have been duly given if personally
delivered or sent by first class mail, or express or air mail or other postal
service, or by certified mail, return receipt requested.
29
<PAGE>
(b) Any notice required by this Agreement shall be forwarded to the
respective addresses and marked for the attention of the persons set forth
below unless such addresses subsequently change by written notice to the
other party:
ABBOTT: Director of Technology Acquisitions
Abbott Diagnostics Division
Abbott Laboratories
D-9RK, Bldg. AP6C
100 Abbott Park Road
Abbott Park, Illinois 60064-6094
Copy to: Divisional Vice President
Domestic Legal Operations
Abbott Laboratories
D-322, Bldg. AP6D
100 Abbott Park Road
Abbott Park, Illinois 60064-6049
CHIRON: Chiron Corporation
4560 Horton Street
Emeryville, California 94608
Attn.: President, Blood Testing
Copy to: General Counsel
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608
(c) Any such notice or other document shall be deemed to have been
effective when received by the addressee. To prove the giving of a notice or
other document it shall be sufficient to show that it was received.
12.10 GOVERNING LAW. All matters affecting the interpretation, form,
validity, performance and termination of this Agreement shall be decided and
interpreted under the laws of the State of New York, excluding any choice of
law rules which may direct application of the laws of any other jurisdiction.
12.11 RELATIONSHIP OF THE PARTIES. The relationship of the parties
under this Agreement is that of independent contractors. Nothing contained
in this Agreement is intended or is to be construed so as to constitute the
parties as partners, joint venturers or agents of the other. Neither party
or its Affiliates has any express or implied right or authority under this
Agreement to assume or
30
<PAGE>
create any obligations or make any representations or warranties on behalf of
or in the name of the other party or its Affiliates.
12.12 HEADINGS. The headings of the Articles and Sections in this
Agreement have been inserted for convenience only and do not constitute part
of this Agreement.
12.13 NO TRADEMARK RIGHTS. No right, express or implied, is granted by
this Agreement to either party to use in any manner the name, trade name or
trademark of the other party in connection with the performance of this
Agreement.
ARTICLE 13
FIELD RESTRICTIONS AND OTHER COVENANTS
13.1 ABBOTT Covenant Regarding Blood Screening.
(a) ABBOTT and its Affiliates shall not label or promote any Licensed
Product or any product governed by Section 2.3 in any respect for use in
Blood Screening; and ABBOTT shall use commercially reasonable efforts to
prevent its Authorized Distributors from labeling or promoting any Licensed
Products or any product governed by Section 2.3 in any respect for use in
Blood Screening.
(b) Further, ABBOTT and its Affiliates and Authorized Distributors
shall include on or with each Licensed Product a statement to the effect that
the Licensed Product is not for use for testing or screening pooled samples
containing specimens from more than one individual, or otherwise in blood or
plasma screening, using language to be determined by ABBOTT and approved by
CHIRON, which approval shall not be unreasonably withheld. The location of
such notice shall be the product insert of such Licensed Products or such
other reasonably prominent location to be determined by ABBOTT.
(c) In the event that ABBOTT or CHIRON becomes aware of any material
use of Licensed Products in Blood Screening, such party will promptly notify
the other in writing of the relevant facts and, if so requested by CHIRON,
ABBOTT will (i) meet and confer with CHIRON in good faith to determine what
steps either or both should take to abate such infringing use and (ii) notify
in writing any of its customers that engages in such infringing use that use
of the relevant Licensed Product in Blood Screening may infringe one or more
of the Licensed Patents.
(d) Without limiting the labeling and promoting obligations under this
Section 13.1, CHIRON shall not sue ABBOTT, its Affiliates, its Authorized
Distributors or its End User customers for the sale or use of a Licensed
Product that is suitable for use both as a Product and as a confirmatory or
supplemental
31
<PAGE>
test in conjunction with the screening of blood, plasma or blood products (a
"Confirmatory Test") if the End User customer has substantial noninfringing
uses for such Licensed Product in the Field or the Transplantation Field.
Further, ABBOTT shall not be obligated to notify such customers pursuant to
Section 13.1(c)(ii) with respect to such Licensed Product.
(e) Nothing in this Section 13.1 shall apply to any product to the
extent that ABBOTT's activity and that of its Affiliates with respect to such
product is either for or through an entity licensed in Blood Screening under
the Licensed Patents.
13.2 PATENT MARKING. ABBOTT and its Affiliates shall include a patent
notice on each Licensed Product to identify those of the Licensed Patents
which such Licensed Product, but for the licenses granted herein, would
infringe one or more Valid Claims (or for which royalties are being paid);
provided, however, identification of Licensed Patents on a Licensed Product
shall in no way be deemed to be an admission by ABBOTT or its Affiliates, or
raise a presumption, that such Licensed Product is in fact covered by such
Licensed Patent.
13.3 CHIRON COVENANT REGARDING FIELD.
(a) CHIRON and its Affiliates shall not, and CHIRON shall require any
of its future licensees under the Licensed Patents that are licensed in Blood
Screening to agree not to, label or promote, in any respect for use in the
Field, any product sold in Blood Screening [CONFIDENTIAL TREATMENT REQUESTED]
, which product detects nucleic acid sequences of HCV.
(b) Further, CHIRON and its Affiliates shall, and CHIRON shall require
its future licensees in Blood Screening to, include with each such HCV
product sold by CHIRON or its Affiliates or licensees in Blood Screening a
statement to the effect that such product is not for use in the Field using
language to be determined by CHIRON and approved by ABBOTT, which approval
shall not be unreasonably withheld. The location of such notice shall be in
the product insert for such product or such other reasonably prominent
location to be determined by CHIRON.
(c) In the event that CHIRON or ABBOTT becomes aware of any material
use of any such product in the Field, such party will promptly notify the
other in writing of the relevant facts and, if so requested by ABBOTT, CHIRON
will (i) meet and confer with ABBOTT in good-faith to determine what steps
either or both of them should take to abate such use and (ii) notify in
writing any of its customers that engage in such use that use of the relevant
product in the Field may infringe one or more of the Licensed Patents.
(d) Nothing in this Section 13.3 shall apply to any product to the
extent that CHIRON's activity and that of its Affiliates or licensees with
respect to such
32
<PAGE>
product either (i) is for or through an entity that is licensed under the
Licensed Patents in the Field or (ii) is within CHIRON's rights to practice
in the Field, pursuant to its rights retained under, and subject to the
limitations of, Section 2.1
13.4 LEAST RESTRICTIVE ALTERNATIVE. ABBOTT's obligations under Section
13.1(b) or 13.1(c)(ii) shall, at ABBOTT's election, be reduced to the least
restrictive such obligation contained in the [CONFIDENTIAL TREATMENT REQUESTED],
if any, from time to time. CHIRON shall notify ABBOTT, in writing, of the
agreement of [CONFIDENTIAL TREATMENT REQUESTED] or any Licensed Third Party with
respect to such obligations, and of any subsequent change thereto. CHIRON shall
have no obligation under Section 13.3(b) or 13.3(c)(ii) more restrictive than
corresponding obligations of ABBOTT under Section 13.1(b) and 13.1(c)(ii),
from time to time.
ARTICLE 14
INFRINGEMENT BY THIRD PARTIES
14.1 NOTICE OF INFRINGEMENT. Each party shall notify the other if it
becomes aware of Infringing Third Party Sales. CHIRON shall have the
exclusive right to take action against any infringement of any of the
Licensed Patents, in its sole discretion, subject to this Article 14.
14.2 INFRINGEMENT LITIGATION.
(a) In the event that "substantial" Infringing Third Party Sales are
occurring in a country in which ABBOTT or its Affiliates or an Authorized
Distributor is selling a Licensed Product (in each such country, the
"Impacted Product"), and ABBOTT has notified CHIRON pursuant to Section 14.1
of the existence of such infringement in [CONFIDENTIAL TREATMENT REQUESTED]
(an "Infringement Notice"), then the provisions of this Section 14.2 shall
apply. For purposes of this Section 14.2, an Infringing Third Party Sale
shall be considered substantial in a country if it achieves market share of
at least [CONFIDENTIAL TREATMENT REQUESTED] of the Aggregated Products in
such country as determined by an Independent Auditor paid for by ABBOTT. For
purposes of this Section 14.2, "Major Country" shall mean the United States,
Germany, United Kingdom or Japan.
(b) If either (i) the Infringement Notice identified an Impacted
Product in the United States and CHIRON fails to institute legal action in
the United States [CONFIDENTIAL TREATMENT REQUESTED] following receipt by
CHIRON of the Infringement Notice and infringement is not otherwise abated,
or (ii) the Infringement Notice identified an Impacted Product in a Major
Country other than the United States and CHIRON fails to institute legal
action against the infringing party in at least one of the United States, the
Netherlands, Germany, United Kingdom or Japan, [CONFIDENTIAL TREATMENT
REQUESTED] following
33
<PAGE>
receipt by CHIRON of the Infringement Notice and infringement is not
otherwise abated; then ABBOTT shall be relieved of the obligation to pay the
portion of Earned Royalties set forth in Section 14.2(c) and
[CONFIDENTIAL TREATMENT REQUESTED], with respect to the Impacted Product
until such time as CHIRON institutes such legal action as described in this
Section 14.2(b); provided, however, that CHIRON need not initiate or continue
any such legal action, if, after reasonably diligent effort (including
reasonably diligent by ABBOTT if requested by CHIRON), CHIRON is unable to
acquire admissible evidence sufficient to bring an infringement action under
the law of the applicable country.
(c) If CHIRON has not instituted such legal action at the end of such
[CONFIDENTIAL TREATMENT REQUESTED], to the extent required under Section 14.2
(b), and such infringement is not otherwise abated, the Earned Royalty with
respect to an Impacted Product shall be reduced by [CONFIDENTIAL TREATMENT
REQUESTED]. If, at the end of each [CONFIDENTIAL TREATMENT REQUESTED]
thereafter, CHIRON has not instituted such legal action, to the extent so
required, and infringement is not otherwise abated, such Earned Royalties shall
be reduced by an [CONFIDENTIAL TREATMENT REQUESTED] of the original Earned
Royalties, such that if legal action required under Section 14.2 (b) has not
commenced and the infringement is not otherwise abated by the end of the
[CONFIDENTIAL TREATMENT REQUESTED] following receipt by CHIRON of the
Infringement Notice, [CONFIDENTIAL TREATMENT REQUESTED] shall be payable
hereunder with respect to the Impacted Product.
(d) The obligations to pay Earned Royalties and Minimum Royalties
shall be reinstated on a prospective basis at such time as ABBOTT receives
written notice of the institution of legal action in accordance with Section
14.2(b) or the infringement is otherwise abated, all subject to Section
14.2(e).
(e) If legal action required under Section 14.2(b) has not been
instituted and the infringement is not otherwise abated for more than
[CONFIDENTIAL TREATMENT REQUESTED] following receipt by CHIRON of the
Infringement Notice, and if, as a result of the infringement, sales of the
Impacted Product in a Major Country by ABBOTT, its Affiliates or an
Authorized Distributor have declined by [CONFIDENTIAL TREATMENT REQUESTED] or
more during the preceding [CONFIDENTIAL TREATMENT REQUESTED] period,
[CONFIDENTIAL TREATMENT REQUESTED], then upon reinstatement of Earned
Royalties and Minimum pursuant to Section 14.2(d), the parties shall meet and
confer regarding possible adjustments to the Earned Royalties and Minimum
Royalties for the Impacted Product in view of such degradation of the market.
The parties will discuss possible rate reductions, as well as a plan for
reinstating the original economic expectations of the parties. It is expected
that any agreement for reduction of Earned Royalties and Minimum Royalties
will be phased out over time, so as to return to the Earned Royalties and
Minimum
34
<PAGE>
Royalties set forth in Exhibit A. If the parties fail to reach agreement on
any such adjustment, the matter shall be submitted for resolution by ADR,
except that in the event of ADR, each party shall submit to the neutral a
proposal with respect to adjustments pursuant to this Section 14.2(e). The
neutral shall be empowered to choose one proposal or the other, but shall not
be empowered to order any such adjustment other than as proposed by one of
the parties.
14.3 ABBOTT and its Affiliates shall cooperate with CHIRON in
connection with any legal action referred to in this Article 14.
ARTICLE 15
EUROPEAN COMMUNITY PROVISIONS
15.1 TERMINATION IN EUROPEAN COMMUNITY. Notwithstanding the provisions
of Article 8, this Agreement, with respect to the European Community, shall
terminate in each member country seventeen (17) years from the Effective Date
or on the expiration of the last to expire of the patents within the Licensed
Patents in such member country based upon a patent existing or a patent
application pending as of the Effective Date, whichever is later; provided,
however, that prior to the termination of this Agreement in the first member
country in which it would otherwise terminate pursuant to the foregoing,
ABBOTT may, in its discretion, elect by written notice to CHIRON to extend
this Agreement as to all such member countries for an additional term which
shall expire on a country-by-country basis on the expiration date of the last
to expire patent within the Licensed Patents existing in such member country
as of the date of such extension.
15.2 COMPETITION NOTIFICATION. If either party (the "Notifying Party")
elects to file a notification with respect to this Agreement (a
"Notification") with the Competition Directorate of Commission of European
Community (the "Commission") in accordance with regulations established by
the Commission, the Notifying Party shall provide a non-confidential version
of the final draft to the other party for comment at least thirty (30) days
before making the filing and shall consider in good faith the modification
thereto, if any, that the other party may propose. The other party shall
execute all documents reasonably required by the Notifying Party and shall
otherwise reasonably cooperate in connection with the Notification. The
Notifying Party shall bear all costs incurred by it relating to the
Notification.
15.3 REFORMATION. If, at any time during the Term, either party
receives a request or other communication from the Commission with respect to
the Notification (a "Request"), such party shall promptly inform the other of
the nature of the Request. In the event that the Commission indicates in a
Statement of Objection(s) that this Agreement will violate the provisions of
Article 81 or 82 of the Treaty of Rome, then the parties shall amend this
Agreement by making those minimal modifications necessary to satisfy the
concerns of the Commission
35
<PAGE>
as set forth in the Statement of Objection(s). Notwithstanding the foregoing,
the parties agree that ABBOTT shall retain substantially the same license
rights at substantially the same royalties as specified under this Agreement.
IN WITNESS WHEREOF this Agreement has been executed by duly authorized
officers of CHIRON and ABBOTT as of the Effective Date.
CHIRON CORPORATION
By: /s/ SEAN P. LANCE
--------------------------
Sean P. Lance
Title: Chairman and Chief Executive Officer
Date: 26 September 1999
ABBOTT LABORATORIES
By: /s/ THOMAS D. BROWN
--------------------------
Thomas D. Brown
Title: Senior Vice President
Diagnostic Operations
Date: September 26, 1999
36
<PAGE>
Attachment I
ALTERNATIVE DISPUTE RESOLUTION
If good faith negotiations fail to resolve any dispute pursuant to the
provisions of Article 11 of the Agreement, alternative dispute resolution
("ADR") shall apply:
a. A party may invoke this ADR provision, by providing written notice
of such invocation to the other party, after best efforts to accomplish a
negotiated settlement pursuant to Article 11 have failed.
b. Any ADR shall be conducted by a sole neutral. The decision of the
neutral as to all matters presented to the neutral shall be final and binding.
c. The parties shall have 21 business days from the date ADR is
invoked to agree upon a neutral. If the parties are unable to agree, then the
neutral shall be selected by the then-president of the CPR Institute of
Dispute Resolution ("CPR"), New York, N.Y. or if, at the time of any such ADR
invocation, CPR is no longer in existence or engaged in such ADR services,
then by the American Arbitration Association.
d. The hearing shall be held no more than 75 days after the selection
of the neutral. All parties shall exchange the items referred to in
subsection (i), (iii), and (iv) of this provision (d) at least 14 days prior
to the hearing, and the items referred to in subsection (ii) of this
provision (d) at least 45 days prior to the hearing:
(i) A copy of all exhibits they intend to use at the hearing;
(ii) A list of all witnesses that will be called in the party's case
in chief and a short summary of the testimony of each witness;
(iii) A proposed ruling on each issue to be resolved; and
(iv) A brief in support of the party's proposed ruling, provided that
such brief shall not exceed 20 pages (including any attachments),
regardless of the number of issues to be resolved.
e. Each party shall be entitled to take deposition testimony from the
other party's identified witnesses provided each deposition shall not exceed
5 hours of testimony taken by such deposing party. Except as expressly set
forth in the preceding sentence, no discovery shall be required or permitted
by any means, including depositions, interrogatories, requests for
admissions, or production of documents.
f. In the case of disputes, or issues within disputes, involving
determination of a monetary amount, percentages, or other similar
quantitative or numerical matters (for example, disputes involving the
parties' inability to reach agreement on an appropriate royalty under any
license which the parties are attempting to negotiate
1
<PAGE>
pursuant to the option grants of Article 3 of the Agreement) the ADR shall be
conducted "baseball" style: the neutral may issue an award only on the terms
requested by one party or the other. The neutral is not free to impose any
award which is not an exact version of the proposed terms submitted by one of
the parties.
g. For all disputes other than those described in the preceding
paragraph f., the neutral shall be free to resolve the dispute in a manner
that is not consistent with the exact version of the proposed terms submitted
by one of the parties.
h. A hearing will be conducted on 2 consecutive days and shall be
governed by the following rules:
(i) Each party shall be entitled to 5 hours of hearing time to
present its case. The neutral shall decide when each party has
utilized its 5 hours.
(ii) Each party shall be entitled to make an opening statement, to
present regular and rebuttal testimony, documents or other evidence,
and to cross-examine the other party's witnesses; provided, however,
cross-examination shall occur immediately following direct testimony
and the time shall be charged against the party conducting the
cross-examination.
i. Within 7 days following the hearing, each party shall submit to the
other party and the neutral a post-hearing brief in support of its proposed
rulings and remedies, provided that such brief shall not exceed 10 pages
(including all attachments) regardless of the number of issues resolved.
j. With respect to disputes concerning the royalty which should be
charged for the licensure of patent rights subject to the option grants of
Article 3 of the Agreement, the neutral, in reaching an award, is free to
consider all relevant economic factors, including:
(i) royalties paid for other comparable intellectual property;
(ii) the absolute value of the technology at issue;
(iii) the relative value of the technology to other technology that
enables substantially the licensed product;
(iv) the effect of "royalty stacking" upon the viability and
profitability of the licensed product;
(v) any aggregation royalty caps or offset/sharing methodology
agreed to by the parties; and
(vi) any royalties which a licensing party hereunder is required to
pay to its licensor.
2
<PAGE>
k. The neutral shall rule in writing within 14 days following the
completion of the hearing.
l. The parties shall split equally the expenses of the neutral.
Insofar as it is the parties' intent to conduct the ADR in an
expeditious manner, the parties hereby acknowledge that all of the terms and
provisions of the foregoing shall be strictly applied unless the parties
agree otherwise, or unless the neutral determines, upon good cause shown
after an opportunity for both sides to present their positions, that
extraordinary circumstances are present which justify modification; provided,
however, the only provisions which shall be subject to modification pursuant
to this paragraph (m) shall be provision (d); the 5 hour time limit set forth
in provision (e); and provisions (h), (i) and (k).
3
<PAGE>
EXHIBIT A
COMPENSATION TO CHIRON
1. LICENSE FEES.
(a) ABBOTT shall pay CHIRON upon the Effective Date an upfront license
fee in the amount of [CONFIDENTIAL TREATMENT REQUESTED] (the "Base License
Fee"). Except as provided in paragraph 1(b) of Exhibit A, the Base License
Fee shall be nonrefundable and fully earned when paid.
(b) In the event that ABBOTT elects to terminate all but not less than
all of its rights under this Agreement pursuant to Section 8.2 by delivering
an irrevocable written notice thereof to CHIRON prior to the earlier of
[CONFIDENTIAL TREATMENT REQUESTED], or such other date as the parties may
mutually agree in writing, or the First Commercial Sale Date, then CHIRON
shall promptly following the receipt of such notice fully refund to ABBOTT,
without interest, the amount of the Base License Fee.
(c) ABBOTT shall pay CHIRON upon the First Commercial Sale Date an
additional payment in the amount of [CONFIDENTIAL TREATMENT REQUESTED] plus
interest from [CONFIDENTIAL TREATMENT REQUESTED], at the rate provided in
Section 5.9, which amount shall be nonrefundable and fully earned when paid.
2. EARNED ROYALTY. Subject to the adjustments referenced in paragraphs 5,
6 and 7 of Exhibit A, and in consideration of the licenses granted pursuant
to Section 2.1, ABBOTT shall pay earned royalties equal to
[CONFIDENTIAL TREATMENT REQUESTED] of Net Sales of Licensed Products (the
"Earned Royalty"; [CONFIDENTIAL TREATMENT REQUESTED].
Earned Royalties shall be payable quarterly commencing with the first
full or partial Calendar Quarter following the Effective Date, within sixty
(60) days following the end of each Calendar Quarter, and shall be
accompanied by a report pursuant to Article 5 of this Agreement.
3. MINIMUM ROYALTY. Notwithstanding the Earned Royalties due pursuant to
paragraph 2 of Exhibit A, and subject to the adjustments referenced in
paragraphs 2, 5, 6, 7, 8 and 9 of Exhibit A, Earned Royalties paid in any
Calendar Quarter shall not be less than a minimum royalty [CONFIDENTIAL
TREATMENT REQUESTED] in such quarter calculated for each category of Licensed
Product (a "Product Category") as follows (the "Minimum Royalty"):
[CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED].
1
<PAGE>
(a) Minimum Royalties for Licensed Products shall be determined on
[CONFIDENTIAL TREATMENT REQUESTED], except to the extent adjusted on a
[CONFIDENTIAL TREATMENT REQUESTED].
(b) At the request of ABBOTT, the parties shall meet and reasonably
consider adjustment to the Minimum Royalty amounts with respect to any Licensed
Product in any country in the event that action by governmental pricing or
reimbursement authority or other governmental agency results in a requirement
that ABBOTT or its Affiliates sell such Licensed Product at a price below
[CONFIDENTIAL TREATMENT REQUESTED] of the [CONFIDENTIAL TREATMENT REQUESTED]
amount for such Licensed Product in such country; provided that no adjustment
shall be made to the Minimum Royalty unless mutually agreed or determined
pursuant to ADR as provided in this subparagraph 3(b). The parties intend that
any adjustments be made to cause the Minimum Royalty with respect to the
affected Licensed Product in the affected country to be consistent with the
economic expectations of parties hereunder to the greatest extent possible, and
to bear a similar relationship to the mandated maximum pricing of the affected
Licensed Product as is borne to the Minimum Royalties specified in paragraph 3.
If the parties are unable to agree on an adjustment mechanism, the matter shall
be submitted to ADR under Article 11, except that any arbitration shall be
conducted "baseball style" as is set forth in paragraph (f) of Attachment 1 of
the Agreement. [CONFIDENTIAL TREATMENT REQUESTED].
(c) ABBOTT shall pay the amount of Minimum Royalties quarterly commencing
with the first full or partial Calendar Quarter following the Effective Date,
within sixty (60) days following the end of each Calendar Quarter. The payment
shall be accompanied by a report pursuant to Article 5, and shall be fully
creditable against Earned Royalties payable pursuant to paragraph 2 of Exhibit A
for the same Calendar Quarter.
4. SINGLE ROYALTY PER LICENSED PRODUCT. Only one payment of Earned Royalty
shall be due with respect to any Net Sales or only one payment of Minimum
Royalty shall be due with respect to any Unit of Licensed Product Shipped,
whatever is higher, irrespective of the number of patents or Valid Claims in the
Licensed Patents covering such Licensed Product.
5. [CONFIDENTIAL TREATMENT REQUESTED] MOST FAVORED LICENSE ADJUSTMENT. The
rates of Earned Royalties and the amounts of Minimum Royalties shall be adjusted
[CONFIDENTIAL TREATMENT REQUESTED] so that the [CONFIDENTIAL TREATMENT
REQUESTED] hereunder, as calculated by the formula:
[CONFIDENTIAL TREATMENT REQUESTED]
By way of example, without limitation, in the event that [CONFIDENTIAL
TREATMENT REQUESTED].
2
<PAGE>
Such adjustment shall be on a product-by-product and country by country
basis and shall be subject to the same terms as are applicable [CONFIDENTIAL
TREATMENT REQUESTED] but in no event higher than the applicable Earned Royalty
rate or Minimum Royalty amounts provided in paragraphs 2 and 3 of Exhibit A,
respectively.
6. ABBOTT MOST FAVORED LICENSEE ADJUSTMENTS.
(a) OPTIONAL ADJUSTMENT. In the event that after the Effective Date
CHIRON or [CONFIDENTIAL TREATMENT REQUESTED] enters into an [CONFIDENTIAL
TREATMENT REQUESTED], ABBOTT shall have the [CONFIDENTIAL TREATMENT REQUESTED].
[CONFIDENTIAL TREATMENT REQUESTED]. For the avoidance of doubt, [CONFIDENTIAL
TREATMENT REQUESTED] but would otherwise retain all rights to most favored
licensee status contained in this Agreement.
(b) MANDATORY ADJUSTMENT. [CONFIDENTIAL TREATMENT REQUESTED] as
provided in this subparagraph 6(b) [CONFIDENTIAL TREATMENT REQUESTED].
(b)(1) ABBOTT's [CONFIDENTIAL TREATMENT REQUESTED] shall be reduced
[CONFIDENTIAL TREATMENT REQUESTED] payable by the [CONFIDENTIAL TREATMENT
REQUESTED].
(b)(2) Except as provided in subparagraphs [CONFIDENTIAL TREATMENT
REQUESTED], if the minimum royalty amount payable [CONFIDENTIAL TREATMENT
REQUESTED]:
[CONFIDENTIAL TREATMENT REQUESTED]
(b)(3) If the [CONFIDENTIAL TREATMENT REQUESTED]:
[CONFIDENTIAL TREATMENT REQUESTED]
(b)(4) If the [CONFIDENTIAL TREATMENT REQUESTED:
[CONFIDENTIAL TREATMENT REQUESTED]
(b)(5) The adjustments provided under these subparagraphs
[CONFIDENTIAL TREATMENT REQUESTED] shall be made on a [CONFIDENTIAL TREATMENT
REQUESTED] and shall be subject to the same terms and limitations as are
applicable to the [CONFIDENTIAL TREATMENT REQUESTED].
(b)(6) If an adjustment is made under subparagraph [CONFIDENTIAL
TREATMENT REQUESTED] to a [CONFIDENTIAL TREATMENT REQUESTED] (as could occur,
for example, [CONFIDENTIAL TREATMENT REQUESTED] under
3
<PAGE>
[CONFIDENTIAL TREATMENT REQUESTED] or otherwise, notwithstanding further
adjustments, if any, caused directly by the [CONFIDENTIAL TREATMENT REQUESTED].
(c) The adjustments shown in subparagraphs [CONFIDENTIAL TREATMENT
REQUESTED]. Licensed Products in other Product Categories shall receive
comparable adjustments, [CONFIDENTIAL TREATMENT REQUESTED] as applied to
[CONFIDENTIAL TREATMENT REQUESTED] adjusted to bear the same relationship to the
Minimum Royalty amount provided in [CONFIDENTIAL TREATMENT REQUESTED].
(d) For the avoidance of doubt, ABBOTT's rights under this paragraph 6
shall apply only to [CONFIDENTIAL TREATMENT REQUESTED] including, without
limitation, licenses granted by CHIRON to [CONFIDENTIAL TREATMENT REQUESTED].
7. [CONFIDENTIAL TREATMENT REQUESTED] ADJUSTMENT. In the event that there are
[CONFIDENTIAL TREATMENT REQUESTED]:
(a) [CONFIDENTIAL TREATMENT REQUESTED]
(b) [CONFIDENTIAL TREATMENT REQUESTED].
[CONFIDENTIAL TREATMENT REQUESTED].
For the avoidance of doubt, it is understood that the [CONFIDENTIAL TREATMENT
REQUESTED], and will continue to do so [CONFIDENTIAL TREATMENT REQUESTED].
8. [CONFIDENTIAL TREATMENT REQUESTED]. [CONFIDENTIAL TREATMENT
REQUESTED] the applicable [CONFIDENTIAL TREATMENT REQUESTED] amount
[CONFIDENTIAL TREATMENT REQUESTED] under the conditions described in
[CONFIDENTIAL TREATMENT REQUESTED] as described in [CONFIDENTIAL TREATMENT
REQUESTED].
(a) ABBOTT shall be entitled to [CONFIDENTIAL TREATMENT REQUESTED], for
so long as any of the following conditions exist [CONFIDENTIAL TREATMENT
REQUESTED] directed towards either other licensed competitors or toward
effecting a reduction in ABBOTT's applicable Minimum Royalty. The [CONFIDENTIAL
TREATMENT REQUESTED] are:
(1) [CONFIDENTIAL TREATMENT REQUESTED].
(2) [CONFIDENTIAL TREATMENT REQUESTED], or if this condition continues
to be satisfied through [CONFIDENTIAL TREATMENT REQUESTED] then for an
[CONFIDENTIAL TREATMENT REQUESTED].
4
<PAGE>
(3) [CONFIDENTIAL TREATMENT REQUESTED], by all others than [CONFIDENTIAL
TREATMENT REQUESTED].
(b) In the event that [CONFIDENTIAL TREATMENT REQUESTED] as follows:
(1) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
For the sake of illustration, in the event that the [CONFIDENTIAL TREATMENT
REQUESTED].
(2) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED]calculated by the following
formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(3) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(c) In the event that [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall
be entitled to [CONFIDENTIAL TREATMENT REQUESTED] as follows:
(1) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
For the sake of illustration,[CONFIDENTIAL TREATMENT REQUESTED].
(2) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
5
<PAGE>
(3) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(d) The adjustment shown in [CONFIDENTIAL TREATMENT REQUESTED] apply to
[CONFIDENTIAL TREATMENT REQUESTED].
(e) NOTWITHSTANDING ANY PROVISIONS OF THIS PARAGRAPH 8, [CONFIDENTIAL
TREATMENT REQUESTED].
9. [CONFIDENTIAL TREATMENT REQUESTED] ADJUSTMENT.
(a) The [CONFIDENTIAL TREATMENT REQUESTED]. Accordingly, during each
Calendar Quarter [CONFIDENTIAL TREATMENT REQUESTED] payable by ABBOTT shall be
subject to the [CONFIDENTIAL TREATMENT REQUESTED] if, and only if, all of the
following conditions are satisfied [CONFIDENTIAL TREATMENT REQUESTED]:
(1) [CONFIDENTIAL TREATMENT REQUESTED];
(2) [CONFIDENTIAL TREATMENT REQUESTED];
(3) [CONFIDENTIAL TREATMENT REQUESTED] during each of the [CONFIDENTIAL
TREATMENT REQUESTED];
(4) [CONFIDENTIAL TREATMENT REQUESTED]
(5) [CONFIDENTIAL TREATMENT REQUESTED].
If all of the foregoing conditions have occurred, [CONFIDENTIAL TREATMENT
REQUESTED] as follows:
(b) In the event that [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall
be entitled [CONFIDENTIAL TREATMENT REQUESTED] as follows:
(1) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
For the sake of illustration, in the event that the AUP of Licensed
Products is [CONFIDENTIAL TREATMENT REQUESTED] ABBOTT would [CONFIDENTIAL
TREATMENT REQUESTED].
6
<PAGE>
(2) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(3) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(c) In the event that [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall
be entitled [CONFIDENTIAL TREATMENT REQUESTED] as follows:
(1) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
For the sake of illustration, [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT
would [CONFIDENTIAL TREATMENT REQUESTED].
(2) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(3) [CONFIDENTIAL TREATMENT REQUESTED], ABBOTT shall be entitled
[CONFIDENTIAL TREATMENT REQUESTED] calculated by the following formula:
[CONFIDENTIAL TREATMENT REQUESTED]
(d) The adjustment shown in subparagraphs [CONFIDENTIAL TREATMENT
REQUESTED] bear the same relationship to the [CONFIDENTIAL TREATMENT REQUESTED]
provided in [CONFIDENTIAL TREATMENT REQUESTED].
(e) Notwithstanding any provision of this paragraph 9, [CONFIDENTIAL
TREATMENT REQUESTED].
7
<PAGE>
10. REPORTING.
(a) CHIRON shall provide ABBOTT with written notice promptly following,
but in any event, [CONFIDENTIAL TREATMENT REQUESTED] after CHIRON becomes aware
of, any of the following:
(1) Any change in the [CONFIDENTIAL TREATMENT REQUESTED] together with
the effective dates of any change;
(2) Any grant by CHIRON [CONFIDENTIAL TREATMENT REQUESTED] of any
Eligible Third Party License. Such notice shall [CONFIDENTIAL TREATMENT
REQUESTED]
(3) The granting of any order described in [CONFIDENTIAL TREATMENT
REQUESTED].
(b) CHIRON further shall provide, and ABBOTT hereby consents to the
provision by CHIRON of, a quarterly report [CONFIDENTIAL TREATMENT REQUESTED].
Such quarterly report shall be delivered not more than ninety (90) days after
the end of each Calendar Quarter, beginning with the first Calendar Quarter or
partial Calendar Quarter following the Effective Date.
(c) In the event that ABBOTT intends to claim [CONFIDENTIAL TREATMENT
REQUESTED] pursuant to paragraphs 7, 8 or 9 of Exhibit A, for any Calendar
Quarter, ABBOTT shall provide to CHIRON a written notice of such claim not later
than thirty (30) days prior to the beginning of such Calendar Quarter, which
notice shall include all information supporting such claim determined in
accordance with paragraphs 7, 8 or 9 of Exhibit A, as the case may be.
(d) CHIRON and ABBOTT shall each have the right to audit information
provided by the other pursuant to this paragraph 10. Such audits shall be
conducted in the same manner as is applicable to audits by CHIRON pursuant to
Sections 5.6 and 5.7.
11. [CONFIDENTIAL TREATMENT REQUESTED] ADJUSTMENTS. ABBOTT shall be
entitled [CONFIDENTIAL TREATMENT REQUESTED].
12. DISPUTE RESOLUTION. Any dispute between CHIRON and ABBOTT regarding
whether any adjustment to or credits against Earned Royalties or Minimum
Royalties under paragraphs 2, 3, 5, 6, 7, 8 and 9 of Exhibit A is appropriate,
and which the parties fail to resolve themselves may only be resolved by resort
to the ADR provisions of Article 11. Until such dispute is resolved, ABBOTT
shall pay CHIRON the Earned Royalty and Minimum Royalty provided for herein
without benefit of the applicable disputed adjustment on the condition that
CHIRON shall repay ABBOTT the amounts of such disputed payments if ABBOTT
prevails in the ADR, plus interest at the rate described in Article 5.9.
8
<PAGE>
EXHIBIT B
PATENT LIST
[CONFIDENTIAL TREATMENT REQUESTED]
<PAGE>
EXHIBIT C
EXISTING LICENSES OR RIGHTS GRANTED IN THE FIELD UNDER THE LICENSED PATENTS
AS OF THE EFFECTIVE DATE
[CONFIDENTIAL TREATMENT REQUESTED]
1
<PAGE>
SCHEDULE 1.1: [CONFIDENTIAL TREATMENT REQUESTED] Patent Rights
APPLICATION NO.
[CONFIDENTIAL TREATMENT REQUESTED]
PATENT NO.
[CONFIDENTIAL TREATMENT REQUESTED]
The patent rights set forth in this Schedule 1.1 shall further include all
patents and applications, including without limitation continuations,
divisionals, continuation-in-part, reissues, reexamined patents and the like,
which base priority upon one or more of the above, and further including all
corresponding foreign applications and granted patents based thereon.
<PAGE>
***CONFIDENTIAL TREATMENT REQUESTED***
EXHIBIT 10.311
SCHEDULE C-1
CROSS-LICENSE AGREEMENT
This Cross-License Agreement, (this "Agreement") is made, effective as of the
Effective Date, as defined below, by and between Chiron Corporation, a Delaware
corporation ("Chiron"), and Chiron Diagnostics Corporation, a Delaware
corporation ("CDC").
BACKGROUND
1. Chiron and Bayer Corporation, an Indiana corporation ("Purchaser"), have
entered into that certain Stock Purchase Agreement dated as of September 17,
1998 (the "Stock Purchase Agreement"), pursuant to which Purchaser is acquiring
the stock of CDC, effective on the Closing, as defined in the Stock Purchase
Agreement (such time referred to herein as the "Effective Date"). Pursuant to
the Stock Purchase Agreement, Chiron and CDC have further entered into that
certain Asset Transfer Agreement (the "Asset Transfer Agreement"), pursuant to
which, prior to the Closing, Chiron will transfer to CDC certain assets of
Chiron. Also pursuant to the Asset Transfer Agreement, prior to the Closing, CDC
will transfer to Chiron certain assets of CDC. Chiron and CDC each wish to
grant licenses to the other under certain patent rights and know-how which will
be owned by the licensing party after giving effect to the Asset Transfer
Agreement, all as further described below.
2. Chiron currently owns or controls certain patent rights relating to
hepatitis C virus ("HCV") and human immunodeficiency virus ("HIV"), and after
giving effect to the Asset Transfer Agreement, Chiron will own or control
certain patent rights theretofore owned or controlled by CDC relating to each of
HCV and HIV. Upon the Effective Date, Chiron is willing to grant licenses to
CDC under certain patent rights relating to each of HCV and HIV for use in
nucleic acid probe assays for in vitro diagnostics (excluding use in Blood
Screening, as defined below), all on the terms and conditions set forth herein.
3. Chiron currently owns or controls certain patent rights other than those
related to HCV or HIV, and after giving effect to the Asset Transfer Agreement,
Chiron will own or control certain patent rights theretofore owned or controlled
by CDC other than those related to HCV and HIV. Upon the Effective Date, Chiron
is willing to grant certain licenses to CDC under such patent rights, all on the
terms and conditions set forth herein.
4. CDC currently owns or controls certain patent rights, and after giving
effect to the Asset Transfer Agreement, CDC will own or control certain patent
rights theretofore owned or controlled by Chiron. Upon the Effective Date, CDC
is willing to grant certain licenses to Chiron under all such patent rights, all
on the terms and conditions set forth herein.
5. Each party is willing to grant to the other certain licenses under
certain know-how, all on the terms and conditions set forth herein.
1
<PAGE>
AGREEMENT
NOW, THEREFORE, in consideration of the above provisions and the mutual
covenants contained herein, the parties agree as follows:
1. DEFINITIONS
Capitalized terms not defined in this Agreement shall have the meanings set
forth in the Stock Purchase Agreement. The following defined terms shall have
the meanings set forth below:
1.1 "AFFILIATE" shall mean an entity that directly, or indirectly
through one or more intermediaries, controls or is controlled by or is under
common control with, a specified entity. For the purposes of this definition,
"control" (including with correlative meanings, the terms "controlling",
"controlled by" and "under common control with"), as applied to any entity,
means (a) the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of that entity, whether
through the ownership of voting securities or by contract or otherwise, and (b)
the ownership of at least fifty percent (50%) of the voting securities of that
entity. Notwithstanding anything to the contrary contained herein, "Affiliate"
shall not include, in the case of Chiron, Novartis AG or any Affiliate of
Novartis AG (other than Chiron and any of its direct or indirect subsidiaries).
For clarity of understanding, following the Effective Date, Affiliates of CDC
shall mean Purchaser and its Affiliates.
1.2 "ANCILLARY AGREEMENTS" shall have the meaning set forth in the
Stock Purchase Agreement.
1.3 "BLOOD SCREENING" shall mean (i) the screening of blood, plasma or
blood components intended for transfusion or for use in blood products (e.g.,
immunoglobulins), and (ii) the screening of any biological materials intended
for transfusion or transplantation, in each case from any donor, including
autologous donors.
1.4 "CDC HCV/HIV PROBE PRODUCT" shall mean a Probe IVD Product which
is researched, developed, manufactured, used or sold by CDC, a CDC Affiliate or
a permitted sublicensee of CDC, under circumstances which would, in the absence
of the licenses granted under Section 2.1, constitute an infringement of a Valid
Claim of a Chiron HCV/HIV Patent.
1.5 "CDC KNOW-HOW" shall mean all Know-How which is owned or
controlled by CDC or the Subsidiaries, as of the Effective Date, after giving
effect to the Asset Transfer Agreement, except for Know-How which CDC is
prohibited from licensing to Chiron hereunder pursuant to third party agreements
binding on CDC as of the Effective Date.
1.6 "CDC NON-HCV/HIV PRODUCT" shall mean an IVD Product (i) which is
researched, developed, manufactured, used or sold by or on behalf of CDC, a CDC
Affiliate or a permitted sublicensee of CDC, under circumstances which would, in
the absence of the licenses granted under Section 2.2, constitute an
infringement of a Valid Claim of a Chiron Non-HCV/HIV Patent, and (ii) which
does not infringe a Valid Claim of a Chiron HCV/HIV Patent.
2
<PAGE>
1.7 "CDC PATENT" shall mean (i) any patent or patent application (or
any patent issued thereon) which is within Included Company Patents or
Transferred Chiron Patents, and any divisions, extensions, renewals, reissues,
reexamination certificates and continuations of such patents and patent
applications; or (ii) any invention which is the subject of a patent application
filed by CDC or its then Affiliates, or a written invention disclosure received
by CDC or its then Affiliates from a person obligated to assign inventions to
CDC or its then Affiliates, in each case within [CONFIDENTIAL TREATMENT
REQUESTED] following the Effective Date, which falls within the scope of the
claims of any Included Company Patent, Transferred Chiron Patent, a patent or
patent application referenced in Schedule 1.7(a) of the Stock Purchase
Agreement, an Excluded Chiron Patent or a Transferred Company Patent, together
with any patent applications claiming such invention (or any patent issued
thereon) and any divisions, extensions, renewals, reissues, reexamination
certificates and continuations thereof; or (iii) any CDC Sublicensable Patent as
to which Chiron has elected, pursuant to Section 2.6, to take a sublicense.
1.8 "CDC SUBLICENSABLE PATENT" shall mean any patent or patent
application (i) which is licensed to CDC or the Subsidiaries by a third party as
of the Effective Date; or which is licensed to Chiron or any Other Chiron
Affiliate by a third party under a license agreement which is assigned to CDC
pursuant to the Asset Transfer Agreement; and (ii) as to which CDC has the right
to grant a sublicense to Chiron.
1.9 "CHIRON HCV/HIV PATENT" shall mean (i) any patent or patent
application (or any patent issued thereon) listed in Schedule 1.7(a) of the
Stock Purchase Agreement, and any divisions, extensions, renewals, reissues,
reexamination certificates and continuations of such patents and patent
applications; or (ii) any invention which is the subject of a patent application
filed by Chiron or its Affiliates, or a written invention disclosure received by
Chiron or its then Affiliates from a person obligated to assign inventions to
Chiron or its then Affiliates, in each case within the [CONFIDENTIAL TREATMENT
REQUESTED] following the Effective Date, which falls within the scope of the
claims of a patent or patent application listed in Schedule 1.7(a) of the Stock
Purchase Agreement, together with any patent applications claiming such
invention (or any patent issued thereon) and any divisions, extensions,
renewals, reissues, reexamination certificates and continuations thereof; or
(iii) any Chiron Sublicensable Patent with respect to HCV or HIV as to which CDC
has elected, pursuant to Section 2.5, to take a sublicense.
1.10 "CHIRON IVD KNOW-HOW" means that Know-How which is owned or
controlled by Chiron or any Other Chiron Affiliate, as of the Effective Date,
after giving effect to the Asset Transfer Agreement, which relates to the
Included Businesses, except for Know-How which Chiron is prohibited from
licensing to CDC hereunder pursuant to third party agreements binding on Chiron
as of the Effective Date.
1.11 "CHIRON NON-HCV/HIV PATENT" shall mean (i) any patent or patent
application (or any patent issued thereon) which is within Excluded Chiron
Patents, and any divisions, extensions, renewals, reissues, reexamination
certificates and continuations of such patents and patent applications; or (ii)
any invention which is the subject of a patent application filed by Chiron or
its Affiliates, or a written invention disclosure received by Chiron or its
Affiliates from a person obligated to assign inventions to Chiron or its
Affiliates, in each case within the [CONFIDENTIAL TREATMENT REQUESTED] following
the Effective Date, which falls
3
<PAGE>
within the scope of the claims of any Included Company Patent, Transferred
Company Patent, Excluded Chiron Patent or Transferred Chiron Patent, together
with any patent applications claiming such invention (or any patent issued
thereon) and any divisions, extensions, renewals, reissues, reexamination
certificates and continuations thereof; or (iii) any Chiron Sublicensable Patent
other than those with respect to HCV or HIV, as to which CDC has elected,
pursuant to Section 2.5, to take a sublicense.
1.12 "CHIRON SUBLICENSABLE PATENT" shall mean a patent or patent
application which is subject to a license agreement identified as an Excluded
Chiron License, or a Transferred Company License, or any other license agreement
covering patents or patent applications which are used in Products or Products
In Development as of the Effective Date, in each case, as to which Chiron has
the right to grant a sublicense to CDC.
1.13 "INFORMATICS PRODUCT" shall mean any product or service
consisting of information technology for use in healthcare, excluding IVD
Products.
1.14 "IVD PRODUCT" shall mean a product for use in IN VITRO testing of
human specimens for the purpose of diagnosis, prognosis, or monitoring the
progress of disease or monitoring the effect of treatment of disease, in the
human from which the specimens were taken. For the avoidance of doubt, IVD
Products expressly exclude all products for use in Blood Screening, and all
Vaccine/Therapeutic Products.
1.15 "KNOW-HOW" shall mean unpatented inventions, discoveries,
information, trade secrets, data, results and biological materials.
1.16 "LICENSED CDC PRODUCT" shall mean a CDC HCV/HIV Probe Product or a
CDC Non-HCV/HIV Product.
1.17 "Licensed Chiron Patent" shall mean a Chiron HCV/HIV Patent or a
Chiron Non-HCV/HIV Patent.
1.18 "LICENSED CHIRON PRODUCT" shall mean a product which is
researched, developed, manufactured, used or sold by Chiron, a Chiron Affiliate
or a permitted sublicensee, under circumstances which would, in the absence of
the licenses granted under Section 2.3 or 2.4, constitute an infringement of a
Valid Claim of a CDC Patent.
1.19 "NET SALES" shall mean the amount billed or invoiced for products
sold by CDC, its Affiliates, or its sublicensees, less:
i) Discounts actually allowed and taken;
ii) Amounts repaid or credited by reason of rejection or return;
iii) To the extent separately stated on purchase orders,
invoices or other documents of sale, taxes levied on and/or other
governmental charges made as to production, or transportation or
insurance charges;
4
<PAGE>
iv) The reasonable value of the instrument, instrument financing,
consumables other than the products in question, and service
components of an operating or capital lease for instrumentation
on which the products are used, for which the charges are included
in the price of the products purchased by the lessee, provided
that the methods for determining such values shall be proposed by
CDC and subject to Chiron's written consent, not to be
unreasonably withheld;
v) Charges for freight, handling and transportation paid by the
selling entity; and
vi) Sales, use and value-added taxes and other similar taxes incurred
and separately stated on invoices.
1.19.1 Net Sales shall include all sales to non-Affiliate third
parties, including sales to Authorized Distributors in countries where,
due to regulatory constraints and/or market practice, substantially all
sales of the relevant CDC HCV/HIV Probe IVD Product and competitive third
party products are made through Authorized Distributors, provided that
CDC shall use reasonable efforts in connection with sales to such
Authorized Distributors to comply with clause (i) immediately below.
With respect to sales to all other Authorized Distributors, if Net Sales
are based on the transfer price to the Authorized Distributor rather than
end user sales, either (i) Net Sales on which royalties shall be
calculated shall be deemed to be not less than the higher of the average
selling price for the applicable product in the United States or the
European Union, or (ii) the parties shall adopt another mechanism for
preserving for Chiron the same economics as if such sales had been made
by CDC or its Affiliate or its sublicensee rather than the Authorized
Distributor. Any such mechanism shall be proposed by CDC and shall be
subject to Chiron's written consent, which shall not be unreasonably
withheld.
1.19.2 For clarity of understanding, Net Sales shall not include
any product furnished to third parties for which no payment is received,
such as experimental, test market, promotional or other free goods. On
the other hand, Net Sales shall include any product furnished in return
for payment, whether or not such product is for commercial, research or
other use. For clarity of understanding, Minimum Royalties shall apply
to each Unit of product shipped to a customer for any purpose, except for
Units supplied to third parties at no charge (i) for use in Purchaser's
preclinical or clinical trials; or (ii) for testing, quality control or
evaluation purposes. Without limiting the foregoing, products furnished
to third parties at price discounts, including without limitation free
goods furnished as part of sales promotions, shall be subject to Minimum
Royalties. A sale shall be deemed to have been made and Earned Royalties
or Maximum Royalties incurred, (except as specifically set forth in this
Section 1.19.2) when the product is shipped ("Shipped"); provided that
where an invoice is issued, the obligations to pay Earned Royalties and
Minimum Royalties hereunder shall arise on the invoice date. Sales to or
between Affiliates shall not be included in Net Sales until an Affiliate
consumes the product in providing a commercial service for a
non-Affiliate third party or Ships the product to a non-Affiliate third
party.
5
<PAGE>
1.19.3 In the event that product subject to royalties hereunder is
sold in combination with another product or active component, other than
instrumentation covered under Section 1.19(iv) above, for a single price
(a "Combination Product"), Net Sales from sales of a Combination Product,
for purposes of calculating royalties due or allocating profits under
this Agreement shall be calculated by multiplying the Net Sales of that
Combination Product by the fraction A/(A+B), where A is the average per
unit selling price in the country of sale, during the applicable
reporting period, of the product subject to royalties hereunder if sold
separately in the country of sale and B is the average per unit selling
price in the country of sale, during the applicable reporting period, of
the other product(s) or component(s) sold separately in the country of
sale. In the event that no such separate sales are made, Net Sales, for
purposes of determining royalty payments on such Combination Products,
shall be a reasonable apportionment of the gross amount invoiced therefor
based upon the relative contribution of the product subject to royalties
hereunder to the price of the Combination Product. Such apportionment
shall be determined by CDC based upon its past practice and experience,
and shall be subject to Chiron's written consent, which shall not be
unreasonably withheld.
1.19.4 In the event that CDC or a CDC Affiliate performs assays
for commercial purposes utilizing CDC HCV/HIV Probe Products, Net Sales
shall mean the invoiced amount for the patient result provided as a
result of performance of such assays, less a reasonable deduction for the
value of the services and or other products provided therewith, less the
applicable deductions pursuant to Section 1.19. The allocation of value
to services or other products provided shall be determined by CDC based
upon its past practice and experience, and shall be subject to Chiron's
written consent, which shall not be unreasonably withheld.
1.20 "OPEN KIT" shall mean a bDNA based assay kit comprising solely the
generic components of bDNA assay kits, then offered as IVD Products, and
excluding any target probe(s).
1.21 "PROBE IVD PRODUCT" shall mean an IVD Product for the detection or
quantification of nucleic acid sequences.
1.22 "RESEARCH TOOL" shall mean a product sold for research use only
and not for use as an IVD Product, the manufacture, use or sale of which, but
for the licenses granted under Section 2.4, would infringe a CDC Patent.
Notwithstanding the foregoing, Research Tools specifically exclude Open Kits.
1.23 "THERAMETRICS PRODUCT" shall mean a product having both an IVD
Product component and a Vaccine/Therapeutic Product component, wherein such
components are contained in a single package and wherein the information
provided by the IVD Product component is medically and functionally related to
the IN VIVO effect provided by the Vaccine/Therapeutic Product component.
6
<PAGE>
1.24 "UNIT" shall mean the number of individual patient results
generated by the use of a CDC HCV/HIV Probe Product, such that the number of
Units contained in such CDC HCV/HIV Probe Product equals the number of patient
results which are obtained through use of such CDC HCV/HIV Probe Product assay
kit, as determined in a manner to be proposed by CDC, and subject to Chiron's
written consent, which shall not be unreasonably withheld.
1.25 "VACCINE/THERAPEUTIC PRODUCT" shall mean any product that is
intended for IN VIVO effect regardless of whether the method of administration
is IN VIVO, or EX VIVO, to prevent, control, treat, mitigate or alter the course
of disease or otherwise maintain or improve health, including for the avoidance
of doubt, IN VIVO or EX VIVO genetic manipulation, excluding all IVD Products.
1.26 "VALID CLAIM" shall mean a claim in any issued, active, unexpired
Licensed Chiron Patent or CDC Patent (as the context indicates) which has not
been withdrawn, canceled, lapsed or disclaimed, or held unpatentable, invalid or
unenforceable by a non-appealed or nonappealable decision by a court or other
appropriate body of competent jurisdiction. The scope of a Valid Claim shall be
limited to its terms as defined by any such court or decision-making body of
competent jurisdiction.
2. LICENSE AND OPTION GRANTS
2.1 CHIRON HCV/HIV PATENTS. Subject to the terms and conditions of
this Agreement and subject to the rights of third parties under existing license
agreements listed in Schedule 2.13(j) of the Stock Purchase Agreement, Chiron
hereby grants to CDC and its Affiliates, for so long as they remain Affiliates,
a worldwide license under the Chiron HCV/HIV Patents to research, develop, make,
have made, use and sell CDC HCV/HIV Probe Products. Such license shall bear
royalties in accordance with Section 3.1.
2.1.1 The license granted under this Section 2.1 is transferable
only pursuant to Section 11.5. CDC shall have the right to grant sublicenses
hereunder as follows:
(a) CDC shall not grant any sublicenses, with respect to
HCV or HIV, prior to the earlier of the effective date of the first license
granted by Chiron pursuant to Section 2.1.3, or the first commercial sale of a
Probe IVD Product by Chiron pursuant to Section 2.1.3, with respect to HCV or
HIV, respectively.
(b) Thereafter, CDC may, with respect to each of HCV and
HIV, grant up to [CONFIDENTIAL TREATMENT REQUESTED], on a cumulative basis. In
lieu of [CONFIDENTIAL TREATMENT REQUESTED], CDC may elect to offer [CONFIDENTIAL
TREATMENT REQUESTED] with respect to each of HCV and HIV, in each of the four
regions identified in Section 2.1.3(b), on a cumulative basis.
(i) Notwithstanding the foregoing, CDC shall not
grant any such sublicense, whether worldwide or regional, without Chiron's prior
written consent (which shall not be unreasonably withheld), [CONFIDENTIAL
TREATMENT REQUESTED].
7
<PAGE>
(ii) After the test set forth in Section 2.1.1 (b)
(i) has been satisfied, CDC may grant sublicenses in its discretion, subject to
the limits of this Section 2.1.1.
(c) Each sublicense granted by CDC hereunder with respect
to HCV shall bear earned royalties and minimum royalties which are at least
[CONFIDENTIAL TREATMENT REQUESTED] (measured as [CONFIDENTIAL TREATMENT
REQUESTED] of the earned royalties or minimum royalties) [CONFIDENTIAL TREATMENT
REQUESTED] earned royalties and minimum royalties payable by [CONFIDENTIAL
TREATMENT REQUESTED] licensees of Chiron pursuant to Section 2.1.3, with respect
to HCV, in the relevant region; provided that after Chiron has granted
[CONFIDENTIAL TREATMENT REQUESTED] authorized under Section 2.1.3 with respect
to any region, or Chiron is engaged in the sale of Probe IVD Product directed to
HCV and Chiron has granted [CONFIDENTIAL TREATMENT REQUESTED] authorized under
Section 2.1.3 with respect to HCV with respect to any region, CDC shall not be
required to impose on its sublicensees earned royalties and minimum royalties
which are [CONFIDENTIAL TREATMENT REQUESTED] than the [CONFIDENTIAL TREATMENT
REQUESTED] earned royalties and minimum royalties payable by [CONFIDENTIAL
TREATMENT REQUESTED] of Chiron pursuant to Section 2.1.3 with respect to HCV in
the relevant region.
(d) The Earned Royalties and Minimum Royalties payable by
CDC to Chiron under this Agreement with respect to sublicensee sales in any
region shall be equal to the applicable amounts payable pursuant to Exhibit A
hereto [CONFIDENTIAL TREATMENT REQUESTED].
(e) Except as provided in this Section 2.1.1, any
sublicense permitted under this Section 2.1.1 shall be subject to all of the
terms and conditions of this Agreement.
(f) In the event that a sublicense granted by CDC pursuant
to Section 2.1.1(b) is terminated, CDC shall have the right to replace such
license consistent with the limitations set forth in this Section 2.1.1.
2.1.2 CDC acknowledges and agrees that the inclusion of CDC
Affiliates within the license grant pursuant to Section 2.1 is intended to
enable CDC to utilize the manufacturing and sales capabilities of its Affiliates
in connection with the manufacture and sale of CDC HCV/HIV Probe Products in a
manner substantially similar to the involvement of such Affiliates in the
manufacture and sale of Purchaser's products generally. CDC and its Affiliates
shall not evade the sublicensing provisions of Section 2.1.1 by creating
affiliates specifically in connection with CDC HCV/HIV Probe Products, or
through other third party arrangements such as joint ventures, collaborations,
or distribution arrangements with distributors other than Authorized
Distributors as defined herein. CDC and its Affiliates are licensed hereunder
only to sell or distribute CDC HCV/HIV Probe Products, under the label, name and
trademark of CDC or its Affiliates, only through the sales force of CDC or its
Affiliates, or through the following entities (which entities are referred to
herein as "Authorized Distributors"): (i) local third party distributors which
are not engaged, and which are not affiliates (based on the criteria in Section
1.1, except that the definition of control shall be based on either
Section 1.1(a) or (b)) of any entity which is engaged, in the global sale of
diagnostic products or (ii) an entity to which CDC is then authorized to grant a
sublicense
8
<PAGE>
pursuant to Section 2.1.1 and with which CDC then enters into a distribution
agreement in lieu of granting a sublicense. CDC and its Affiliates are not
licensed to perform OEM manufacturing of CDC HCV/HIV Probe Products for a third
party other than an Authorized Distributor; to supply CDC HCV/HIV Probe Products
for resale to any third party other than an Authorized Distributor; or to permit
any Authorized Distributor or other third party to sell any CDC HCV/HIV Probe
Product under another third party label, name or trademark or to permit any
Authorized Distributor or other third party to sell any CDC HCV/HIV Probe
Product under its own label, name or trademark for use on an instrument bearing
the label name or trademark of another party, except pursuant to a sublicense
authorized pursuant to Section 2.1.1.
2.1.3 The license granted to CDC and its Affiliates under this
Section 2.1 shall be semi-exclusive with respect to Probe IVD Products.
Semi-exclusive means that, in addition to licenses to third parties existing as
of the date of the Stock Purchase Agreement, Chiron retains the right to
practice under the Chiron HCV/HIV Patents itself, subject to the Non-Competition
Agreement, and/or to grant [CONFIDENTIAL TREATMENT REQUESTED] under the Chiron
HCV/HIV Patents, in each case to research, develop, make, have made, use and
sell Probe IVD Products with respect to each of HCV and HIV, as follows:
(a) Except to the extent CDC otherwise consents pursuant
to Section 2.1.3(e) below, with respect to each of HCV and HIV, Chiron may grant
up to [CONFIDENTIAL TREATMENT REQUESTED] with respect to Probe IVD Products if
Chiron is not directly engaged in the sale of Probe IVD Products directed to HCV
or HIV, as the case may be, or Chiron may grant [CONFIDENTIAL TREATMENT
REQUESTED] if Chiron is directly engaged in the sale of Probe IVD Products
directed to HCV or HIV, as the case may be.
(b) (i) If Chiron has granted one worldwide license
pursuant to Section 2.1.3(a), and Chiron is not then directly engaged in the
sale of Probe IVD Products with respect to HCV or HIV, as applicable, Chiron
shall thereafter have the right, in Chiron's sole discretion, in lieu of the
[CONFIDENTIAL TREATMENT REQUESTED] permitted pursuant to Section 2.1.3(a), to
grant a license for each of HCV and HIV in each of the following four regions:
(aa) North America, (bb) the European Union, (cc) Japan and (dd) all other
countries of the world.
(ii) If Chiron has not granted any worldwide
license pursuant to Section 2.1.3(a), and Chiron is not directly engaged in the
sale of Probe IVD Products with respect to HCV or HIV, as applicable, Chiron
shall have the right to grant up to [CONFIDENTIAL TREATMENT REQUESTED] for each
of HCV and HIV in each of the four regions described above with CDC's prior
written consent. Such regional sublicenses may not be granted until the
expiration of [CONFIDENTIAL TREATMENT REQUESTED] after the Effective Date.
After the [CONFIDENTIAL TREATMENT REQUESTED] the Effective Date, regional
sublicenses pursuant to this Section 2.1.3 (b) (ii) may be granted only with
CDC's prior written consent, not to be unreasonably withheld, unless and until
Chiron has granted [CONFIDENTIAL TREATMENT REQUESTED]; and thereafter Chiron
shall have the right to grant any further regional licenses pursuant to this
Section 2.1.3 (b) at its sole discretion. In the event that Chiron elects to
grant [CONFIDENTIAL TREATMENT REQUESTED] with respect to HCV, the provisions of
Paragraph 3(b) of Exhibit A shall apply in lieu of the provisions of Paragraph
3(a) of Exhibit A.
9
<PAGE>
(c) If Chiron chooses to engage directly in sales of Probe
IVD Products directed to HCV (subject to the Non-Compete Agreement), such
activities of Chiron shall replace [CONFIDENTIAL TREATMENT REQUESTED] Chiron is
permitted to grant under Section 2.1.3(a) if Chiron's sales are worldwide; or if
Chiron's sales are regional, such activities shall replace [CONFIDENTIAL
TREATMENT REQUESTED] of the [CONFIDENTIAL TREATMENT REQUESTED] which Chiron is
permitted to grant under Section 2.1.3 (b), in each region where Chiron sells
such Probe IVD Product directed to HCV. For the avoidance of doubt, it is
understood that Chiron shall have no right to engage directly in sales of IVD
Probe Products directed to HCV in any country in which [CONFIDENTIAL TREATMENT
REQUESTED] (whether global or regional) granted by Chiron under this Section
2.1.3 are in effect.
(d) The limitations with respect to Chiron's ability to
grant licenses under the Chiron HCV/HIV Patents set forth in Sections 2.1.3(a)
and (b) shall be effective from the date of the Stock Purchase Agreement. With
respect to each license which Chiron is permitted to grant under this Section
2.1.3:
(i) Chiron shall have the right to select the
licensee and negotiate the terms of the license in its complete and sole
discretion, except as expressly agreed in this Agreement.
(ii) Chiron shall retain 100% of the proceeds of
any such license.
(iii) Any such additional licenses shall be subject
to the terms set forth in Paragraph 3 of Exhibit A.
(iv) Such additional licenses shall not include the
rights to grant sublicenses, except to Affiliates for so long as they remain
Affiliates of the licensee, and shall contain provisions not less restrictive
than those set forth in Section 2.1.2.
(e) With respect to each of HCV and HIV, Chiron shall not
have the right to grant licenses under the Chiron HCV/HIV Patents for the
research, development, manufacture, use or sale of Probe IVD Products beyond
those permitted under Section 2.1.3(a) or (b) except with the prior written
consent of CDC, which may be granted in CDC's sole discretion. In the event
that a license granted by Chiron pursuant to Section 2.13(a) or (b) is
terminated, Chiron shall have the right to replace such license with a new
license, consistent with the limitations set forth in Section 2.1.3(a) or (b).
(f) Notwithstanding the foregoing, Chiron retains a
non-exclusive right under the Chiron HCV/HIV Patents to conduct research with
respect to Probe IVD Products.
(g) The following provisions shall apply with respect to
third party patents directed to HCV, which are within the scope of Valid Claims
of Chiron HCV/HIV Patents, and Valid Claims of which, but for licenses granted
pursuant to this Section 2.1.3 (g), would be infringed by the manufacture, use
or sale of CDC HCV/HIV Probe Products directed to HCV which being sold or under
development as of the Effective Date ("Third Party HCV Patents").
10
<PAGE>
(i) If a Third Party HCV Patent is owned or
controlled by a licensee of Chiron pursuant to Section 2.1.3 (a) or (b), Chiron
agrees that it will not acquire a license under such Third Party HCV Patent for
use in Probe IVD Products (but without limiting Chiron's rights to acquire a
license only for use in Blood Screening), unless Chiron [CONFIDENTIAL TREATMENT
REQUESTED].
(ii) If a Third Party HCV Patent is owned by an
entity other than a licensee of Chiron pursuant to Section 2.1.3 (a) or (b), and
if Chiron acquires a license under such Third Party HCV Patent for use in Probe
IVD Products (but without limiting Chiron's right to acquire a license only for
use in Blood Screening), Chiron will [CONFIDENTIAL TREATMENT REQUESTED].
(h) All licenses entered into by Chiron pursuant to this
Section 2.1.3 shall be with parties actively engaged, or reasonably expected to
be actively engaged, in the sale and distribution of Probe IVD Products in the
region or regions covered by the license and the terms thereof shall be
bona-fide commercial terms negotiated at arm's length.
2.2 CHIRON NON-HCV/HIV PATENTS. Subject to the terms and conditions
of this Agreement, and subject to any rights of third parties existing as of the
date of the Stock Purchase Agreement under license agreements listed in Schedule
2.13(j) of the Stock Purchase Agreement, Chiron hereby grants to CDC and its
Affiliates (i) an exclusive worldwide license, under the Chiron Non-HCV/HIV
Patents to research, develop, make, have made, use and sell CDC Non-HCV/HIV
Products and Open Kits; and (ii) a non-exclusive worldwide license, under the
Chiron Non-HCV/HIV Patents to research, develop, make, have made, use and sell
Research Tools. CDC shall have the right to grant sublicenses under such
licenses, except to the extent restricted pursuant to Section 2.5. [CONFIDENTIAL
TREATMENT REQUESTED].
2.3 CDC PATENTS.
(a) Subject to the terms and conditions of this Agreement, CDC
hereby grants to Chiron and its Affiliates an exclusive worldwide license, with
the right to sublicense except to the extent restricted pursuant to Section 2.6,
under the CDC Patents to research, develop, make, have made, use and sell any
and all products for use in Blood Screening.
(b) To the extent any CDC Patents are subject to the exclusive
license to Ortho under the Chiron/Ortho Agreement, CDC hereby grants Chiron an
exclusive worldwide license, with right to sublicense, except to the extent
restricted pursuant to Section 2.6, under such CDC Patents, to research,
develop, make, have made, use and sell any and all products subject to the
Chiron/Ortho Agreement.
(c) CDC hereby grants to Chiron a non-exclusive worldwide
license under the CDC Patents, (i) to research, develop, make, have made, use
and sell any and all Vaccine/Therapeutic Products and Informatics Products, with
the right to sublicense except to the extent restricted pursuant to Section 2.6;
and (ii) subject to the Non-Competition Agreement, to
11
<PAGE>
conduct internally or for or with third parties, research of all types and for
all purposes, whether internal, collaborative, commercial, or non-commercial.
(d) CDC hereby grants to Chiron a non-exclusive, worldwide
license under the CDC Patents, to research, develop, make, have made, use and
sell any and all Therametrics Products, with the right to sublicense except to
the extent restricted pursuant to Section 2.6, and subject to the following.
Chiron hereby grants to CDC the option to manufacture and supply on an exclusive
basis and on commercially reasonable terms, any IVD Product which is a component
of a Therametrics Product, if the manufacture, use or sale of such IVD Product
would, but for the license granted hereunder, infringe a Valid Claim of a CDC
Patent. Such option shall be exercisable by CDC on written notice to Chiron
within [CONFIDENTIAL TREATMENT REQUESTED] following receipt by CDC of written
notice from Chiron describing the IVD Product in question. If CDC exercises
such option, the parties shall negotiate in good faith a supply agreement on
reasonable commercial terms. Any terms which cannot be agreed upon within
[CONFIDENTIAL TREATMENT REQUESTED] after exercise of the option shall be
submitted for resolution under Article 10. If CDC fails to exercise the option,
Chiron shall be free to manufacture or have manufactured and sell the IVD
Product pursuant to the license granted herein.
(e) [CONFIDENTIAL TREATMENT REQUESTED]. For avoidance of
doubt, this Section 2.3 (e) shall not apply to any supply agreement pursuant to
Section 2.3(d).
2.4 OPTION FOR RESEARCH TOOLS. CDC hereby grants to Chiron an option
to obtain one or more non-exclusive licenses, on commercially reasonable terms
and royalty rates to be negotiated in good faith, under the CDC Patents, to
make, have made, use and sell Research Tools. Such option shall be exercised by
Chiron on a Research Tool by Research Tool basis.
2.5 CHIRON SUBLICENSABLE PATENTS.
2.5.1 [CONFIDENTIAL TREATMENT REQUESTED] following the Effective
Date, Chiron shall grant sublicenses to CDC under any or all of the Chiron
Sublicensable Patents, as requested by CDC by its giving written notice thereof
to Chiron. Such sublicenses shall have the same scope and be subject to the
same terms and conditions as set forth in Section 2.1, in the case of Chiron
Sublicensable Patents claiming HCV or HIV; and shall have the same scope and be
subject to the same terms and conditions as set forth in Section 2.2, in the
case of other Chiron Sublicensable Patents, in each case to the extent permitted
under the terms of the underlying third party license. [CONFIDENTIAL TREATMENT
REQUESTED] following the Effective Date, Chiron shall not grant any sublicenses
to third parties under the Chiron Sublicensable Patents which would preclude
Chiron from granting the rights to CDC set forth above. Following [CONFIDENTIAL
TREATMENT REQUESTED], Chiron shall be free to grant any sublicenses under the
Chiron Sublicensable Patents to third parties under any terms and conditions,
including the granting of exclusive sublicenses. In the event that CDC requests
such a sublicense [CONFIDENTIAL TREATMENT REQUESTED] the Effective Date, Chiron
will grant such sublicense, subject to any and all intervening rights of third
parties, to the extent Chiron is then permitted to do so.
12
<PAGE>
2.5.2 All sublicenses granted to CDC hereunder shall be subject
to all of the terms and conditions of the underlying third party license
agreements; including without limitation all royalty and other payment
obligations to the third party licensor; provided that CDC shall be subject to
such obligations only from the time of the grant of such sublicense to CDC but
only to the extent attributable solely to sales of licensed products by CDC, its
Authorized Distributors, or, to the extent permitted hereunder, its Affiliates
and sublicensees, under such sublicenses; and further PROVIDED that
[CONFIDENTIAL TREATMENT REQUESTED] shall be due Chiron (as opposed to a third
party licensor) with respect to any such sublicenses. Upon its election to
receive a sublicense, CDC shall be obligated to perform the obligations of a
licensee under the underlying third party license with respect to its activities
as a sublicensee. CDC shall pay Chiron all amounts owing to the third party
licensor with respect to CDC's activities in sufficient time for Chiron to meet
its payment requirements to the third-party licensors. If required under the
third-party license, the parties shall execute any documentation necessary to
give effect to such sublicense. CDC and its Affiliates shall indemnify and
defend Chiron against any loss or claim resulting from a breach of an underlying
license relating to Chiron Sublicensable Patents based on the acts or omissions
of CDC or its Affiliates, Authorized Distributors or permitted sublicensees.
2.6 CDC SUBLICENSABLE PATENTS.
2.6.1 [CONFIDENTIAL TREATMENT REQUESTED] following the Effective
Date, CDC shall grant sublicenses to Chiron under any or all of the CDC
Sublicensable Patents as requested by Chiron by its giving written notice
thereof to CDC. Such sublicenses shall have the same scope and be subject to
the same terms and conditions as set forth in Section 2.3, to the extent
permitted under the terms of the underlying third party license. [CONFIDENTIAL
TREATMENT REQUESTED] following the Effective Date, CDC shall not grant any
sublicenses under the CDC Sublicensable Patents which would preclude CDC from
granting to Chiron the rights set forth above. Following [CONFIDENTIAL
TREATMENT REQUESTED], CDC shall be free to grant any sublicenses under the CDC
Sublicensable Patents to third parties under any terms and conditions, including
the granting of exclusive sublicenses. In the event that Chiron requests such a
sublicense [CONFIDENTIAL TREATMENT REQUESTED] the Effective Date, CDC will grant
such sublicense, subject to any and all intervening rights of third parties, to
the extent CDC is then permitted to do so.
2.6.2 All sublicenses granted to Chiron hereunder shall be
subject to all of the terms and conditions of the underlying third party license
agreements, including without limitation all royalty and other payment
obligations to the third party licensor, provided that Chiron shall be subject
to such obligations only from the time of the grant of such sublicense to Chiron
but only to the extent attributable solely to sales of licensed products by
Chiron, or its Affiliates or sublicensees, under such sublicenses; PROVIDED
further that [CONFIDENTIAL TREATMENT REQUESTED] shall be due CDC (as opposed to
a third party licensor) with respect to any such sublicenses. Upon its election
to receive a sublicense, Chiron shall be obligated to perform the obligations of
licensee under such underlying third party license with respect to its
activities as sublicensee. Chiron shall pay to CDC all amounts owing to the
third party licensor with respect to Chiron's activities in sufficient time for
CDC to meet its payment requirements to the third-party licensors. If required
under the third party license, the parties shall execute any documentation
necessary to give effect to such sublicense. Chiron shall indemnify and defend
CDC against any loss or claim resulting from a
13
<PAGE>
breach of an underlying license relating to CDC Sublicensable Patents based on
the acts or omissions of Chiron, its Affiliates or permitted sublicensees.
2.7 KNOW-HOW.
(a) Recognizing the difficulty in segregating unpatented
information transferred to CDC from that which remains with Chiron, (i) CDC
hereby grants to Chiron a perpetual, irrevocable, non-exclusive, royalty-free
license under CDC Know-How, for any and all purposes, with right to sublicense
and to transfer; and (ii) Chiron hereby grants to CDC a perpetual, irrevocable,
non-exclusive, royalty-free license under the Chiron IVD Know-How for all
purposes, with right to sublicense and to transfer. Chiron and CDC each agree
to use the same degree of care with respect to disclosure of Chiron IVD Know-How
and CDC Know-How as such party uses with respect to other Know-How owned by it.
CDC Know-How and Chiron IVD Know-How shall not be deemed Information received
from the other party for purposes of Article 8.
(b) Notwithstanding the foregoing, the parties acknowledge that
title to CDC Know-How existing as of the Effective Date which is subject to the
exclusive license to Ortho under the Chiron/Ortho Agreement has been transferred
to Chiron under the Asset Transfer Agreement as part of the Excluded
Hepatitis/Retrovirus Patents and Know-How. Any such know-how which remains in
the possession of CDC shall remain subject to such exclusive license to Ortho.
2.8 RETAINED INTERESTS. Each party retains all right, title and
interest in and to all of its patents, patent applications, know-how and other
intellectual property except to the extent expressly granted to the other party,
under this Agreement, the Stock Purchase Agreement or the Ancillary Agreements.
For the avoidance of doubt, Chiron grants no rights or interests to CDC or its
Affiliates in or to any patents, patent applications, Know-How or other
intellectual property ("Chiron Intellectual Property"), except Chiron
Intellectual Property which is related to the continued conduct of the Business,
including Chiron Intellectual Property that covers Products or Products in
Development, but excluding Chiron Intellectual Property which does not cover
Products or Products in Development and may cover Future Products.
2.9 [CONFIDENTIAL TREATMENT REQUESTED]; MEDICARE DATABASE. Subject to
the terms and conditions of the agreement, Chiron hereby grants to
CDC and its Affiliates a non-exclusive worldwide [CONFIDENTIAL TREATMENT
REQUESTED] license, without right to sublicense, under the following
technologies, solely for the purpose of research and development of IVD
Products: (i) the patent applications set forth in Exhibit B hereto,
together with any patents issued thereon and any divisions, extensions,
renewals, reissues, reexamination certificates and continuations thereof
(collectively, [CONFIDENTIAL TREATMENT REQUESTED]); and (ii) that certain
medicare database retained by Chiron as part of the Informatics Business (the
"Medicare Database"). The Medicare Database is made available to CDC and its
Affiliates as it exists at Closing. Nothing herein shall require Chiron to
maintain, improve or enhance such database following the Closing. If Chiron
elects to improve or enhance such database, or to add information to it,
Chiron agrees to offer CDC and its Affiliates such improvements or
enhancements, and/or a subscription to access such additional information on
commercially reasonable terms.
Promptly following the Effective Date, Chiron shall facilitate
access by CDC to the [CONFIDENTIAL TREATMENT REQUESTED] software and the
Medicare database, including, but not limited to, providing or obtaining
connectivity or free standing electronic copies where appropriate for CDC to
have effective access to such software and database in an independently
useable form.
Nothing herein shall require Chiron to take any action to
prosecute, maintain or defend any [CONFIDENTIAL TREATMENT REQUESTED] patent
application or patents.
Nothing herein shall be deemed to grant CDC or its Affiliates
any right to commercialize [CONFIDENTIAL TREATMENT REQUESTED] or the Medicare
Database, or any products using, incorporating or based on [CONFIDENTIAL
TREATMENT REQUESTED] or the Medicare Database.
2.10 OTHER SUBLICENSES. Notwithstanding the restrictions on
sublicensing set forth in Section 2.1.1, Chiron hereby consents to the grant
by CDC of sublicenses as set forth in the following agreements, in connection
with the assignment, transfer and conveyance of such agreements from Chiron
to CDC, which sublicenses shall not count against the limits set forth in
Section 2.1.1: [CONFIDENTIAL TREATMENT REQUESTED].
3. ROYALTIES, FEES AND RECORDS
3.1 CDC HCV/HIV PROBE PRODUCTS. In addition to any amounts payable
pursuant to Section 2.5, if any, CDC and its Affiliates agree to make payments
to Chiron as set forth in Exhibit A. Exhibit A also sets forth the manner in
which such compensation may be adjusted.
3.2 LICENSES UNDER CHIRON NON-HCV/HIV PATENTS, CDC PATENTS, CDC
KNOW-HOW, CHIRON IVD KNOW-HOW. [CONFIDENTIAL TREATMENT REQUESTED] with respect
to the licenses granted under Sections 2.2, 2.3, 2.7, or 2.9 except those
payable pursuant to Section 2.5 or 2.6, if any.
3.3 LICENSE FEE. Conditioned upon the occurrence of the Closing under
the Stock Purchase Agreement, CDC hereby agrees to pay Chiron a license fee of
[CONFIDENTIAL TREATMENT REQUESTED] payable on the Effective Date. CDC shall be
entitled to a refund of the portion of such license fee which has not then
become non-refundable, in accordance with the
14
<PAGE>
schedule set forth below, in the event that CDC elects to terminate all, but not
less than all, licenses granted to it under this Agreement (a "CDC
Termination"). The portions of the license fee which are non-refundable shall
increase over time, as follows, and between anniversaries of the Effective Date,
shall increase ratably to the levels set forth below.
DATE OF CDC TERMINATION NON-REFUNDABLE PORTION OF
LICENSE FEE
On Effective Date [CONFIDENTIAL TREATMENT
REQUESTED]
One year after Effective Date [CONFIDENTIAL TREATMENT
REQUESTED]
Two years after Effective Date [CONFIDENTIAL TREATMENT
REQUESTED]
Three years after Effective Date [CONFIDENTIAL TREATMENT
REQUESTED]
3.4 RECORDS AND REPORTS. CDC shall keep complete and accurate records
of the sale by it, its Affiliates, and permitted sublicensees of products
subject to Earned Royalties or Minimum Royalties (each as defined in Exhibit A)
pursuant to Exhibit A, and the sublicensed party shall keep complete and
accurate records of the sale of products for which royalties are payable under
Section 2.5 or 2.6, as the case may be. Within 60 days following the end of
each calendar quarter commencing with the first full or partial calendar quarter
following the Effective Date, CDC shall deliver to Chiron a written report for
such period setting forth, for each country to the extent relevant, the Net
Sales of products subject to Earned Royalties or Minimum Royalties under Exhibit
A and, with respect to products subject to Minimum Royalties under Exhibit A,
the number of Units of each type of such products sold, which report shall also
set forth the amounts payable pursuant to Exhibit A, and the calculation of such
amounts, for such period. Each party shall deliver to the other such reports as
are required pursuant to Section 2.5 or 2.6, as the case may be.
3.5 AUDIT.
(a) Chiron shall have the right to audit the records of CDC, its
Affiliates, and permitted sublicensees using an independent certified public
accounting firm reasonably acceptable to CDC, during reasonable business hours
and on reasonable notice but not more than once per calendar year, solely for
the purpose of verifying the earned Royalties and Minimum Royalties payable
pursuant to this Agreement for the twelve (12) full quarters immediately
preceding the date of the audit, provided that such accountants agree to keep
all information received strictly confidential and agree to provide to Chiron
only the information necessary to verify the calculation of amounts due
hereunder.
(b) If any such audit discloses an underpayment of [CONFIDENTIAL
TREATMENT REQUESTED] or more for the period of such audit, which shall be at
least four (4) full quarters in length, CDC shall bear the costs of such audit.
Otherwise such audit shall be at the expense of Chiron. Underpayments resulting
from withholding taxes pursuant to Section 4.3 or currency controls pursuant to
Section 4.5 shall not be deemed underpayments for the purposes of this Section
3.5 (b).
15
<PAGE>
4. PAYMENT
4.1 QUARTERLY PAYMENT. Payments shall be made as provided in Exhibit
A, except that any payments required pursuant to Sections 2.5 or 2.6 shall be
made in accordance with the applicable third party license agreement.
4.2 PAYMENT METHOD; DEFAULT INTEREST. All payments under this
Agreement shall be made by bank wire transfer to the bank account designated in
writing by the party receiving the royalty payments. Any late payments shall
bear interest at the lesser of (i) [CONFIDENTIAL TREATMENT REQUESTED] rate as
published in the Wall Street Journal as of the date payment is due; or (ii) the
maximum rate permitted by applicable law.
4.3 WITHHOLDING TAX. Except as otherwise required under Section 2.5
or 2.6, where required to do so by applicable law or treaty, the royalty-paying
party shall withhold taxes required to be paid to a taxing authority on account
of such income to the payee, and the royalty-paying party shall furnish the
payee with satisfactory evidence of such withholding and payment in order to
permit the payee to obtain a tax credit or other relief as may be available
under the applicable law or treaty. The royalty-paying party shall cooperate
with the payee in obtaining exemption from withholding taxes where available
under applicable laws and treaties.
4.4 CURRENCY. All payments shall be in U.S. Dollars and shall be made
on the dates set forth herein. The Net Sales amount calculated hereunder for
sales in countries other than the United States shall be converted into
equivalent United States Dollars in accordance with the methods used for
internal financial reporting purposes within Purchaser, unless otherwise
required pursuant to Section 2.5 or 2.6.
4.5 CURRENCY CONTROLS. If, by law, regulations, or fiscal policy of a
particular country, payment as provided for above is restricted or forbidden,
notice thereof in writing will be given to the payee and payment of the royalty
will be made through such lawful means or methods as the payee designates. If
the payee fails to so designate such lawful means or methods within 60 days
after such notice is given to the payee, the payment of royalties by the
royalty-paying party will be made by the deposit thereof in local currency to
the credit of the payee in a recognized banking institution designated by the
payee or, if none be designated by the payee within such period of 60 days, in a
recognized banking institution of which the royalty-paying party shall notify
the payee.
5. REPRESENTATIONS AND WARRANTIES
5.1 EXCEPT AS SPECIFICALLY SET FORTH IN THE STOCK PURCHASE AGREEMENT,
NO PARTY MAKES ANY REPRESENTATION OR WARRANTIES, EITHER EXPRESS OR IMPLIED,
ARISING BY LAW OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT WILL ANY
PARTY LICENSING TECHNOLOGY TO THE OTHER PARTY HAVE, AS A RESULT OF SUCH LICENSE,
ANY OBLIGATION OR LIABILITY FOR LOSS OF REVENUE OR PROFIT, OR FOR INCIDENTAL OR
CONSEQUENTIAL DAMAGES.
16
<PAGE>
In particular, with no limitation implied, nothing in this Agreement will
be construed as:
(i) A warranty or representation as to the validity or scope of any of
the Licensed Chiron Patents or the CDC Patents;
(ii) A warranty or representation that anything made, used, sold, or
otherwise disposed of under the licenses granted in this Agreement
is or will be free from infringement of patents of third parties;
(iii) An obligation to bring or prosecute actions or suits against third
parties for infringement, except as set forth in Section 6.4;
(iv) Except as otherwise provided in the Stock Purchase Agreement or
the Ancillary Agreements, conferring the right to use in
advertising, publicity, or otherwise any trademark, trade name, or
any contraction, abbreviation, simulation, or adaptation thereof,
of another party; or
(v) Except to the extent expressly provided in Article 2 hereof,
conferring by implication, estoppel, or otherwise any license or
rights under any patents or other proprietary rights of Chiron,
CDC or their respective Affiliates.
6. PATENT MATTERS
6.1 PATENT PROSECUTION. Each party shall be responsible, at its sole
expense and in its sole discretion, for the filing, prosecution, maintenance,
defense and enforcement of patents owned by it.
6.2 EXCHANGE OF INFORMATION. The parties shall keep each other
currently advised in writing of any substantial changes in the status of their
respective patent rights which are licensed hereunder, including but not limited
to notice of the issuance of patents on pending patent applications included
therein, reexaminations, reissues, and interferences and oppositions, and
provide further updates on the status of such patent rights at the request of
the other party. The parties need not disclose information subject to
attorney-client privilege.
6.3 INFRINGEMENT OF THIRD PARTY PATENT RIGHTS. CDC shall promptly
notify Chiron in the event that it becomes aware of any claim alleging that the
manufacture, use or sale of any CDC HCV/HIV Probe Product infringes any third
party patent or intellectual property rights. Chiron shall promptly notify CDC
in the event that it becomes aware of any claim alleging that the manufacture,
use or sale of any Licensed Chiron Product utilizing any CDC Patents relating to
bDNA infringes any third party patent or intellectual property right. Pursuant
to Section 9.1, the party manufacturing or selling the product in question (the
"Product Owning Party") shall be responsible for the defense of such claim, at
its sole cost, except as provided herein. Chiron, in its sole discretion, shall
have the exclusive right (but not the obligation) to assume and
17
<PAGE>
solely manage the defense of any such claim, at Chiron's expense, to the extent
that such claim relates to specific HCV or HIV nucleotide sequences, or the
defense of such claim relates to activities or intellectual property of Chiron.
CDC shall have the exclusive right (but not the obligation) to assume and solely
manage the defense of any such claim, at CDC's expense, to the extent such claim
relates to bDNA technology, or the defense of such claim relates to activities
or intellectual property of CDC. If the other party elects to exercise such
right with respect to any such defense, the Product Owning Party shall take all
appropriate and necessary actions to assist the other party in such defense. If
the other party elects not to assume control of such defense, the Product
Owning Party shall nonetheless keep the other party fully and promptly informed
with respect thereto, including provision of notice of all discovery relating to
the other party's activities or intellectual property, and copies of all
documents and deposition records with respect thereto. Nothing in Section 6.3
shall limit in any way the Product Owning Party's obligations under Section 9.1
with respect to such claim, including without limitation the Product Owning
Party's obligation to indemnify the other party and the other party's Affiliates
against any damages or other liabilities arising from any such action.
6.4 INFRINGEMENT BY THIRD PARTIES.
6.4.1 Each party shall notify the other if it becomes aware of
infringement by third parties of any patent rights licensed hereunder, (other
than Chiron Sublicensable Patents or CDC Sublicensable Patents) if such
infringement is within the field of uses licensed to such party under this
Agreement. The patent owning party shall have the exclusive right to take
action against such infringement in its sole discretion, subject to this Section
6.4.
6.4.2 In the event that a third party is engaged in the sale of
Probe IVD Products which infringe the Chiron HCV/HIV Patents (other than a
Chiron Sublicensable Patent), the parties shall meet and confer, and negotiate
in good faith regarding patent enforcement or licensing strategy, recognizing
that (i) Chiron will control any litigation with respect to such patent
enforcement, and (ii) that each party will have an interest in any settlement of
such infringement involving a license under the Chiron HCV/HIV Patents which is
not specifically authorized under Section 2.1.1 or 2.1.3.
In general, the parties intend to utilize licensing solutions to
the extent such licenses can be structured to fairly protect the economic
interests of the parties. If, however, the parties agree to pursue legal
action, the parties shall also agree upon a reasonable allocation of both
litigation costs and recoveries.
6.4.3 In the event that (i) the parties fail to reach agreement
pursuant to Section 6.4.2; and (ii) the infringing product sold by the third
party in a country is "substantially competitive" with a CDC HCV/HIV Probe
Product directed to HCV which is then sold by CDC, a CDC Affiliate, an
Authorized Distributor or a CDC sublicensee in the same country (an "Affected
CDC Product"); and (iii) CDC has notified Chiron pursuant to Section 6.4.1 of an
Affected CDC Product in [CONFIDENTIAL TREATMENT REQUESTED] (the "6.4.1.Notice"),
then the provisions of this Section 6.4.3 shall apply. For this purpose, a
third party infringing product shall be considered "substantially competitive"
in a country if it achieves a market share in at least [CONFIDENTIAL TREATMENT
REQUESTED] of the market for Probe IVD Products directed to HCV in such country.
For this purpose, "Major Country" shall mean the United States, Germany, the
United Kingdom or Japan.
18
<PAGE>
(a) If either (i) the 6.4.1 Notice identified an
Affected CDC Product in the United States, and Chiron fails to institute
legal action in the United States within [CONFIDENTIAL TREATMENT REQUESTED]
following receipt by Chiron of the 6.4.1 Notice and the infringement is not
otherwise abated, or (ii) the 6.4.1 Notice identified an Affected CDC Product
in a Major Country other than the United States, and Chiron fails to
institute legal action against the infringing party in at least one of the
United States, The Netherlands, Germany, the United Kingdom or Japan, within
[CONFIDENTIAL TREATMENT REQUESTED] following receipt by Chiron of the 6.4.1.
Notice, and the infringement is not otherwise abated; then CDC or its
sublicensee shall be relieved of the obligation to pay that portion of Earned
Royalties set forth in Section 6.4.3(b), and [CONFIDENTIAL TREATMENT REQUESTED],
with respect to Affected CDC Products until such time as Chiron institutes such
legal action as described in this Section 6.4.3 (a).
(b) If Chiron has not instituted such legal action at the
end of such [CONFIDENTIAL TREATMENT REQUESTED] period and the infringement is
not otherwise abated, the Earned Royalties with respect to the Affected CDC
Products shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED]. If, at the end
of each [CONFIDENTIAL TREATMENT REQUESTED] thereafter, Chiron has not instituted
such legal action and the infringement is not otherwise abated, such Earned
Royalties shall be reduced by an additional [CONFIDENTIAL TREATMENT REQUESTED]
of the original Earned Royalties, such that if the legal action has not
commenced and the infringement is not otherwise abated by the end of the
[CONFIDENTIAL TREATMENT REQUESTED] from receipt by Chiron of the 6.4.1 Notice,
[CONFIDENTIAL TREATMENT REQUESTED] shall be payable hereunder with respect to
the Affected CDC Products.
(c) The obligations to pay Earned Royalties and Minimum
Royalties shall be reinstated on a prospective basis at such time as CDC
receives written notice of the institution of legal action in accordance with
Section 6.4.3 (a) or the infringement is otherwise abated, all subject to
Section 6.4.3 (d).
(d) If legal action as described in Section 6.4.3 (a) has
not been instituted and the infringement is not otherwise abated for more than
[CONFIDENTIAL TREATMENT REQUESTED] following receipt by Chiron of the 6.4.1
Notice, and if, as a result of the infringement, sales of the Affected CDC
Product in a Major Country by CDC, its Affiliate, sublicensee or Authorized
Distributor have declined by [CONFIDENTIAL TREATMENT REQUESTED] or more during
the preceding [CONFIDENTIAL TREATMENT REQUESTED] period, then upon reinstatement
of Earned Royalties and Minimum Royalties pursuant to Section 6.4.3 (c), the
parties shall meet and confer regarding possible adjustments to the Earned
Royalties and Minimum Royalties for the Affected CDC Product in view of such
degradation of the market. The parties will discuss possible rate reductions,
as well as a plan for reinstating the original economic expectations of the
parties. It is expected that any agreed upon reduction of Earned Royalties or
Minimum Royalties will be phased out over time, so as to return to the Earned
Royalties and Minimum Royalties set forth in Exhibit A. If the parties fail to
reach agreement on any such adjustment, the matter shall be submitted for
resolution pursuant to Article 10, except that in the event of arbitration, each
party shall submit to the neutral a proposal with respect to adjustments
pursuant to this Section 6.4.3(d). The neutral shall be empowered to choose
19
<PAGE>
one proposal or the other, but shall not be empowered to order any such
adjustment other than as proposed by one of the parties.
6.4.4 CDC and its sublicensees shall cooperate with Chiron in
connection with any legal action brought hereunder. Any recovery by Chiron in
any such legal action shall first be applied to reimburse all costs incurred by
Chiron or CDC in connection with such action, and the remainder shall be
allocated between the parties as agreed pursuant to Section 6.4.2; or, if no
agreement has been reached, the remainder shall be retained by Chiron.
7. TERM, TERMINATION
7.1 TERM. This Agreement shall be effective as of the Effective Date,
and shall remain in force until the expiration of the last to expire of the
Licensed Chiron Patents and the CDC Patents (provided, however, that no
royalties shall be payable only with respect to CDC HCV/HIV Probe Products
unless the manufacture, use or sale of which would, in the absence of a license,
constitute an infringement of a Valid Claim of Chiron HCV/HIV Patents).
7.2 EARLY TERMINATION. Either party may terminate the licenses
granted hereunder to the other party, without affecting the licenses granted to
the terminating party, in the following events:
(a) If the other party materially breaches this Agreement and
has failed to cure or demonstrate the nonexistence of the breach within 60 days
after receipt of a written notice and demand to cure such breach; or
(b) If the other party files in any court or agency pursuant
to any bankruptcy or insolvency law a petition in bankruptcy or insolvency or
for reorganization or similar arrangement or for the appointment of a
receiver or trustee of such party or its assets; if the other party is served
with an involuntary petition against it in any insolvency proceeding, upon
the ninety-first (91st) day after such service if such involuntary petition
has not previously been stayed or dismissed; or if the other party makes an
assignment for the benefit of its creditors. All licenses granted under or
pursuant to this Agreement are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to
"intellectual property" as defined under Section 101(52) of the U.S.
Bankruptcy Code. The parties agree that the licensee of such rights under
this Agreement shall retain and may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, subject to performance by such
licensee of its preexisting obligations under this Agreement.
7.3 VOLUNTARY TERMINATION. CDC shall have the right to voluntarily
terminate all, but not less than all, rights and licenses granted to CDC or its
Affiliates under this Agreement, during the three years following the Effective
Date, on not less than six months prior written notice to Chiron. No such
termination shall affect any rights or licenses granted to Chiron or its
Affiliates hereunder.
20
<PAGE>
7.4 SURVIVAL. The following provisions of this Agreement shall
survive expiration or termination of this Agreement, together with all
obligations accrued prior to such expiration or termination: Article 1,
Section 2.7, Section 2.8, Section 3.4, Section 3.5, Section 5.1, Section 6.3,
any agreement reached pursuant to Section 6.4.2, this Section 7.4, Article 8,
Article 9, and Article 10.
8. CONFIDENTIAL INFORMATION
From time to time during the term of this Agreement, Chiron and CDC may
provide to each other information concerning patents, patent applications,
license agreements and other confidential or proprietary information related to
this Agreement (the "Information"). Each party receiving the Information (the
"Receiving Party") shall during the term of this Agreement and for a period of
three years after termination hereof: (i) maintain the Information in
confidence, (ii) not disclose the Information to any third party, other than
employees, agents or consultants of the Receiving Party or its Affiliates or
sublicensees who have a need to know the Information and who are bound by
confidentiality obligations to the Receiving Party not less restrictive than
those contained herein and (iii) not use the Information for any purpose not
directly related to performance or otherwise authorized under this Agreement.
The obligations of this Article 8 shall not apply to any Information which is or
which becomes generally known to the public by publication or by means other
than a breach of a duty by the Receiving Party; or which is otherwise known by
the Receiving Party at the time of disclosure by the other party; or which
otherwise becomes available to the Receiving Party from a third party not in
breach of confidentiality obligations to the other party; or which is developed
by the Receiving Party independent of any disclosure from the other party. The
Receiving Party shall also be permitted to make disclosures of Information which
are reasonably necessary in connection with a possible grant of a permitted
sublicense by the Receiving Party or in due diligence related to a possible
acquisition, merger, consolidation, substantial asset transfer, or similar
transaction of the Receiving Party, provided that the recipient is bound to the
Receiving Party by confidentiality obligations with respect to the Confidential
Information no less restrictive than those set forth herein. Nothing herein
shall prevent the Receiving Party from making such disclosures of Information as
are reasonably required by law, regulation, or order of any court or
governmental agency, provided that the Receiving Party has provided reasonable
advance notice to allow the disclosing party the opportunity to seek a
protective order or otherwise contest, prevent or limit such disclosure. Upon
termination of this Agreement for any reason, the Receiving Party shall return,
or at the option of the disclosing party, certify destruction of, all
Information and copies thereof; provided that the Receiving Party may retain one
copy thereof in its law department files solely for evidentiary and regulatory
purposes.
9. INDEMNIFICATION
9.1 MUTUAL INDEMNITIES. Chiron shall indemnify, defend and hold
harmless CDC and its Affiliates and their officers, directors, shareholders,
employees, representatives and agents, against any claim, demand, loss, damage
or injury, including reasonable attorneys' fees, arising from, relating to, or
otherwise in respect of the manufacture, use or sale of Licensed Chiron
Products, provided, however, that such indemnity shall not extend to damages
arising directly from any breach or willful or negligent act of CDC or its
Affiliates. CDC shall indemnify, defend and hold harmless Chiron and its
Affiliates and their officers, directors, shareholders, employees,
representatives and agents, against any claim, demand, loss, damage or injury,
including reasonable
21
<PAGE>
attorneys' fees, arising from, relating to or otherwise in respect of the
manufacture, use or sale of Licensed CDC Products, provided, however, that such
indemnity shall not extend to damages arising directly from any breach or
willful or negligent act of Chiron or its Affiliates.
9.2 INDEMNIFICATION PROCEDURES. A party claiming indemnification
pursuant to Section 9.1 (the "indemnified party") shall promptly notify the
other party (the "indemnifying party") in writing upon becoming aware of any
claim to which such indemnification may apply. Delay in providing such notice
shall constitute a waiver of the indemnifying party's indemnity obligations
hereunder if, and only if, the indemnifying party's ability to defend such claim
is materially impaired thereby. The indemnifying party shall have the right to
assume and control the defense of the claim at its own expense. If the right to
assume and have sole control of the defense is exercised, the indemnified party
shall have the right to participate in, but not to control, such defense at its
own expense, and the indemnifying party's indemnity obligations shall be deemed
not to include attorneys' fees and litigation expenses incurred by indemnified
party after the assumption of the defense by indemnifying party. If the
indemnifying party does not assume the defense of the claim, the indemnified
party may defend the claim at the indemnifying party's expense. The indemnified
party will not settle or compromise the claim without the prior written consent
of indemnifying party, and the indemnifying party will not settle or compromise
the claim in any manner which would have an adverse effect on the indemnified
party without the consent of the indemnified party, which consent, in each case,
will not be unreasonably withheld. The indemnified party shall reasonably
cooperate with the indemnifying party and will make available to indemnifying
party all pertinent information under the control of the indemnified party, all
at the expense of the indemnifying party.
10. ALTERNATIVE DISPUTE RESOLUTION
10.1 The parties recognize that bona fide disputes as to certain
matters may arise from time to time. In the event of the occurrence of such a
dispute, either party may, by written notice to the other party, have such
dispute referred to the respective Presidents of Chiron and CDC or their
successors, for attempted resolution by good faith negotiations within 30 days
after such notice is received. In the event that such designated officers are
not able to resolve the referred dispute within the 30-day period, either party
may invoke the provisions of Section 10.2.
10.2 Any dispute, controversy or claim arising out of or relating to
the validity, construction, enforceability or performance of this Agreement
shall be settled by binding Alternative Dispute Resolution ("ADR") in the manner
described below:
10.2.1 If a party intends to begin an ADR to resolve a dispute,
that party shall provide written notice (the "ADR Request") to counsel for the
other party informing the other party of its intention and the issues to be
resolved. From the date of the ADR Request and until such time as any matter
has been finally settled by ADR, the running of the time periods contained in
Section 7.2 as to which a party must cure a breach of this Agreement shall be
suspended as to the subject matter of the dispute.
22
<PAGE>
10.2.2 Within 10 business days after the receipt of the ADR
Request, the other party may, by written notice to the counsel for the party
initiating ADR, add additional issues to be resolved. Within 20 business days
following the receipt of the ADR Request a neutral shall be selected by the
then-President of the Center for Public Resources ("CPR"), 680 Fifth Ave., New
York, New York 10019. The neutral shall be an individual who shall preside in
resolution of any disputes between the parties. The neutral selected shall be a
member of the Judicial Panel of the CPR and shall not be an employee, director
or shareholder of any party or of an Affiliate of any party and shall agree to
comply with the time deadlines imposed by this Section 10.2 and such extension
of times as the parties may agree upon. Any party shall have 10 business days
from the date the neutral is selected to object in good faith to the selection
of that person. If any party makes such an objection, the then-President of the
CPR shall, as soon as possible thereafter, elect another neutral under the same
conditions set forth above. This second selection shall be final.
10.2.3 No later than 90 business days after selection, the neutral
shall hold a hearing to resolve each of the issues identified by the parties and
shall render the award as expeditiously thereafter as possible but in no event
more than 60 days after the close of hearings, except in an extraordinary
situation where such time limitation would deprive either party of procedural
due process. In making the award the neutral shall rule on each disputed issue
and shall adopt in whole or in part the proposed ruling of one of the parties on
each disputed issue. Such ruling and award shall be in writing, and shall set
forth the reasons therefor.
10.2.4 The parties intend that discovery, although permitted as
described below, will be limited except in exceptional circumstances, as
determined by the neutral. The neutral shall permit limited discovery as
necessary for an understanding of any legitimate issue raised in the ADR,
including the production of documents. Each party shall be permitted but not
required to take the deposition of not more than five persons, and each such
deposition shall not exceed six hours in length. If the neutral believes that
exceptional circumstances exist, and additional discovery is necessary for a
full and fair resolution of the issues, additional discovery as the neutral
deems necessary may be ordered. At the hearing the parties may present
testimony (either by live witness or deposition) and documentary evidence. The
hearing shall be held at such place as is agreed upon by the parties or if they
are unable to agree at a place designated by the neutral. Each party shall have
the right to be represented by counsel. The neutral shall have sole discretion
with regard to the admissibility of any evidence and all other matters relating
to the conduct of the hearing. The neutral shall in rendering a decision, apply
the substantive law of New York without giving effect to any rules or laws
relating to arbitration, and shall attempt to resolve any dispute based upon the
terms of this Agreement as written. The decision of the neutral shall be final
and not appealable, except in cases of fraud or bad faith on the part of the
neutral or any party to the ADR proceeding in connection with the conduct of
such proceedings.
10.2.5 At least 15 business days prior to the date set for the
hearing, each party shall submit to the other party and the neutral a list of
all documents on which the party intends to rely in any oral or written
presentation to the neutral and a list of all witnesses, if any, the party
intends to call at the hearing together with a brief summary of each witness'
expected testimony. At least five business days prior to the hearing, each
party must submit to the neutral and serve on the other party a proposed ruling
on each issue to be resolved. The document containing the proposed rulings
shall be limited to the proposed rulings, and shall contain no argument or
analysis of the facts or issues,
23
<PAGE>
and shall be limited to not more than 50 pages. No more than five business
days following the close of hearings, the parties may each submit post hearing
briefs to the neutral addressing the evidence and issues to be resolved. The
post-hearing briefs shall not be more than 30 pages.
10.3 The neutral shall determine the proportion in which the parties
shall pay the costs and fees of the ADR. Unless otherwise determined by the
neutral, each party shall pay its own costs (including, without limitation,
attorneys' fees) and expenses in connection with such ADR.
10.4 The ADR proceeding shall be confidential, and the neutral shall
issue appropriate protective orders to safeguard each parties' Information.
Except as required by law, no party shall make (or instruct the neutral to make)
any public announcement with respect to the proceedings or decision of the
neutral without the prior written consent of each other party. The existence of
any dispute submitted to ADR, and the award of the neutral, shall be kept in
confidence by the parties and the neutral, except as required in connection with
the enforcement of such award or as otherwise required by applicable law.
10.5 Any judgment upon the award rendered by the neutral may be entered
in any court having jurisdiction thereof.
10.6 Nothing in this Article 10 shall be deemed to preclude a party
from bringing suit against the other party in a court of competent jurisdiction
to enforce, or enjoin infringement of, such party's intellectual property
rights.
11. MISCELLANEOUS
11.1 PROVISIONS CONTRARY TO LAW. In performing this Agreement, the
parties shall comply with all applicable laws. Nothing in this Agreement shall
be construed so as to require the violation of any law, and wherever there is
any conflict between any provision of this Agreement and any law the law shall
prevail, but in such event the affected provision of this Agreement shall be
adjusted only to the extent necessary to bring it within the applicable law,
provided that such adjustment shall be consistent with the intent of the
parties, as evidenced by this Agreement as a whole.
11.2 NOTICES. Any notice, report, demand or other communication
required or permitted to be given under this Agreement shall be in writing in
English, and shall be delivered by hand or sent by prepaid telex, cable or
telecopy or sent, postage prepaid, by registered, certified or express mail with
return receipt requested, or reputable overnight courier service and shall be
deemed given when so delivered by hand, telexed, cabled or telecopied or, if
mailed, on the date shown on the return receipt, as follows (unless changed by
notice so given):
(i) For Chiron:
Chiron Corporation
4560 Horton Street
Emeryville, California
U.S.A.
Telefax: (510) 923-3177
Attn: President
24
<PAGE>
cc: General Counsel
Telefax: (510) 654-5360
(ii) For CDC:
Chiron Diagnostics Corporation
333 Coney Street
East Walpole, Massachusetts 02032-1597
Telefax: (508) 660-8100
Attn: President
in each case, with a copy to Purchaser:
Bayer Corporation
Business Group Diagnostics
511 Benedict Avenue
Tarrytown, New York 10591-5097
Telefax: (914) 524-3594
Attn: Division Counsel
11.3 FORCE MAJEURE. Neither party to this Agreement shall be liable
for delay or failure in the performance of any of its obligations, other than an
obligation to make payments to the other party hereunder, if such delay or
failure is due to causes beyond its reasonable control, including, without
limitation, acts of God, fires, earthquakes, strikes and labor disputes, acts of
war, civil unrest or intervention of any governmental authority, but any such
delay or failure shall be remedied by such party as soon as is reasonably
possible.
11.4 USE OF NAMES. Except as provided in the Stock Purchase Agreement
and the other Ancillary Agreements, no party shall use the name of the other in
any promotional communications or advertising, without the prior written consent
of the party whose name is used.
11.5 ASSIGNMENT
11.5.1 Chiron may assign its rights as a licensee of any CDC
Patent or CDC Know-How under this Agreement to any Affiliate of Chiron or any
successor in interest to all or substantially all of that part of Chiron's
business to which such CDC Patent or CDC Know-How relates; and Chiron may assign
its rights as a licensor hereunder in whole or in part to any successor in
interest to some or all of Licensed Chiron Patents or Chiron IVD Know-How, as
applicable. CDC may assign its rights as a licensee of any Licensed Chiron
Patent or Chiron IVD Know-How under this Agreement to any Affiliate of CDC or
any successor in interest to all or substantially all of that part of CDC's
business to which such Licensed Chiron Patent or Chiron IVD Know-How relates;
and CDC may assign its rights as a licensor hereunder in whole or in part to any
successor in interest to some or all of CDC Patents or the CDC Know-How, as
applicable.
25
<PAGE>
11.5.2 Except as set forth in this Section 11.5, no party shall
have the right or power to assign its rights and obligations under this
Agreement without the prior written consent of the other party hereto. This
Agreement shall inure to the benefit of and be binding on the parties' permitted
assigns and successors in interest. In the event of a transfer of any Licensed
Chiron Patent, CDC Patent, CDC Know-How or Chiron IVD Know-How, the transferor
shall make provisions for the continued enjoyment of the rights under such
Licensed Chiron Patent, CDC Patent, CDC Know-How or Chiron IVD Know-How granted
under this Agreement.
11.6 NO THIRD-PARTY BENEFICIARIES. Except as set forth in Article 9,
this Agreement is entered into solely for the benefit of the parties hereto and
Purchaser, and the provisions of this Agreement shall be for the sole and
exclusive benefit of such parties. Nothing herein contained will be deemed to
create any third party beneficiaries or confer any benefit or rights on or to
any person not a party hereto other than Purchaser, and no person not a party
hereto shall be entitled to enforce any provisions hereof or exercise any rights
hereunder or other than Purchaser.
11.7 WAIVERS AND MODIFICATIONS. The failure of any party to insist on
the performance of any obligation hereunder shall not act as a waiver of such
obligation. No waiver, modification, release or amendment of any obligation
under this Agreement shall be valid or effective unless in writing and signed by
both parties hereto.
11.8 CHOICE OF LAW. This Agreement is subject to and shall be
construed and enforced in accordance with the laws of the State of New York.
11.9 HEADINGS. The headings of the Sections of this Agreement have
been inserted for convenience of reference only and do not constitute a part of
this Agreement.
11.10 ENTIRE AGREEMENT. This Agreement, together with the Stock
Purchase Agreement, the other Ancillary Agreements and any agreement executed
and delivered by the parties hereto concurrently herewith and the Exhibits
attached hereto, constitutes the entire agreement between Chiron and CDC with
respect to the subject matter hereof. There are no representations, warranties,
covenants or undertakings with respect to the subject matter hereof other than
those expressly set forth herein or therein. This Agreement, the Stock Purchase
Agreement and the other Ancillary Agreements supersede all prior agreements
between the parties with respect to the subject matter hereof, other than the
Confidentiality Agreement.
26
<PAGE>
11.11 COUNTERPARTS. This Agreement may be executed in any number of
counterparts with the same effect as if all parties had signed the same
document. All such counterparts shall be deemed an original, shall be construed
together and shall constitute one and the same instrument.
IN WITNESS WHEREOF, the parties have duly executed this Agreement on the date(s)
written below.
CHIRON CORPORATION CHIRON DIAGNOSTICS
CORPORATION
By: /s/ JAMES R. SULAT By: /s/ WILLIAM G. GREEN
--------------------------------- ---------------------------------
Name: /s/ James R. Sulat Name: /s/ William G. Green
------------------------------- --------------------------------
Title: /s/ Chief Financial Officer Title: /s/ Assistant Secretary
------------------------------ -------------------------------
Date: /s/ November 30, 1998 Date: /s/ November 30, 1998
------------------------------- --------------------------------
Exhibits
A Compensation to Chiron
Attachment A-1: Summary of Adjustments to HCV Earned Royalties and
Minimum Payments
B [CONFIDENTIAL TREATMENT REQUESTED] Patent Applications
27
<PAGE>
Exhibit A
COMPENSATION TO CHIRON
1. EARNED ROYALTY. In consideration of the licenses granted pursuant to
Section 2.1, CDC agrees to pay earned royalties as a percentage of Net Sales of
CDC HCV/HIV Probe Products, as follows:
[CONFIDENTIAL TREATMENT REQUESTED]
(a) Earned Royalties shall be adjusted [CONFIDENTIAL TREATMENT
REQUESTED].
(b) Earned Royalties shall be payable quarterly commencing with the
first full or partial calendar quarter following the Effective Date, within
sixty (60) days following the end of each calendar quarter, and shall be
accompanied by a report pursuant to Section 3.4 of this Agreement.
2. MINIMUM ROYALTY. CDC agrees to pay Chiron a minimum patent royalty
[CONFIDENTIAL TREATMENT REQUESTED] of CDC HCV/HIV Probe Products shipped which
are directed to HCV ("Minimum Royalty"). Initially, such Minimum Royalties
shall be as follows:
[CONFIDENTIAL TREATMENT REQUESTED]
(a) Minimum Royalties shall be determined on [CONFIDENTIAL TREATMENT
REQUESTED], excluding those countries in which the Minimum Royalties are
adjusted pursuant to Paragraph 2(b). Minimum Royalties in such countries shall
be determined on a country by country, product by product basis. Minimum
Royalties shall be adjusted, [CONFIDENTIAL TREATMENT REQUESTED].
(b) At the request of Purchaser, the parties agree to meet and
reasonably consider adjustment to the Minimum Royalty with respect to any CDC
HCV/HIV Probe Product in any country in the event that action by a governmental
pricing or reimbursement authority or other governmental agency results in a
requirement that CDC sell such CDC HCV/HIV Probe Product at a price below
[CONFIDENTIAL TREATMENT REQUESTED] for such product in such country, provided
that no adjustment shall be made to the Minimum Royalty unless mutually agreed
or determined pursuant to the last sentence of this Paragraph 3 (b). The
parties intend that adjustments be made to cause the Minimum Royalty with
respect to the affected CDC HCV/HIV Probe Product in the affected country to be
consistent with the economic expectations of the parties hereunder to the
greatest extent possible, and to bear a similar relationship to the mandated
maximum pricing of the product as is borne by the Minimum Royalties specified in
Paragraph 2. If the parties are unable to agree on an adjustment mechanism, the
matter shall be submitted for resolution under Article 10, except that any
arbitration shall be conducted in the same manner as is set forth in Section
6.4.3 (d).
28
<PAGE>
(c) Minimum Royalties shall be payable quarterly commencing with the
first full or partial calendar quarter following the Effective Date, within
sixty (60) days following the end of each calendar quarter, shall be accompanied
by a report pursuant to Section 3.4, and shall be fully creditable against
Earned Royalties payable pursuant to Paragraph 1 above for the same calendar
quarter.
3. MOST FAVORED LICENSEE. In the event that Chiron grants any license to
any third party under the Chiron HCV/HIV Patents for any Probe IVD Product
pursuant to Section 2.1.3, Chiron agrees to give written notice to CDC of its
intent to grant such license, without specifying the identity of the potential
licensee, at least [CONFIDENTIAL TREATMENT REQUESTED] prior to the effective
date of such license. Chiron further agrees to give written notice to CDC of
the granting of any such additional license [CONFIDENTIAL TREATMENT REQUESTED]
following the effective date thereof, which notice shall identify [CONFIDENTIAL
TREATMENT REQUESTED].
(a) In the event that Chiron grants [CONFIDENTIAL TREATMENT REQUESTED]
pursuant to Section 2.1.3(a), and subject to paragraph 3(c), the [CONFIDENTIAL
TREATMENT REQUESTED] hereunder with respect CDC HCV/HIV Probe Products directed
to HCV shall [CONFIDENTIAL TREATMENT REQUESTED], and the [CONFIDENTIAL TREATMENT
REQUESTED] with respect to CDC HCV/HIV Probe Products directed to HIV shall
[CONFIDENTIAL TREATMENT REQUESTED], each on a product-by-product basis, without
action by CDC, [CONFIDENTIAL TREATMENT REQUESTED]. With respect to CDC HCV/HIV
Probe Products directed to HCV, in determining the [CONFIDENTIAL TREATMENT
REQUESTED]. Such [CONFIDENTIAL TREATMENT REQUESTED] shall be effective
prospectively from the later of the date of execution of the third party license
or the date on which the third party earned royalties and minimum royalties
become effective. The foregoing [CONFIDENTIAL TREATMENT REQUESTED] shall be
made on a [CONFIDENTIAL TREATMENT REQUESTED] if [CONFIDENTIAL TREATMENT
REQUESTED] third party license [CONFIDENTIAL TREATMENT REQUESTED] granted by
Chiron are [CONFIDENTIAL TREATMENT REQUESTED]. Otherwise, Paragraph 3(b) shall
apply.
(b) In the event that Chiron elects to grant [CONFIDENTIAL TREATMENT
REQUESTED] with respect to HCV or HIV pursuant to Section 2.1.3(b), the
following provisions shall apply in lieu of Paragraph 3(a) with respect to such
[CONFIDENTIAL TREATMENT REQUESTED]. Subject to Paragraph 3(c), the
[CONFIDENTIAL TREATMENT REQUESTED] hereunder with respect to CDC HCV/HIV Probe
Products directed to HCV and sold [CONFIDENTIAL TREATMENT REQUESTED]
shall [CONFIDENTIAL TREATMENT REQUESTED], and the [CONFIDENTIAL TREATMENT
REQUESTED] with respect to CDC HCV/HIV Probe Products directed to HIV and sold
[CONFIDENTIAL TREATMENT REQUESTED] shall be [CONFIDENTIAL TREATMENT REQUESTED],
each on a product by product basis, without action by CDC, to [CONFIDENTIAL
TREATMENT REQUESTED].
29
<PAGE>
(c) In no event shall [CONFIDENTIAL TREATMENT REQUESTED] made pursuant
to Paragraph 3(a) or 3(b) result in [CONFIDENTIAL TREATMENT REQUESTED]. For the
avoidance of doubt, Attachment A-1 describes the application of Paragraphs 3(a),
(b) and (c) in various licensing situations.
(d) [CONFIDENTIAL TREATMENT REQUESTED] as specified in Paragraph 3(a)
or 3(b) will be made only if the patent portfolio licensed to the third party
with respect to HCV does not contain any patents or patent applications which
are owned by Chiron, or licensed to Chiron with right to sublicense, and which
are not Chiron HCV/HIV Patents. If additional HCV patents or patent
applications are offered to the third party, either (i) Chiron will offer to
include such patents or patent applications within the Chiron HCV/HIV Patents on
the terms set forth in this Agreement [CONFIDENTIAL TREATMENT REQUESTED], or
(ii) [CONFIDENTIAL TREATMENT REQUESTED] specified in Paragraph 3(a) or 3(b) will
not be made.
(e) In addition, if [CONFIDENTIAL TREATMENT REQUESTED] the third party
referenced in Paragraph 3(a), taken as a whole, are more favorable to the
licensee than the corresponding terms of this Agreement, CDC shall have the
right to substitute, on a prospective basis, all, but not less than all, of such
terms for the corresponding terms of this Agreement, by giving written notice to
Chiron within thirty (30) days following receiving notice of such license terms.
Such substituted terms shall become effective upon Chiron's receipt of the
written notice from CDC accepting such terms.
(f) CDC shall remain liable hereunder for all amounts payable to
Chiron under the original terms of this Agreement with respect to all product
sales prior to the effective date of [CONFIDENTIAL TREATMENT REQUESTED] terms
pursuant to Paragraph 2 (b) or Paragraph 3 (a), (b) or (d) above.
4. SINGLE ROYALTY PER PRODUCT. Only one Earned Royalty and Minimum Royalty
shall be due with respect to a sale of any CDC HCV/HIV Probe Product,
irrespective of the number of patents or Valid Claims in the Licensed Chiron
Patents covering such product, and such Earned Royalty and Minimum Royalty shall
be those applicable to HCV if such product is covered by Valid Claim in the
Licensed Chiron Patents directed to both HCV and HIV.
30
<PAGE>
Attachment A-1
Application of Adjustments to HCV and HIV Earned Royalties and Minimum Royalties
[CONFIDENTIAL TREATMENT REQUESTED]
EXAMPLE OF HCV ROYALTY CALCULATION
[CONFIDENTIAL TREATMENT REQUESTED]
31
<PAGE>
EXHIBIT B
[CONFIDENTIAL TREATMENT REQUESTED]
<PAGE>
Chiron Corporation
CHIRON 4560 Horton Street
Emeryville, California 9460802916
510.655.8730
May 28, 1999
CONFIDENTIAL
Paul Hastings
3848A 26th Street
San Francisco, CA 94131
Dear Paul:
We are pleased to confirm the terms of our offer to you as President, BioPharma
Commercial at Chiron Corporation, reporting to Sean Lance. You will be elected
as a corporate Vice President and confirmation of your role as an executive
officer of Chiron will take place at the next Board of Directors meeting. You
will be a member of Chiron's Executive Committee.
Your starting salary will be $325,000 per annum. You will be eligible to
participate in Chiron's Annual Incentive Plan (AIP) program. The results of the
company, the BioPharma Commercial division and your own performance during the
calendar year determine awards under this program. You will be eligible for an
award of between 0 and 120% of your base salary. Your award for 1999 will be
prorated according to your employment date.
You will be eligible to participate in our stock option program. Subject to the
approval of the Board of Directors, we will award you a stock option grant of
180,000 shares to purchase Chiron common stock. Of the total, 100,000 option
shares will vest over a four-year period, with the first 25% of the shares
vesting at the one-year grant anniversary and the other 75% vesting on a
pro-rated monthly basis over the remaining three years of the vesting period.
The remaining 80,000 shares will vest 100% on the fourth anniversary of the
grant date. The exercise price of the option will be set at the fair market
value (as defined in the Option Plan) of a share of Chiron stock on the date the
option is approved. We expect the grant to be approved and effective by the end
of the month in which your employment begins. Beginning in year 2000 you will be
eligible for further stock option grants based on your performance.
We are prepared to make you a loan of $150,000 which must be used exclusively
for the purchase of your principal residence and which must be secured by a
second deed of trust on that residence. It will be interest free and will be
forgiven $50,000 per year beginning with the first anniversary of your
employment. The loan is repayable within 90 days should you voluntarily resign.
If your employment is terminated for reason other than cause, amounts remaining
on the loan will be forgiven at the end of your employment with Chiron. Any
taxes arising from imputed income or loan forgiveness are your responsibility.
In the event your employment is severed for reason other than cause, you will be
eligible for a minimum severance benefit of one year of base salary plus bonus,
the bonus portion being calculated as the average of the prior 2 years bonus
payments. This benefit is in lieu of any other Chiron severance plan payments
you might be due.
<PAGE>
The information sheets following your offer letter contain some of the
highlights of Chiron's benefits programs. You should note that, while this offer
is being made under the terms of our current benefits and compensation programs,
changes do occur from time to time and any system-wide changes that occur will
apply to you as well.
Some of the benefit programs are effective immediately upon your employment,
while others are dependent upon established enrollment periods. Your group
medical insurance benefits generally start on the first day of the month
FOLLOWING your date of hire. If, however, your date of hire is the first
business day of the month, your coverage becomes effective on that date. Note
also that, with few exceptions, Chiron extends benefits coverage to qualified
family members, including opposite- and same-sex domestic partners.
As a part of Chiron's routine medical surveillance program, employees with
certain project assignments may be advised to provide a baseline blood sample
for archival storage. The Chiron Occupational Health Department will notify you
if a baseline blood draw is recommended.
This offer is contingent upon your ability, as required by federal law, to
establish your employment eligibility as a U.S. citizen, a U.S. lawful permanent
resident, or an individual specifically authorized for employment in the U.S. by
the Immigration and Naturalization Service.
Under California law, employment with Chiron is not for any specified term and
can be terminated at any time for any reason by you or Chiron. Any contrary
representations that have been made or may be made to you are superseded by this
offer. When you accept the offer, the terms described in this letter and the
Chiron Employee Invention and Confidential Information Agreement shall
constitute the terms of your employment.
We are delighted that you have accepted our offer. Sean Lance, Rusty Williams
and all the other executives you have met look forward to your joining the team.
We look forward to your start date of some time between June 14 and July 1. As
soon as you have a sense of when that will be, let us know. Please call me if
you have any questions on the terms of the offer as outlined. Otherwise, please
sign and return this at your earliest convenience.
Sincerely,
CHIRON CORPORATION
/s/ LINDA SHORT
- -----------------------------------
Linda Short
Vice President, Corporate Resources
Enclosures
cc: Sean Lance
Please indicate your understanding of the terms of this offer and your
acceptance of this offer by signing this letter and returning the letter to me
as soon as possible.
/s/ PAUL J. HASTINGS 5/29/99
- -------------------------------------------
Name Date
<PAGE>
CHIRON CORPORATION
EMPLOYEE BENEFITS AS OF 1/1/99
INSURANCE BENEFITS
MEDICAL INSURANCE Chiron offers several medical plans to eligible
employees and their eligible dependents (spouse,
domestic partner and/or children). All medical plans
include prescription and vision benefits. Employee
contributions are pretax.
DENTAL INSURANCE Chiron offers 2 dental plans to eligible employees
and their eligible dependents (spouse, domestic
partner and/or children). Employee contributions are
pretax.
LIFE INSURANCE Eligible employees can purchase coverage for
themselves of $10,000, or 1, 2, 3, 4 or 5 times
annual salary. The maximum coverage is $800,000 for
the first 2 times salary and an additional $800,000
for the next 3 times salary. Employee contributions
are pretax.
DEPENDENT LIFE Eligible employees can purchase life insurance
INSURANCE coverage for eligible dependents on an after-tax
basis. Options include $10,000, $20,000 or $50,000
for spousal coverage and $5,000 or $10,000 for
children.
ACCIDENTAL DEATH & Eligible employees can purchase coverage for
DISMEMBERMENT themselves of 1, 2, 3, 4 or 5 times annual salary.
The maximum coverage is $800,000 for the first 2
times salary and an additional $800,000 for the next
3 times salary. Employee contributions are pretax.
TRAVEL ACCIDENT Chiron provides Travel Accident Insurance coverage of
3 times annual salary at no cost to employees. This
provides 24-hour coverage for travel to and from work
or on company business.
SHORT-TERM Through the short-term disability program, Chiron
DISABILITY provides eligible employees with 100% of salary for
the first 30 calendar days less state disability or
similar payments, and 80% of salary for the next 150
days of disability less state disability or similar
payments. Chiron provides this coverage at no cost to
the employee.
LONG-TERM For eligible employees disabled for more than 180
DISABILITY days, Chiron provides 60% of monthly salary up to
$18,000 per month. Chiron provides this coverage at
no cost to the employee. Eligible employees also have
the option to purchase an additional 6 2/3% of
monthly salary up to $20,000 per month, reduced by
any other income benefits.
WORKERS' All employees are covered by Chiron's Workers'
COMPENSATION Compensation insurance.
INVESTMENT PROGRAMS
401(K) PLAN Participation in the Chiron Corporation 401(k) plan
is available to eligible employees on the first of
the month following date of hire or immediately, if
date of hire is the first business day of the month.
Employees may designate pre-tax contributions of 1%
to 15% of salary. The Company provides a maximum 4%
match on employee contributions and the match is
vested immediately. For newly eligible employees
there is a waiting period of 1 year before matching
contributions are given.
EMPLOYEE STOCK Eligible employees may purchase Chiron stock at a
discount below market price.
<PAGE>
PURCHASE PLAN Participation in the plan depends upon the employee's
date of hire. Employees can contribute to this
program from 3% to 15% of their base salary on an
after-tax basis.
STOCK OPTION PLAN Chiron has a Stock Option Program. The granting of
options to eligible employees is subject to Board of
Directors' approval and program guidelines.
TIME-OFF BENEFITS
EXECUTIVE TIME OFF Each January 1, executive employees receive an
allocation of 4 weeks of time off. The allocation may
be taken in whole or in part anytime throughout the
year. Any unused time at the end of the year will not
accrue from year to year. No reporting of time off is
needed. There will be no pay out for unused time off
either at the end of the year or at termination.
FIXED HOLIDAYS Eligible employees receive up to 8 paid holidays per
year.
LEAVE OF ABSENCE Chiron grants leaves of absence to accommodate
employees' medical/maternity disability and family or
personal needs.
OTHER BENEFITS
FLEXIBLE SPENDING Chiron offers Health Care and Dependent Care
reimbursement accounts to eligible employees. These
accounts give employees the advantage of paying for
eligible health and dependent care expenses with
pretax dollars.
EMPLOYEE ASSISTANCE Chiron provides a confidential counseling and
PROGRAM referral service to all employees and their families.
EDUCATIONAL Regular full-time employees are eligible, after 6
ASSISTANCE months of service, for up to $2,000 per year in
reimbursement of tuition, textbooks, and lab expenses
for classes directly related to their jobs.
CREDIT UNION Regular full-time and part-time employees and members
of their families or household are eligible to join.
PREPAID LEGAL A Prepaid Legal Plan is available to eligible
employees to provide affordable, basic legal
services. Employees pay for this benefit on an
after-tax basis.
DEPENDENT CARE Eligible employees are provided with this counseling,
CONNECTION education and referral service which provides
information regarding child care, elder care,
adoption and prenatal planning.
NOTE: ELIGIBLE EMPLOYEES ARE DEFINED AS REGULARLY SCHEDULED TO WORK
20 HOURS OR MORE PER WEEK. COVERAGE FOR MOST BENEFITS IS EFFECTIVE THE
FIRST OF THE MONTH FOLLOWING DATE OF HIRE, OR IMMEDIATELY IF THE DATE OF
HIRE IS THE FIRST BUSINESS DAY OF THE MONTH, UNLESS OTHERWISE NOTED.
<PAGE>
PROMISSORY NOTE
$150,000 JULY 20, 1999
Emeryville, California
FOR VALUE RECEIVED, the undersigned, PAUL J. HASTINGS (the
"Borrower"), hereby promises to pay CHIRON CORPORATION, a Delaware corporation
or order ("Lender"), the principal sum of ONE HUNDRED FIFTY THOUSAND DOLLARS AND
NO/100THS CENTS ($150,000), in lawful money of the United States of America,
with interest equal to zero percent (0%) per annum, to purchase that certain
improved real property located at 61 Hartford Street, San Francisco, San
Francisco County, California (the "Property") constituting Borrower's principal
residence in California (the "Loan").
1. All payments of principal and any other amounts payable on or in
respect of this Note or the indebtedness evidenced hereby shall be made to the
account of Lender at its principal office located at 4560 Horton Street,
Emeryville, California 94608, or to such other place as Lender may from time to
time designate by written notice to Borrower. All payments shall be in lawful
money of the United States of America.
2. The principal amount of One Hundred Fifty Thousand Dollars ($150,000)
hereunder shall become due and payable on the earlier to occur of the following:
(i) July 20, 2002, which is three (3) years from the date hereof (the "Maturity
Date"), or (ii) such earlier date as described in Paragraph 4 or 6 below, as
applicable (the "Repayment Date").
3. Notwithstanding the foregoing provisions, the principal amount of this
Note shall be reduced and forgiven in three (3) annual increments of Fifty
Thousand Dollars ($50,000.00) beginning on the first anniversary after July 20,
1999, and on each successive anniversary date thereafter, through and including
the Maturity Date, with the outstanding principal balance due in full on the
Repayment Date, if and only if on the applicable forgiveness date, Borrower
continues to be a full-time employee of Chiron Corporation or an affiliate
thereof.
4. Notwithstanding the foregoing provisions, in the event that Chiron
Corporation or an affiliate thereof terminates Borrower's services for cause, or
Borrower voluntarily leaves Chiron Corporation or an affiliate thereof, prior to
the Maturity Date of the Loan, the outstanding principal balance of the Loan
owing through the Repayment Date shall become immediately due and payable and
shall be repaid by Borrower within a reasonable period not to exceed 90 days
from the date of Borrower's leaving the full-time employ of Chiron Corporation
or an affiliate thereof.
<PAGE>
5. Borrower and Lender agree that the indebtedness evidenced by this Note
shall be Borrower's sole and personal liability, and shall be secured by a Deed
of Trust executed by Borrower in favor of Lender and recorded against the
Property, which Deed of Trust shall be subordinate to that of the liens secured
by first and second mortgagors' Deeds of Trust encumbering the Property.
Borrower agrees to use his best efforts to enable Lender to record such Deed of
Trust in favor of Lender for the total amount of this Loan, as soon as
practicable after Borrower closes escrow on the purchase of the Property with
first and second mortgagors.
6. Notwithstanding the foregoing provisions, in the event that Chiron
Corporation or an affiliate thereof terminates Borrower's services for any
reason other than for cause prior to the Maturity Date of the Loan, the
outstanding balance shall be forgiven entirely.
7. Nothing herein shall be deemed to create any obligation of continued
employment on the part of the Borrower or Chiron Corporation.
8. Borrower and Lender agree that upon recordation of a Deed of Trust
covering the Property in substantially the form attached hereto as ADDENDUM 1,
the obligations of Borrower under this Note shall become subject to the terms of
that certain Deed of Trust which contains the following provision: "In the event
the herein described property or any part thereof, or any interest therein is
sold, agreed to be sold, conveyed or alienated by the Trustor (Borrower), or by
the operation of law or otherwise, all obligations secured by this instrument,
irrespective of the maturity dates expressed therein, at the option of the
holder hereof and without demand or notice shall immediately become due and
payable."
9. In the event that Borrower intends to, sell, agrees to sell, transfers
or conveys his interest in the Property or any part thereof or any interest
therein, Lender and Borrower agree that they shall execute in writing an
agreement as to a substitution of security for the indebtedness covered
hereunder, or Lender will repay this Note in full.
10. Should the indebtedness evidenced by this Note be collected by action
at law, or in bankruptcy, receivership or other court proceeding, or should this
Note be placed in the hands of attorneys for collection after default, Borrower
agrees to pay, upon demand of Lender, in addition to principal and any other
sums, if any, due and payable hereunder, court costs and reasonable attorneys'
fees and other reasonable collection charges, whether suit be brought or not,
unless prohibited by law. Borrower hereby waives diligence, presentment, protest
and demand of every kind and (to the full extent permitted by law) the right to
plead any statute of limitations as a defense to any demand or action hereunder
or in connection with any security herefor, and hereby agrees that no failure on
the part of Lender to exercise any power, right or privilege hereunder, or to
insist upon prompt compliance with the terms hereof, shall constitute a waiver
thereof.
2
<PAGE>
11. In the event of any failure on the part of Borrower to make any payment
when due, Borrower hereby agrees to pay, upon demand of Lender, in addition to
principal and any other sums, if any, due and payable hereunder, court costs and
reasonable attorneys' fees and other reasonable collection charges that Lender
shall be entitled to recover from Borrower, whether suit be brought or not.
12. Any notice to either party hereto may be given by delivering the same
in writing to such party in person, or by sending the same by registered or
certified mail, postage prepaid, to the following mailing addresses or to any
other mailing addresses within the State of California of which the parties
notify each other:
Borrower: Paul J. Hastings
61 Hartford Street
San Francisco, California 94114
Lender: Chiron Corporation
4560 Horton Street
Emeryville, California 94608
Attn: Office of the General Counsel
13. In the event that any one or more of the provisions contained in this
Note shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other provision of this Note, but this Note shall be construed as if such
invalid, illegal or unenforceable provisions had never been contained herein or
therein.
14. Any failure of the Lender to exercise or enforce any right hereunder
shall not constitute a waiver of such right. All rights of the Lender hereunder
shall be cumulative and not alternative and shall be in addition to any other
rights and remedies granted to the Lender pursuant to any other agreement, by
statute, or by law.
15. Borrower shall not assign, convey, transfer, delegate, subordinate or
otherwise, mortgage, hypothecate or encumber, any of his interest, rights or
obligations hereunder to any other party.
16. This Note may not be changed orally, but only by an agreement in
writing signed by the parties against whom enforcement of any waiver, change,
modification or discharge is sought.
3
<PAGE>
17. This Note shall be construed and enforced in accordance with, and
governed by, the laws of the State of California and shall be binding upon and
shall inure to the benefit of the parties hereto and their respective heirs,
executors, administrators, legal representatives, successors and assigns.
WITNESS the due execution hereof with the intent of being legally
bound, effective as of the date first set forth above.
BORROWER:
/s/ PAUL J. HASTINGS July 19, 1999
- -------------------- -------------
PAUL J. HASTINGS Date
4
<PAGE>
EXECUTION COPY
AMENDMENT dated as of January 3, 1994, among CIBA-GEIGY
LIMITED, a Swiss corporation ("Ciba"), CIBA-GEIGY
CORPORATION, a New York corporation ("CCorp"), CIBA BIOTECH
PARTNERSHIP, INC., a Delaware corporation ("Holdings"), and
CHIRON CORPORATION, a Delaware corporation (the "Company").
WHEREAS Ciba, CCorp, Holdings and the Company have entered
into the Investment Agreement dated as of November 20, 1994 (the "Investment
Agreement") (capitalized terms used but not defined herein shall have the
meanings assigned to them in the Investment Agreement).
WHEREAS Ciba, CCorp, Holdings and the Company wish to amend
certain provisions of the Investment Agreement.
NOW THEREFORE in consideration of the transactions
contemplated by the Investment Agreement and for other good and valuable
consideration, the sufficiency and receipt of which are hereby acknowledged, the
parties hereto hereby agree as follows:
SECTION 1. Section 1.04(ii) of the Investment Agreement is
amended by deleting therefrom the words "the JV Vax Shares, in each case" and
inserting immediately preceding the "(y)" therein the following phrase "a fully
executed deed of transfer for the transfer of the JV Vax Shares and".
SECTION 2. Section 5.15(a) of the Investment Agreement is
amended by adding immediately following the words "post retirement benefit
liabilities" therein the words "associated with current and former U.S.
Diagnostics employees".
SECTION 3. Section 5.15 of the Investment Agreement is amended
by adding the following subsection (c) immediately following subsection (b)
thereof:
"(c) (i) Within 10 days after the completion of Diagnostics'
year-end audit for fiscal year 1994, Diagnostics shall prepare and
deliver to Ciba a statement (the "Statement"), certified by
Diagnostics' independent auditors, setting forth Diagnostics' net
shareholders' equity (calculated in accordance with paragraph (a)
above).
<PAGE>
2
During the 30-day period following Ciba's receipt of the
Statement, Ciba and its independent auditors shall be permitted to
review the working papers of Diagnostics' independent auditors relating
to the Statement. The Statement shall become final and binding upon the
parties on the thirtieth day following delivery thereof, unless Ciba
gives written notice of its disagreement with the Statement (a "Notice
of Disagreement") to Diagnostics and the Company prior to such date.
Any Notice of Disagreement shall specify in reasonable detail the
nature of any disagreement so asserted and be accompanied by a
certificate of Ciba's independent auditors that they concur with the
position taken by Ciba in the Notice of Disagreement. If a Notice of
Disagreement is received by the Company in a timely manner, then the
Statement (as revised in accordance with clause (I) or (II) below)
shall become final and binding upon the Company and Ciba on the earlier
of (I) the date Ciba and the Company resolve in writing any differences
they have with respect to the matters specified in the Notice of
Disagreement or (II) the date any disputed matters are finally resolved
in writing by the Accounting Firm (as defined below).
During the 30-day period following the delivery of a Notice of
Disagreement, the Company and Ciba shall seek in good faith to resolve
in writing any differences which they may have with respect to the
matters specified in the Notice of Disagreement. At the end of such
30-day period, the Company and Ciba shall submit to an independent
accounting firm (the "Accounting Firm") for review and resolution any
and all matters which remain in dispute and which were properly
included in the Notice of Disagreement. The Accounting Firm shall be a
nationally recognized independent public accounting firm as shall be
agreed upon by Ciba and the Company in writing. Ciba and the Company
agree to use reasonable efforts to cause the Accounting Firm to render
a decision resolving the matters submitted to it within 30 days
following such submission. The cost of resolving any matters set forth
in a Notice of Disagreement (including the fees and expenses of the
Accounting Firm and reasonable attorney fees and expenses of the
parties) pursuant to this Section 5.15(c) shall be borne by Ciba and
the Company in inverse proportion as they may prevail on matters
resolved by the Accounting Firm, which proportionate allocations shall
also be determined by
<PAGE>
3
the Accounting Firm at the time the determination of the Accounting
Firm is rendered on the merits of the matters submitted.
(ii) If the amount of Diagnostics' net shareholders equity
(calculated in accordance with paragraph (a) above) set forth in the
Statement is less than $188,651,000, Ciba shall, within 10 business
days after the Statement becomes final and binding on the parties, make
payment by wire transfer in immediately available funds of the amount
of such difference, together with interest thereon at a rate equal to
the rate of interest from time to time announced publicly by Citibank,
N.A. as its prime rate, calculated on the basis of the actual number of
days elapsed over 365, from the Closing Date to the date of payment.
(iii) The scope of the disputes to be resolved by the
Accounting Firm is limited to whether the calculation of net
shareholder's equity was done in accordance with U.S. generally
accepted accounting principles applied consistently with the principles
and assumptions used in the preparation of the Diagnostics Balance
Sheet and in accordance with paragraph (a) above, and whether there
were mathematical errors in the Statement, and the Accounting Firm is
not to make any other determination."
SECTION 4. (a) The parties hereto hereby agree that the
execution of the promissory note dated the date hereof by Diagnostics in favor
of Ciba evidencing indebtedness to Ciba pursuant to Section 5.15(b) of the
Investment Agreement (the "CCD Promissory Note") shall (i) be deemed not to
result in any representation and warranty set forth in Section 3.03 of the
Investment Agreement being false or incorrect in any respect on the Closing Date
and (ii) not constitute or cause to occur a Diagnostics Revaluation Event under
the Investment Agreement.
(b) The parties hereto hereby agree that the principal amount
of the CCD Promissory Note shall be adjusted downward to the extent that
Diagnostics' year-end audit for fiscal year 1994 shows that, as of December 31,
1994, the amount of indebtedness of Diagnostics to third parties is greater than
$43,916,000 (or shall be adjusted upward to the extent that such indebtedness is
less than such amount), and, in either case, such adjustment shall be effective
retroactively to January 1, 1995. The parties
<PAGE>
4
further agree to take any actions reasonably necessary to effectuate the
foregoing, including the Company causing Diagnostics to execute an amended
promissory note. The parties further agree that the calculations of
Diagnostics' net shareholders' equity made pursuant to Section 3 hereof shall
be made after giving effect to any adjustment to the principal amount of the
CCD Promissory Note in accordance with this Section 4(b).
SECTION 5. The parties hereto agree that the delivery to C.
William Zadel of the letter from the Company dated January 4, 1995 setting forth
the principal terms of Mr. Zadel's continuing employment with the Company and
the businesses constituting Diagnostics, and the discussions which have taken
place between Mr. Zadel and representatives of the Company, shall be deemed to
satisfy in all respects the covenant of the Company set forth in the first
sentence of Section 5.08(e) of the Investment Agreement.
SECTION 6. As soon as is reasonably practical following the
execution of this Amendment, Ciba will deliver to the Company a schedule of
those filings required to be made following the Closing in certain foreign
jurisdictions due to a change of control with respect to certain of the
subsidiaries of Diagnostics. The parties agree that the Company shall coordinate
the preparation and making of such filings, with the reasonable cooperation of
Ciba, including, to the extent deemed appropriate by the Company, cooperation in
facilitating the employment of the present counsel of Ciba and its subsidiaries
in connection with such filings. The Company and Ciba agree that costs and
expenses incurred in connection with the identification of jurisdictions in
which such filings must be made, and the preparation and making of such filings
shall be shared equally by the Company and Ciba.
SECTION 7. (a) This Amendment constitutes the entire agreement
and understanding of the parties with respect to the subject matter hereof and
supersedes any and all prior agreements and understandings, oral or written,
relating to the subject matter hereof. This Amendment shall be construed in
accordance with and governed by the law of the State of Delaware. This Amendment
may be executed in any number of counterparts, each of which shall be an
original but all of which, when taken together, shall constitute but one
instrument. Except as expressly set forth herein, this Amendment shall not by
implication or
<PAGE>
5
otherwise limit, impair, constitute a waiver of, or otherwise affect the
rights and remedies of the parties under the Investment Agreement or any of
the Ancillary Agreements.
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Amendment to be duly executed by their respective authorized officers
as of the date first above written.
CIBA-GEIGY LIMITED,
by /s/ Herbert Gut
------------------------------------
Name: Herbert Gut
Title: Senior Division Counsel
by /s/ Steven Ballmer
------------------------------------
Name: Steven Ballmer
Title: Tax Counsel
CIBA-GEIGY CORPORATION,
by
------------------------------------
Name:
Title:
CIBA-BIOTECH PARTNERSHIP,
INC.,
by
------------------------------------
Name:
Title:
CHIRON CORPORATION,
by /s/ William J. Rutter
------------------------------------
Name:
Title:
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Amendment to be duly executed by their respective authorized officers
as of the date first above written.
CIBA-GEIGY LIMITED,
by
------------------------------------
Name:
Title:
by
------------------------------------
Name:
Title:
CIBA-GEIGY CORPORATION,
by /s/ John J. McGraw
------------------------------------
Name: John J. McGraw
Title: Vice President and
General Counsel
CIBA BIOTECH PARTNERSHIP,
INC.,
by /s/ John J. McGraw
------------------------------------
Name: John J. McGraw
Title: Vice President
CHIRON CORPORATION,
by
------------------------------------
Name:
Title:
<PAGE>
EXECUTION COPY
SUPPLEMENTAL AGREEMENT dated as of January 3,
1995, among CIBA-GEIGY LIMITED, a Swiss corporation
("Ciba"), CIBA-GEIGY CORPORATION, a New York
corporation ("CCorp"), CIBA BIOTECH PARTNERSHIP, INC.,
a Delaware corporation ("Holdings"), and CHIRON
CORPORATION, a Delaware corporation (the "Company").
WHEREAS Ciba, CCorp, Holdings and the Company have entered into the
Investment Agreement dated as of November 20, 1994 (the "Investment
Agreement") (capitalized terms used but not defined herein shall have the
meanings assigned to them in the Investment Agreement);
WHEREAS the Investment Agreement provides for Ciba and CCorp to
cause Holdings to transfer to the Company the Diagnostics Shares and the Ciba
Biocine Business as consideration for 6,600,000 newly issued shares of Common
Stock to be purchased by Holdings;
WHEREAS the parties wish to structure the transfer of the
Contributed Businesses in the forms described herein;
NOW, THEREFORE, in consideration of the transactions contemplated by
the Investment Agreement and for other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, the parties hereto
hereby agree as follows:
SECTION 1. The parties hereto agree that, notwithstanding anything
to the contrary contained in the Investment Agreement, at the Closing the
transfer of the Contributed Businesses to the Company shall be effected as
follows:
(a) Ciba and CCorp shall cause JV US Holdings to merge with and into
Chiron Biocine Acquisition Corporation and the Company shall cause Chiron
Biocine Acquisition Corporation to merge with JV US Holdings, with Chiron
Biocine Acquisition Corporation as the surviving corporation, all upon the
terms and subject to the conditions of an agreement and plan of merger
substantially in the form of Exhibit A hereto. The consideration to be
received in the merger by the holders of shares of common stock of JV US
Holdings shall include the amounts owed by the Company to Ciba
<PAGE>
2
or its subsidiaries pursuant to Section 1.04(iv)(3) of the Investment
Agreement and consummation of such merger shall satisfy the Company's
obligation to repay such amounts at the Closing pursuant to such Section 1.04
(iv)(3).
(b) The Company shall cause Chiron CCD Acquisition Corporation
to merge with and into Diagnostics and Ciba and CCorp shall cause
Diagnostics to merge with Chiron CCD Acquisition Corporation, with
Diagnostics as the surviving corporation, all upon the terms and
subject to the conditions of an agreement and plan of merger
substantially in the form of Exhibit B hereto.
(c) Upon the terms and subject to the conditions of the
Investment Agreement, the Company shall purchase from Ciba, CCorp or a
subsidiary of Ciba, and Ciba, CCorp or a subsidiary of Ciba shall sell,
transfer and deliver to the Company, the JV Vax Shares, in consideration
for which the Company shall issue, sell, transfer and deliver to Ciba, CCorp,
Holdings, or a subsidiary of Ciba 700,000 New Shares.
SECTION 2. The parties hereto hereby agree that the transfer of the
Contributed Businesses pursuant to SECTION 1 hereof rather than according to
ARTICLE I of the Investment Agreement and the satisfaction of the Company's
obligation under Section 1.04(iv)(3) of the Investment Agreement by means
of consummation of the merger contemplated by SECTION 1(a) hereof shall be
deemed not to result in (i) any representation or warranty set forth in the
Investment Agreement or any Ancillary Agreement being false or incorrect in
any respect and (ii) any covenant or agreement set forth in the Investment
Agreement or any Ancillary Agreement being breached in any respect.
SECTION 3. This Supplemental Agreement constitutes the entire agreement
and understanding of the parties with respect to the subject matter hereof
and supersedes any and all prior agreements and understandings, oral or
written, relating to the subject matter hereof. This Supplemental Agreement
shall be construed in accordance with and governed by the law of the State of
Delaware. This Supplemental Agreement may be executed in any number of
counterparts, each of which shall be an original but all of which, when taken
together, shall constitute but one instrument. Except as expressly set forth
herein, this Supplemental Agreement shall not by implication or otherwise
<PAGE>
3
limit, impair, constitute a waiver of, or otherwise affect the rights and
remedies of the parties under the Investment Agreement or any of the
Ancillary Agreements.
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Supplemental Agreement to be duly executed by their respective
authorized officers as of the date first above written.
CIBA-GEIGY LIMITED,
by /s/ Herbert Gut
-------------------------------------
Name: Herbert Gut
Title: Senior Division Counsel
by /s/ Steven Ballmer
-------------------------------------
Name: Steven Ballmer
Title: Tax Counsel
CIBA-GEIGY CORPORATION,
by
-------------------------------------
Name:
Title:
CIBA BIOTECH PARTNERSHIP,
INC.,
by
-------------------------------------
Name:
Title:
CHIRON CORPORATION,
by
-------------------------------------
Name:
Title:
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Supplemental Agreement to be duly executed by their respective
authorized officers as of the date first above written.
CIBA-GEIGY LIMITED,
by
-------------------------------------
Name:
Title:
by
-------------------------------------
Name:
Title:
CIBA-GEIGY CORPORATION,
by /s/ John J. McGraw
-------------------------------------
Name: John J. McGraw
Title: Vice President and
General Counsel
CIBA BIOTECH PARTNERSHIP,
INC.,
by /s/ John J. McGraw
-------------------------------------
Name: John J. McGraw
Title: Vice President
CHIRON CORPORATION,
by /s/ William J. Rutter
-------------------------------------
Name:
Title:
<PAGE>
EXHIBIT A
AGREEMENT AND PLAN OF MERGER dated
as of January 4, 1995 (hereinafter called
this "AGREEMENT"), among CIBA-GEIGY BIOCINE
CORPORATION, a Delaware corporation
("BIOCINE"), CHIRON CORPORATION, a Delaware
corporation ("CHIRON") and CHIRON BIOCINE
ACQUISITION CORPORATION, a Delaware
corporation and a wholly owned subsidiary of
Chiron ("B ACQUISITION").
WHEREAS, Biocine desires to merge with and into B Acquisition and B
Acquisition desires to merge with Biocine, all upon the terms and subject to
the conditions of this Agreement; and
WHEREAS, the respective Boards of Directors of Biocine and B Acquisition
have approved the merger of Biocine into B Acquisition as set forth below
(the "MERGER"), upon the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises and conditions
contained herein, the parties hereto hereby agree as follows:
SECTION 1. THE MERGER. Upon the terms and subject to the conditions of
this Agreement and in accordance with the Delaware General Corporation Law
(the "DGCL"), at the Effective Time (as hereinafter defined) Biocine shall be
merged with and into B Acquisition (as of the Effective Time, the "SURVIVING
CORPORATION") and the separate corporate existence of Biocine shall thereupon
cease. Following the Merger, the Surviving Corporation shall succeed to and
assume all the rights and obligations of Biocine in accordance with the DGCL,
and the separate corporate existence of the Surviving Corporation as a
corporation under the laws of the State of Delaware, with all its rights,
privileges, powers, immunities, purposes and franchises, shall continue
unaffected by the Merger. The Merger shall have the effects set forth in the
DGCL, including Section 259 thereof.
SECTION 2. CONDITIONS OF MERGER; EFFECTIVE TIME. After this Agreement
has been approved and adopted by the affirmative vote or consent of the
stockholders of each of Biocine and B Acquisition, in each case in accordance
with
<PAGE>
2
their respective certificates of incorporation and the DGCL, the parties
hereto shall cause a certificate of merger or other appropriate documents
meeting the requirements of the DGCL (in any such case, the "CERTIFICATE OF
MERGER") to be properly executed in accordance with the relevant provisions
of the DGCL and filed in accordance with the DGCL. The Merger shall become
effective as of the date and time when the Delaware Certificate of Merger is
duly filed with the Secretary of State of the State of Delaware (the date and
time the Merger becomes effective being the "EFFECTIVE TIME").
SECTION 3. CERTIFICATE OF INCORPORATION; BY-LAWS; DIRECTORS; OFFICERS.
(a) CERTIFICATE OF INCORPORATION. The Certificate of Incorporation of B
Acquisition, as in effect immediately prior to the Effective Time, shall
continue in full force and effect and shall be the Certificate of
Incorporation of the Surviving Corporation, until thereafter changed or
amended as provided therein or by applicable law.
(b) BY-LAWS. As of the Effective Time, the By-laws of B Acquisition, as
in effect immediately prior to the Effective Time, shall continue in full
force and effect and shall be the By-laws of the Surviving Corporation, until
thereafter changed or amended as provided therein or by applicable law.
(c) DIRECTORS. The directors of B Acquisition at the Effective Time
shall be the directors of the Surviving Corporation, until the earlier of
their resignation or removal or until their respective successors are duly
elected and qualified, as the case may be.
(d) OFFICERS. The officers of B Acquisition at the Effective Time shall
be the officers of the Surviving Corporation, until the earlier of their
resignation or removal or until their respective successors are duly elected
and qualified, as the case may be.
SECTION 4. CONVERSION OF SHARES. As of the Effective Time, and without
any further action on the part of any holder of the common stock, par value
$1.00 per share, of Biocine ("BIOCINE COMMON STOCK") or any holder of the
common stock, par value $0.01 per share, of B Acquisition ("B ACQUISITION
COMMON STOCK"), each of the
<PAGE>
3
following transactions shall be deemed to occur simultaneously:
(a) Each issued and outstanding share of Biocine Common Stock shall be
converted into and exchanged for (i) 3,900 fully paid and nonassessable
shares of the common stock, par value $0.01 per share, of Chiron ("CHIRON
COMMON STOCK") plus (ii) a cash payment in the amount of $[23,746.00].
(b) Each share of B Acquisition Common Stock issued and outstanding
immediately prior to the Effective Time shall remain issued and outstanding
and shall constitute, after the Effective Time, one fully paid and
nonassessable share of the common stock, par value $0.01 per share, of the
Surviving Corporation.
SECTION 5. EXCHANGE OF CERTIFICATES. If a holder of record (immediately
prior to the Effective Time) of shares of Biocine Common Stock outstanding
immediately prior to the Effective Time presents (after the Effective Time)
to Chiron a certificate or certificates which immediately prior to the
Effective Time represented such shares, then, in exchange for the surrender
and cancelation of such certificate or certificates, Chiron shall issue to
such holder of record a certificate or certificates representing the shares
of Chiron Common Stock and pay to such holder of record the amount of cash
into which such shares of Biocine Common Stock were converted in accordance
with Section 4. Until surrendered as contemplated by this Section 5, each
certificate which immediately prior to the Effective Time represented
outstanding shares of Biocine Common Stock shall be deemed to represent only
the right to receive upon such surrender a certificate representing the
shares of Chiron Common Stock and the amount of cash into which such shares
of Biocine Common Stock were converted, as contemplated by this Section 5.
SECTION 6. MODIFICATION OR AMENDMENT. This Agreement may be amended or
modified, at any time prior to the filing of the Certificate of Merger with
the Secretary of State of the State of Delaware, by the mutual written
consents of Biocine and B Acquisition, by action of their respective Boards
of Directors; PROVIDED, HOWEVER, that after any required approval of the
Merger by the stockholders of Biocine or B Acquisition, there shall be made
no amendment that by law requires further approval by
<PAGE>
4
such stockholders without the further approval of such stockholders.
SECTION 7. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties.
SECTION 8. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware.
<PAGE>
5
IN WITNESS WHEREOF, this Agreement has been duly executed and
delivered by the duly authorized officers of the parties hereto on the
date first hereinabove written.
CIBA-GEIGY BIOCINE
CORPORATION,
by
-------------------------------------
Name:
Title:
CHIRON CORPORATION,
by
-------------------------------------
Name:
Title:
CHIRON BIOCINE ACQUISITION
CORPORATION,
by
-------------------------------------
Name:
Title:
<PAGE>
EXHIBIT B
AGREEMENT AND PLAN OF MERGER dated
as of January 4, 1995 (hereinafter called
this "AGREEMENT"), among CIBA CORNING
DIAGNOSTICS CORP., a Delaware corporation
("CCD"), CHIRON CORPORATION, a Delaware
corporation ("CHIRON") and CHIRON CCD
ACQUISITION CORPORATION, a Delaware
corporation and a wholly owned subsidiary of
Chiron ("C ACQUISITION").
WHEREAS, C Acquisition desires to merge with and into CCD and CCD
desires to merge with C Acquisition, all upon the terms and subject to the
conditions of this Agreement; and
WHEREAS, the respective Boards of Directors of C Acquisition and CCD
have approved the merger of C Acquisition into CCD as set forth below (the
"MERGER"), upon the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises and conditions
contained herein, the parties hereto hereby agree as follows:
SECTION 1. THE MERGER. Upon the terms and subject to the conditions of
this Agreement and in accordance with the Delaware General Corporation Law
(the "DGCL"), at the Effective Time (as hereinafter defined) C Acquisition
shall be merged with and into CCD (as of the Effective Time, the "SURVIVING
CORPORATION") and the separate corporate existence of C Acquisition shall
thereupon cease. Following the Merger, the Surviving Corporation shall
succeed to and assume all the rights and obligations of C Acquisition in
accordance with the DGCL, and the separate corporate existence of the
Surviving Corporation as a corporation under the laws of the State of
Delaware, with all its rights, privileges, powers, immunities, purposes and
franchises, shall continue unaffected by the Merger. The Merger shall have
the effects set forth in the DGCL, including Section 259 thereof.
SECTION 2. CONDITIONS OF MERGER; EFFECTIVE TIME. After this Agreement
has been approved and adopted by the affirmative vote or consent of the
stockholders of each of C Acquisition and CCD, in each case in accordance
with their respective certificates of incorporation and the DGCL, the parties
hereto shall cause a certificate of merger or other appropriate documents
meeting the requirements of the DGCL
<PAGE>
2
(in any such case,. the "CERTIFICATE OF MERGER") to be properly executed in
accordance with the relevant provisions of the DGCL and filed in accordance
with the DGCL. The Merger shall become effective as of the date and time when
the Delaware Certificate of Merger is duly filed with the Secretary of State
of the State of Delaware (the date and time the Merger becomes effective
being the "EFFECTIVE TIME").
SECTION 3. CERTIFICATE OF INCORPORATION; BY-LAWS; DIRECTORS; OFFICERS.
(a) CERTIFICATE OF INCORPORATION. The Certificate of Incorporation of
CCD, as in effect immediately prior to the Effective Time, shall continue in
full force and effect and shall be the Certificate of Incorporation of the
Surviving Corporation, until thereafter changed or amended as provided
therein or by applicable law.
(b) BY-LAWS. As of the Effective Time, the By-laws of CCD, as in effect
immediately prior to the Effective Time, shall continue in full force and
effect and shall be the By-laws of the Surviving Corporation, until
thereafter changed or amended as provided therein or by applicable law.
(c) DIRECTORS. The directors of C Acquisition at the Effective Time
shall be the directors of the Surviving Corporation, until the earlier of
their resignation or removal or until their respective successors are duly
elected and qualified, as the case may be.
(d) OFFICERS. The officers of CCD at the Effective Time shall be the
officers of the Surviving Corporation, until the earlier of their resignation
or removal or until their respective successors are duly elected and
qualified, as the case may be.
SECTION 4. CONVERSION OF SHARES. As of the Effective Time, and without
any further action on the part of any holder of the common stock, par value
$0.01 per share, of C Acquisition ("C ACQUISITION COMMON STOCK") or any
holder of the common stock, par value $10.00 per share, of CCD ("CCD COMMON
STOCK"), each of the following transactions shall be deemed to occur
simultaneously:
(a) Each issued and outstanding share of C Acquisition Common Stock
shall be converted into and exchanged for ten fully paid and nonassessable
shares of
<PAGE>
3
Common Stock, par value $10 per share, of the Surviving Corporation.
(b) Each share of CCD Common Stock issued and outstanding immediately
prior to the Effective Time shall be converted into and exchanged for 200
fully paid and nonassessable shares of the common stock, par value $0.01 per
share, of Chiron ("Chiron Common Stock").
SECTION 5. EXCHANGE OF CERTIFICATES. (a) If a holder of record
(immediately prior to the Effective Time) of shares of CCD Common Stock
outstanding immediately prior to the Effective Time presents (after the
Effective Time) to Chiron a certificate or certificates which immediately
prior to the Effective Time represented such shares, then Chiron shall issue
to such holder of record, in exchange for the surrender and cancelation of
such certificate or certificates, a certificate or certificates representing
the shares of Chiron Common Stock into which such shares of CCD Common Stock
were converted in accordance with Section 4. Until surrendered as
contemplated by this Section 5(a), each certificate which immediately prior
to the Effective Time represented outstanding shares of CCD Common Stock
shall be deemed to represent only the right to receive upon such surrender a
certificate representing the shares of Chiron Common Stock into which such
shares of CCD Common Stock were converted, as contemplated by this Section
5(a).
(b) If a holder of record (immediately prior to the Effective Time) of
shares of C Acquisition Common Stock outstanding immediately prior to the
Effective Time presents (after the Effective Time) to CCD a certificate or
certificates which immediately prior to the Effective Time represented such
shares, then CCD shall issue to such holder of record, in exchange for the
surrender and cancelation of such certificate or certificates, a certificate
or certificates representing the shares of CCD Common Stock into which such
shares of C Acquisition Common Stock were converted in accordance with
Section 4. Until surrendered as contemplated by this Section 5(b), each
certificate which immediately prior to the Effective Time represented
outstanding shares of C Acquisition Common Stock shall be deemed to represent
only the right to receive upon such surrender a certificate representing the
shares of CCD Common Stock into which such shares of C Acquisition Common
Stock were converted, as contemplated by this Section 5(b).
SECTION 6. MODIFICATION OR AMENDMENT. This Agreement may be amended or
modified, at any time prior to the filing of the Certificate of Merger with the
Secretary
<PAGE>
4
of State of the State of Delaware, by the mutual written consents of C
Acquisition and CCD, by action of their respective Boards of Directors;
PROVIDED, HOWEVER, that after any required approval of the Merger by the
stockholders of C Acquisition or CCD, there shall be made no amendment that by
law requires further approval by such stockholders without the further approval
of such stockholders.
SECTION 7. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each of
the parties and delivered to the other parties.
SECTION 8. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware.
<PAGE>
5
IN WITNESS WHEREOF, this Agreement has been duly executed and delivered
by the duly authorized officers of the parties hereto on the date first
hereinabove written.
CIBA CORNING DIAGNOSTICS
CORP.,
by
-------------------------------------
Name:
Title:
CHIRON CORPORATION,
by
-------------------------------------
Name:
Title:
CHIRON CCD ACQUISITION
CORPORATION,
by
-------------------------------------
Name:
Title:
<PAGE>
AMENDMENT WITH RESPECT TO EMPLOYEE STOCK OPTION
ARRANGEMENTS, dated January 3, 1995, among CIBA-GEIGY
LIMITED, a Swiss corporation ("Ciba"), CIBA-GEIGY
CORPORATION, a New York corporation ("CCorp"), CIBA BIOTECH
PARTNERSHIP, INC., a Delaware corporation ("Holdings"), and
CHIRON CORPORATION, a Delaware corporation (the "Company").
WHEREAS Ciba, CCorp, Holdings and the Company have entered into the
Investment Agreement dated as of November 20, 1994 (the "Investment
Agreement") (capitalized terms used but not defined herein shall have the
meanings assigned to them in the Investment Agreement);
WHEREAS the Investment Agreement provides in Section 5.14 thereof for the
implementation of arrangements regarding Employee Stock Options;
WHEREAS the parties wish to make certain changes to the arrangements
provided in Section 5.14 as set forth below;
NOW, THEREFORE, in consideration of the transactions contemplated by the
Investment Agreement and for other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, the parties hereto
hereby agree as follows:
SECTION 1. The parties hereto agree that, notwithstanding anything to
the contrary contained in Section 5.14 of the Investment Agreement:
(a) All payments to be made to holders of Stock Options pursuant to
Section 5.14 shall be made by Ciba direct to the person entitled thereto, and
not by the Company. The parties shall work out methods and procedures for
effecting such payments, and the Company will provide, at its own expense,
such information and administrative support services as shall be required
therefor, including information regarding required withholdings. Such payments
shall be made, and the related arrangements shall be effected, at no added
expense to Ciba. Information detailing each amount so paid and each amount
withheld with respect thereto and the nature thereof shall be prepared by the
Company for the benefit of both parties. The parties shall cooperate with
respect to the application of and arrangements related to such withheld
amounts.
(b) The definition of "Options Tranche" set forth in the last sentence of
Section 5.14(a) shall be amended to read in full as follows: "An 'Options
Tranche' shall mean that portion of a series of options
<PAGE>
with the same expiration date and exercise price that vest on the same date."
(c) The parties intend, and the last proviso of Section 5.14(b)
shall be interpreted to mean, that only such portion of a Type-A Non-Vested
Options with respect to which the Type-A Non-Vested Option Payment Right was
exercised shall be cancelled.
(d) Pursuant to Section 5.14(d) the Company has determined that
shareholder approval is desirable with respect to any right to a payment under
Section 5.14 that may be made to any director or officer as defined in Rule
16a-1 of the Exchange Act ("Section 16(b) Persons"). Accordingly, the
parties have agreed that the right of any Section 16(b) Person to payment
under Section 5.14 shall be embodied in an amendment to the Company's Stock
Option plans, which amendment shall be submitted to the stockholders of the
Company for approval at the next regularly scheduled meeting. Any right to
such payment is expressly conditioned upon such approval being obtained, and
no such payment shall be made prior thereto. Upon obtaining such approval,
such payment shall be made by Ciba to each Section 16(b) Person in an amount
equal to the aggregate Option Participation Payment such person would have
been entitled to under Section 5.14 had such payment been made on the Closing
Date, increased at a rate of 6% per annum calculated from the Closing Date to
the date such payment shall actually be made by Ciba; provided that such
increased payments shall be required only for amounts payable under Sections
5.14(a) and (b) for Vested Option Payment Rights and Type A Non-Vested
Option Payment Rights, as the case may be, exercised on or prior to the fifth
business day after such approval is obtained and for all amounts payable
under Section 5.14(c).
(e) The parties agree that Ciba shall have the right to review at
all reasonable times the books, records and other information of the Company
relating to the derivation and recipients of amounts paid by Ciba pursuant to
Section 5.14, as amended, to verify that such amounts paid were correctly
paid and calculated.
(f) The parties agree that Ciba shall have the right at any time to
review the books, records and any other information of the Company relating
to the derivation and recipients of amounts paid by Ciba pursuant hereto to
verify that such amounts paid were correctly paid and calculated.
2.
<PAGE>
(g) The Company agrees to indemnify and hold harmless Ciba and its
subsidiaries and affiliates and any of their present, former and future
directors, officers, employees, trustees, representatives, attorneys and
advisers from, against and in respect of any damages, claims, losses, charges,
actions, suits, proceedings, deficiencies, taxes, interest, penalties and
reasonable costs and expenses (including attorneys' fees) ("Liabilities")
imposed on, sustained, incurred or suffered by or asserted against any of
them, directly or indirectly, relating to, arising out of or in connection
with, Ciba's payments to holders of Stock Options in accordance herewith,
excluding any Liabilities that would have been imposed on Ciba relating to,
arising out of or in connection with Section 5.14 as the same shall have been
in effect on the date of the execution of the Investment Agreement and without
giving effect to this Amendment, in any case including, but not limited to,
the reimbursement by the Company of any amounts paid by Ciba that were not
properly payable in accordance with Section 5.14 of the Investment Agreement
and the terms hereof.
(h) The parties hereby acknowledge and agree that the Section
references in the proviso to Section 5.14(e) are to "Section 5.14(a)" and
"Section 5.14(b)", respectively.
SECTION 2. This Amendment constitutes the entire agreement and
understanding of the parties with respect to the subject matter hereof and
supersedes any and all prior agreements and understandings, oral or written,
relating to the subject matter hereof. Capitalized terms used herein and not
otherwise defined herein shall have the meaning assigned to such terms in the
Investment Agreement. This Supplemental Agreement shall be construed in
accordance with and governed by the law of the State of Delaware. This
Supplemental Agreement may be executed in any number of counterparts, each of
which shall be an original but all of which, when taken together, shall
constitute but one instrument. Except as expressly set forth herein, this
Supplemental Agreement shall not by implication or otherwise limit, impair,
constitute a waiver of, or otherwise affect the rights and remedies of the
parties under the Investment Agreement or any of the Ancillary Agreements.
3.
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Amendment with Respect Stock Option Arrangements to be duly executed by
their respective authorized officers as of the date first above
written.
CIBA-GEIGY LIMITED,
by /s/ Dr. Herbert Gut
-------------------------------------
Name: Dr. Herbert Gut
Title: Senior Division Counsel
by /s/ Peter Sidler
-------------------------------------
Name: Peter Sidler
Title: Senior Tax and
Corporate Counsel
CIBA-GEIGY CORPORATION,
by
-------------------------------------
Name:
Title:
CIBA BIOTECH PARTNERSHIP, INC.
by
-------------------------------------
Name:
Title:
CHIRON CORPORATION
by
-------------------------------------
Name:
Title:
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Amendment with Respect Stock Option Arrangements to be duly executed by
their respective authorized officers as of the date first above
written.
CIBA-GEIGY LIMITED,
by
-------------------------------------
Name:
Title:
by
-------------------------------------
Name:
Title:
CIBA-GEIGY CORPORATION,
by /s/ John J. McGraw
-------------------------------------
Name:
Title:
CIBA BIOTECH PARTNERSHIP, INC.
by /s/ John J. McGraw
-------------------------------------
Name:
Title:
CHIRON CORPORATION
by
-------------------------------------
Name:
Title:
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this
Amendment with Respect Stock Option Arrangements to be duly executed by
their respective authorized officers as of the date first above
written.
CIBA-GEIGY LIMITED,
by
-------------------------------------
Name:
Title:
by
-------------------------------------
Name:
Title:
CIBA-GEIGY CORPORATION,
by
-------------------------------------
Name:
Title:
CIBA BIOTECH PARTNERSHIP, INC.
by
-------------------------------------
Name:
Title:
CHIRON CORPORATION
by /s/ William J. Rutter
-------------------------------------
Name:
Title:
<PAGE>
[Novartis Corporation Letterhead]
**CONFIDENTIAL TREATMENT REQUESTED**
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608-2916
Attn: William G. Green, Esq.
Senior Vice President and General Counsel
VIA FAX AND FEDERAL EXPRESS
September 30, 1999
Gentlemen:
This letter confirms the agreement between Chiron Corporation ("Chiron") on
behalf of itself and its wholly-owned subsidiary Chiron S.p.A., on the one hand,
and Novartis Corporation ("Novartis") to amend that certain Limited Liability
Company Agreement between them dated as of December 28, 1995, as amended (the
"LLC Agreement") in certain respects and to amend and to cause Chiron Funding
LLC (the "Company") to amend that certain Royalty Agreement between Chiron,
Chiron S.p.A. and the Company dated as of December 28, 1995 (the "Royalty
Agreement"). Terms not defined in this letter shall have the meaning set forth
in the LLC Agreement.
1. The parties hereby consent to the waiver and release by the Company of any
right to exercise a co-promotion option under paragraph 2.1.1(c) of the
LLC Agreement with respect to [CONFIDENTIAL TREATMENT REQUESTED]
developed and manufactured by [CONFIDENTIAL TREATMENT REQUESTED] as
licensee of Chiron patents and know how covering such vaccine (the
"[CONFIDENTIAL TREATMENT REQUESTED]" ). Accordingly, no co-promotion
right or Residual Right will arise under paragraph 4.3. or 4.4 of the LLC
Agreement with respect to [CONFIDENTIAL TREATMENT REQUESTED].
2. In lieu of any royalty or other amounts payable under Paragraph 1 of the
Royalty Agreement with respect to [CONFIDENTIAL TREATMENT REQUESTED],
Chiron shall pay and cause its Affiliates to pay to the Company (i)
[CONFIDENTIAL TREATMENT REQUESTED] of all net proceeds received by Chiron
or its Affiliates as upfront fees or running royalties from
[CONFIDENTIAL TREATMENT REQUESTED] or from any sub-licensee of
[CONFIDENTIAL TREATMENT REQUESTED] or successor licensee of Chiron or its
Affiliates in consideration of the grant of license rights under Chiron
patents or know how covering [CONFIDENTIAL TREATMENT REQUESTED] and (ii)
a Base Royalty Rate of [CONFIDENTIAL TREATMENT REQUESTED] of Net Sales by
Chiron and its Affiliates as distributors of [CONFIDENTIAL TREATMENT
REQUESTED].
<PAGE>
3. In consideration of Novartis' consent to this letter agreement, Chiron
shall pay and cause its Affiliates to pay directly to Novartis (i)
[CONFIDENTIAL TREATMENT REQUESTED] of all net proceeds received by Chiron
or its Affiliates as upfront fees or running royalties from
[CONFIDENTIAL TREATMENT REQUESTED] or from any sub-licensee of
[CONFIDENTIAL TREATMENT REQUESTED] or successor licensee of Chiron or its
Affiliates in consideration of the grant of license under Chiron patents
or know how covering [CONFIDENTIAL TREATMENT REQUESTED] and (ii) a
royalty of [CONFIDENTIAL TREATMENT REQUESTED] of Net Sales by Chiron and
its Affiliates as distributors of [CONFIDENTIAL TREATMENT REQUESTED].
Chiron's obligations under this Paragraph 3 shall terminate upon the
exercise by Chiron of the Buyout Right under Paragraph 4.1 of the LLC
Agreement.
4. For the avoidance of doubt, amounts paid directly to Novartis under
Paragraph 3 above do not affect the calculation of the Buyout Amount under
Paragraph 4.1 of the LLC Agreement or the length of the Royalty Term under
Section 3 of the Royalty Agreement, while amounts paid to the Company
under Paragraph 2 above would affect such calculation.
5. Parties acknowledge Chiron has requested and Novartis has agreed that
Novartis' obligation to purchase Units pursuant to section 2.3.2 of the
LLC Agreement is increased from not to exceed $250 million to not to
exceed $265 million. Parties further acknowledged that the effect of such
increase is to reduce to $702.5 million the Maximum Borrowing Amount as
defined in section 5.12 of that certain Investment Agreement between
Novartis and Chiron dated as of November 20, 1994 and as amended by
Paragraph E.1. of that certain FTC Agreement between Novartis and Chiron,
dated as of November 27, 1996. Further, parties confirm the terms of the
agreement of December 24, 1997.
If the foregoing accurately reflects our understanding effective as of the date
of this letter, please sign and return a copy.
Very truly yours,
NOVARTIS CORPORATION
by: /s/ JEFF BENJAMIN
Jeff Benjamin
Vice President and
Associate General Counsel
Agreed Chiron Corporation by:
/s/ WILLIAM G. GREEN
cc: Herbert Gut, Esq., Novartis Pharma AG
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CHIRON
CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET DATED SEPTEMBER 30,
1999 AND UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1999<F5>
<PERIOD-START> JAN-01-1999
<PERIOD-END> SEP-30-1999<F5>
<CASH> 205,768
<SECURITIES> 1,347,243<F1>
<RECEIVABLES> 197,419
<ALLOWANCES> 0
<INVENTORY> 95,149
<CURRENT-ASSETS> 1,276,034
<PP&E> 550,858
<DEPRECIATION> 232,396
<TOTAL-ASSETS> 2,474,568
<CURRENT-LIABILITIES> 371,192
<BONDS> 350,736<F2>
0
0
<COMMON> 1,819
<OTHER-SE> 1,685,324<F3>
<TOTAL-LIABILITY-AND-EQUITY> 2,474,568
<SALES> 308,295
<TOTAL-REVENUES> 569,046
<CGS> 138,215
<TOTAL-COSTS> 138,215
<OTHER-EXPENSES> 225,958<F4>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 17,866
<INCOME-PRETAX> 121,451
<INCOME-TAX> 18,938
<INCOME-CONTINUING> 102,513
<DISCONTINUED> 26,297
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 128,810
<EPS-BASIC> 0.71
<EPS-DILUTED> 0.69
<FN>
<F1>CONSISTS OF SHORT-TERM AND NONCURRENT INVESTMENTS IN MARKETABLE DEBT
SECURITIES.
<F2>CONSISTS OF CONVERTIBLE SUBORDINATED DEBENTURES AND NOTES PAYABLE, NET OF
CURRENT MATURITIES.
<F3>CONSISTS OF ADDITIONAL PAID-IN CAPITAL, ACCUMULATED DEFICIT, COST OF TREASURY
STOCK, AND ACCUMULATED OTHER COMPREHENSIVE LOSS.
<F4>CONSISTS OF RESEARCH AND DEVELOPMENT, RESTRUCTURING AND REORGANIZATION CHARGES
AND OTHER OPERATING EXPENSES.
<F5>DURING THE FIRST QUARTER OF 1999, THE COMPANY CHANGED ITS FISCAL YEAR FROM
A 52 OR 53-WEEK YEAR ENDING ON THE SUNDAY NEAREST THE LAST DAY IN DECEMBER, TO
A CALENDAR YEAR ENDING ON DECEMBER 31.
</FN>
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CHIRON
CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET DATED SEPTEMBER 30,
1998 AND UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1998<F5>
<PERIOD-START> JAN-01-1998
<PERIOD-END> SEP-30-1998<F5>
<CASH> 80,468
<SECURITIES> 339,496<F1>
<RECEIVABLES> 348,015
<ALLOWANCES> 0
<INVENTORY> 177,441
<CURRENT-ASSETS> 886,260
<PP&E> 820,781
<DEPRECIATION> 306,505
<TOTAL-ASSETS> 1,960,449
<CURRENT-LIABILITIES> 373,593
<BONDS> 405,865<F2>
0
0
<COMMON> 1,782
<OTHER-SE> 1,140,116<F3>
<TOTAL-LIABILITY-AND-EQUITY> 1,960,449
<SALES> 278,091
<TOTAL-REVENUES> 512,147
<CGS> 124,462<F6>
<TOTAL-COSTS> 124,462<F6>
<OTHER-EXPENSES> 217,364<F6><F4>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 18,638
<INCOME-PRETAX> 77,097
<INCOME-TAX> 15,539
<INCOME-CONTINUING> 61,558
<DISCONTINUED> 102,745
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 164,303
<EPS-BASIC> 0.93
<EPS-DILUTED> 0.91
<FN>
<F1>CONSISTS OF SHORT-TERM AND NONCURRENT INVESTMENTS IN MARKETABLE DEBT SECURITIES.
<F2>CONSISTS OF CONVERTIBLE SUBORDINATED DEBENTURES, CAPITAL LEASE OBLIGATIONS AND
NOTES PAYABLE, NET OF CURRENT MATURITIES.
<F3>CONSISTS OF ADDITIONAL PAID-IN CAPITAL, ACCUMULATED DEFICIT, AND ACCUMULATED
OTHER COMPREHENSIVE LOSS.
<F4>CONSISTS OF RESEARCH AND DEVELOPMENT, WRITE-OFF OF PURCHASED IN-PROCESS
TECHNOLOGIES, RESTRUCTURING AND REORGANIZATION CHARGES AND OTHER OPERATING
EXPENSES.
<F5>ACTUAL FISCAL YEAR END WAS JAN-03-1999. ACTUAL INTERIM PERIOD END WAS
SEPTEMBER 27, 1998. FOR PRESENTATION PURPOSES, DATES USED IN THE CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS AND NOTES REFER TO THE FISCAL MONTH END.
<F6>DURING THE SECOND QUARTER OF 1999, THE COMPANY COMPLETED THE
IMPLEMENTATION OF AN INTEGRATED INFORMATION SYSTEM. AS A RESULT, CERTAIN
PREVIOUSLY REPORTED AMOUNTS HAVE BEEN RECLASSIFIED TO CONFORM WITH THE
SEPTEMBER 30, 1999 PRESENTATION.
</FN>
</TABLE>
